nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-208-12-4-68nogr-2253Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESПоражения органов пищеварения при постковидном синдроме. Клинические рекомендацииGastrointestinal disorders in post-COVID syndrome. Clinical guidelineshttps://orcid.org/0000-0002-1095-8787ГриневичВ. Б.GrinevichV. B.

Гриневич Владимир Борисович, доктор медицинских наук, профессор, заведующий 2 кафедрой (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Vladimir B. Grinevich, Head of 2nd Therapy department of postgraduate education, DSci, professor

6 Akademika Lebedev street, St. Petersburg, 194044

Scopus Author ID: 7005167197

https://orcid.org/0000-0001-8736-5851ЛазебникЛ. Б.LazebnikL. B.

Лазебник Леонид Борисович, доктор медицинских наук, профессор кафедры терапии и профилактической медицины; президент Научного общества гастроэнтерологов России; вице-президент Российского научного медицинского общества терапевтов

127473, г. Москва, ул. Делегатская, д. 20, стр.1

Leonid B. Lazebnik, Vice President of the RSMST, President of the GSSR, Doctor of Medical Sciences, Professor of the Department of Internal Medicine and Preventive Medicine

20, p. 1, Delegatskaya St., Moscow, 127473

Scopus Author ID: 7005446863

Leonid.borisl@gmail.comhttps://orcid.org/0000-0001-8347-0531КравчукЮ. А.KravchukYu. A.

Кравчук Юрий Алексеевич, доктор медицинских наук, профессор 2 кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Yurii A. Kravchuk, M.D., D. Sc. (Medicine), Professor of 2nd Therapy department of postgraduate education

6 Akademika Lebedev street, St. Petersburg, 194044

РадченкоВ. Г.RadchenkoV. G.

Радченко Валерий Григорьевич, доктор медицинских наук, профессор 2-й кафедры (терапии усовершенствования врачей); вицепрезидент НОГР

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Valery G. Radchenko, Doctor of Medical Sciences, Professor of the 2nd Department (Therapy of Advanced Training of Doctors); Vice- President of Scientifi c Society of Gastroenterology of Russia

6 Akademika Lebedev street, St. Petersburg, 194044

https://orcid.org/0000-0002-8858-5642ТкаченкоЕ. И.TkachenkoE. I.

Ткаченко Евгений Иванович, доктор медицинских наук, профессор 2 кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Evgeniy I. Tkachenko, professor of 2nd Therapy department of postgraduate education, DSci, professor

6 Akademika Lebedev street, St. Petersburg, 194044

Scopus Author ID: 7102256824

ПершкоА. М.PershkoA. M.

Першко Анатолий Михайлович, доктор медицинских наук, профессор 2-й кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Anatoly M. Pershko, M.D., D. Sc. (Medicine), Professor of 2nd Therapy Department of Postgraduate Education

6 Akademika Lebedev street, St. Petersburg, 194044

https://orcid.org/0000-0001-5623-4226СеливёрстовП. В.SeliverstovP. V.

Селиверстов Павел Васильевич, кандидат медицинских наук, доцент кафедры внутренних болезней, клинической фармакологии и нефрологии

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Pavel V. Seliverstov, Candidate of Medical Sciences, Associate Professor of the Department of Internal Diseases, Clinical Pharmacology and Nephrology

6 Akademika Lebedev street, St. Petersburg, 194044

https://orcid.org/0000-0003-4839-9578СаликоваС. П.SalikovaC. P.

Саликова Светлана Петровна, доктор медицинских наук, доцент, доцент 2 кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Svetlana P. Salikova, doctor of medical Sciences, associate Professor 2 chair (therapy postgraduate doctors)

6 Akademika Lebedev street, St. Petersburg, 194044

https://orcid.org/0000-0002-3679-1874ЖдановК. В.ZhdanovK. V.

Жданов Константин Валерьевич, доктор медицинских наук, профессор, член-корреспондент РАН, начальник кафедры инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Konstantin V. Zhdanov, M.D., Ph.D., Professor, Head of Department of Infectious diseases (with course of medical parasitology and tropical diseases)

6 Akademika Lebedev street, St. Petersburg, 194044

Scopus Author ID: 6602691874,

Researcher ID: Q-8867–2016

https://orcid.org/0000-0002-4398-7525КозловК. В.KozlovK. V.

Козлов Константин Вадимович, доктор медицинских наук, доцент кафедры инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Konstantin V. Kozlov, Doctor of Medical Sciences, Associate Professor of the Department of Infectious Diseases (with the course of medical parasitology and tropical diseases)

6 Akademika Lebedev street, St. Petersburg, 194044

МакиенкоВ. В.MakienkoV. V.

Макиенко Валентина Вадимовна, кандидат медицинских наук, доцент 2-й кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Valentina V. Makienko, Ph.D. (Medicine), Associated Professor of 2nd Therapy Department of Postgraduate Education

6 Akademika Lebedev street, St. Petersburg, 194044

https://orcid.org/0000-0002-2785-6699ПотаповаИ. В.PotapovaI. V.

Потапова Ирина Валентиновна, кандидат медицинских наук, доцент 2-й кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Irina V. Potapova, Ph.D. (Medicine), Associated Professor of 2nd Therapy Department of Postgraduate Education

6 Akademika Lebedev street, St. Petersburg, 194044

https://orcid.org/0000-0002-2785-6699ИванюкЕ. С.IvanyukE. S.

Иванюк Елена Сергеевна, кандидат медицинских наук, старший преподаватель 2-й-й кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Elena S. Ivanyuk, Ph.D. (Medicine), Senior Lecturer of 2nd Therapy Department of Postgraduate Education

6 Akademika Lebedev street, St. Petersburg, 194044

Scopus Author ID: 57225888992

https://orcid.org/0000-0002-3247-0600ЕгоровД. В.EgorovD. V.

Егоров Денис Владимирович, кандидат медицинских наук, старший преподаватель 2-й кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Denis V. Egorov, Ph.D. (Medicine), Senior Lecturer of 2nd Therapy Department of Postgraduate Education

6 Akademika Lebedev street, St. Petersburg, 194044

https://orcid.org/0000-0002-8445-8363СасЕ. И.SasE. I.

Сас Евгений Иванович, доктор медицинских наук, профессор 2 кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Evgeny I. Sas, M.D., D. Sc. (Medicine), Professor of 2nd Therapy department of postgraduate education

6 Akademika Lebedev street, St. Petersburg, 194044

КоржеваМ. Д.KorzhevaM. D.

Коржева Мария Дмитриевна, преподаватель 2-й кафедры (терапии усовершенствования врачей)

194044, Санкт- Петербург, улица Академика Лебедева, д. 6

Maria D. Korzheva, Lecturer of 2nd Therapy Department of Postgraduate Education

6 Akademika Lebedev street, St. Petersburg, 194044

https://orcid.org/0000-0002-0083-8845КозловаН. М.KozlovaN. M.

Козлова Наталья Михайловна, заведующий кафедрой факультетской терапии, профессор, доктор медицинских наук

664003, г. Иркутск, ул. Красного Восстания, д. 1

Nataliya M. Kozlova, Head of the Department of Faculty Therapy, professor MD professor MD

1 str. Krasnogo Vosstaniya, Irkutsk, 664003

https://orcid.org/0000-0003-3279-6448РатниковаА. К.RatnikovaA. K.

Ратникова Анна Константиновна, врач-кардиолог приемного отделения; заведующая отделением

194291, Санкт- Петербург, пр. Культуры, д. 4

Anna K. Ratnikova, cardiologist, head of department

4 Kulturi avenue, St. Petersburg, 194291

https://orcid.org/0000-0002-9645-8408РатниковВ. А.RatnikovV. A.

Ратников Вячеслав Альбертович, доктор медицинских наук, профессор, заместитель генерального директора – медицинский директор, врач-рентгенолог

194291, Санкт- Петербург, пр. Культуры, д. 4

Vyacheslav A. Ratnikov, DSci, professor, deputy general director – medical director, radiologist

4 Kulturi avenue, St. Petersburg, 194291

https://orcid.org/0000-0003-0331-0963СиткинС. И.SitkinS. I.

Ситкин Станислав Игоревич, кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии имени С. М. Рысса, заведующий НИГ эпигенетики и метагеномики

191015, г. Санкт- Петербург, ул. Кирочная, д. 41,

197341, Санкт- Петербург, ул. Аккуратова, д. 2

Stanislav I. Sitkin, Dr. med., Associate Professor of Dpt. on Propedeutics, Gastroenterology and Dietology n. a. S. M. Riss, Head of Laboratory on Epigenetics a. Metagenomics

41 Kirochnaya street, Str., Petersburg, 191015,

2 Akkuratova Str., St. Petersburg, 197341

Scopus Author ID: 6603071466

https://orcid.org/0000-0002-3763-8994БолиеваЛ. З.BolievaL. Z.

Болиева Лаура Зелимхановна, доктор медицинских наук, профессор, заведующая кафедрой фармакологии с клинической фармакологией, главный внештатный специалист- пульмонолог и аллерголог- иммунолог

362019 Республика Северная Осетия- Алания, г. Владикавказ, ул.Пушкинская, 40

Laura Z. Bolieva, Doctor of Medical Sciences, Professor, Head of the Department of Pharmacology with Clinical Pharmacology, voluntary Doctor in Chief on Pulmonology a. Allergology- Immunology

40 Pushkinskaya st., Vladikavkaz, 362019, Republic of North Ossetia- Alania

Scopus 16315059200

https://orcid.org/0000-0002-8844-2465ТуркинаС. В.TurkinaC. V.

Туркина Светлана Владимировна, доктор медицинских наук, профессор кафедры внутренних болезней педиатрического и стоматологического факультетов

400131, Волгоградская область, г. Волгоград, площадь Павших борцов, д. 1

Svetlana V. Turkina, Doctor of Medical Sciences, Professor of the Department of Internal Diseases of Pediatric and Dental Faculties

1, Pavshikh Bortsov Sq., Volgograd, 400131

Scopus SC 6505698721;

Web of Science Researcher ID: GMX-2135–2022

https://orcid.org/0000-0001-7069-2725АбдулганиеваД. И.AbdulganievaD. I.

Абдулганиева Диана Ильдаровна, доктор медицинских наук, профессор, зав. кафедрой госпитальной терапии; главный внештатный специалист терапевт МЗ Республики Татарстан

420012, Республика Татарстан, г. Казань, ул. Бутлерова, д. 49

Diana I. Abdulganieva, Doctor of Medical Sciences, Professor, Head of the Department of Hospital Therapy of Kazan State Medical University; Chief Freelance Specialist Therapist of the Ministry of Health of the Republic of Tatarstan

49 Butlerova st., Tatarstan, Kazan

Scopus Author ID: 39161040600

https://orcid.org/0000-0002-2489-602XЕрмоловаТ. В.ErmolovaT. V.

Ермолова Татьяна Владиславовна, Доцент кафедры факультетской терапии

191015, г. Санкт- Петербург, ул. Кирочная, д. 41

Tatiana V. Ermolova, Аss. Professor of Faculty Therapy Department

41 Kirochnaya street, Str., Petersburg, 191015

Scopus Author ID: 57199607813

КожевниковаС. А.KozhevnikovaS. A.

Кожевникова Светлана Алексеевна, кандидат медицинских наук, доцент кафедры терапевтических дисциплин ИДПО

394036, г. Воронеж, ул. Студенческая, д. 10

Svetlana A. Kozhevnikova, Candidate of Medical Sciences, Associate Professor of the Therapeutic Disciplines Department of the Institute of Additional Professional Education (IAPE)

12 Studencheskaya Street, 394036 Voronezh

https://orcid.org/0000-0003-1496-0689ТарасоваЛ. В.TarasovaL. V.

Тарасова Лариса Владимировна, доктор медицинских наук, профессор, зав. кафедрой факультетской и госпитальной терапии

428015, г. Чебоксары, Московский проспект, д. 15

Larisa V. Tarasova, Doctor of Medica l Sciences, Professor, Head of the Department of Faculty and Hospital Therapy

15 Moskow avenue, Cheboksary, 428015

https://orcid.org/0000-0002-2375-517XМязинР. Г.MyazinR. G.

Мязин Роман Геннадиевич, кафедра пропедевтики внутренних болезней, кандидат медицинских наук, доцент

400131, Волгоградская область, г. Волгоград, площадь Павших борцов, д. 1

Roman G. Myazin, department of propaedeutics of internal medicine, сand. of sci. (med.), assistant professor

1, Pavshikh Bortsov Sq., Volgograd, 400131

https://orcid.org/0000-0002-0699-2480ХомерикиН. М.KhomerikiN. M.

Хомерики Наталья Михайловна, кандидат медицинских наук, доцент кафедры гастроэнтерологии Факультета усовершенствования врачей (ФУВ)

129110, Москва, ул.Щепкина д. 61/2

Natalia M. Khomeriki, MD, PhD, Associate Professor of the Department of Postgraduate Medical Education

61/2, Schepkina str., Moscow, 129110

https://orcid.org/0000-0002-5930-8849ПилатТ. Л.PilatT. L.

Пилат Татьяна Львовна, доктор медицинских наук, профессор, ведущий научный сотрудник

105275, Москва, проспект Буденного, д. 31

Tatiana L. Pilat, Dr. Sci. (Med.), Leading Researcher

31 Budenova avenue, Moscow, 105275

https://orcid.org/0000-0003-3186-8024КузьминаЛ. П.KuzminaL. P.

Кузьмина Людмила Павловна, доктор биологическтх наук, профессор, заместитель директора по научной работе; профессор кафедры медицины труда, авиационной, космической и водолазной медицины

105275, Москва, проспект Буденного, д. 31,

119991, г. Москва, ул. Трубецкая, д. 8, стр. 2

Lyudmila P. Kuzmina, Dr. of Sci. (Bio.), professor, deputy director for science; Professor of the Department of Occupational Medicine, Aviation, Space and Diving Medicine

31 Budenova avenue, Moscow, 105275,

8,2 Trubetskaya, Moscow, 119991

https://orcid.org/0000-0003-1178-7534ХанферьянР. А.KhanferyanR. A.

Ханферьян Роман Авакович, доктор медицинских наук, профессор

117198, Москва, ул. Миклухо- Маклая, д. 6

Roman A. Khanferyan, Dr. Sci. (Med.), Professor of the Medical Institute

6 Miklukho- Maklaya str., Moscow, 117198

https://orcid.org/0000-0002-0992-1709НовиковаВ. П.NovikovaV. P.

Новикова Валерия Павловна, доктор медицинских наук, профессор, заведующая кафедрой пропедевтики детских болезней с курсом общего ухода за детьми, заведующая лабораторией медико- социальных проблем в педиатрии

194100, г. Санкт- Петербург, ул. Литовская, д. 2

Valeriya P. Novikova, MD, PhD, DSc, professor, Head of the Department of Propedeutics of Childhood Diseases with a course in general child care, Head of the Laboratory of Medical and Social Problems in Pediatrics

2, Litovskaya st., St. Petersburg, 194100

Scopus Author ID: 572006834469

https://orcid.org/0000-0003-2613-1503ПолунинаА. В.PoluninaA. V.

Полунина Анна Владимировна, аспирант кафедры пропедевтики детских болезней с курсом общего ухода за детьми, лаборант- исследователь лаборатории медико- социальных проблем в педиатрии

194100, г. Санкт- Петербург, ул. Литовская, д. 2

Anna V. Polunina, postgraduate student of the Department of Propedeutics of Childhood Diseases with a course in general child care, research laboratory assistant at the Laboratory of Medical and Social Problems

2, Litovskaya st., St. Petersburg, 194100

https://orcid.org/0000-0001-7308-7280ХавкинА. И.KhavkinA. I.

Хавкин Анатолий Ильич, доктор медицинских наук, профессор, руководитель Московского областного центра детской гастроэнтерологии и гепатологии; главный научный сотрудник отдела гастроэнтерологии Научно- исследовательского клинического института педиатрии им. академика Ю. Е. Вельтищева; профессор кафедры педиатрии с курсом детских хирургических болезней

г. Москва, ул. Островитянова, д. 1

Anatoly I. Khavkin, Doctor of Medical Sciences, Professor and Head; Chief Researcher, Department of Gastroenterology Researcher Clinical Institute of Pediatric named after academician Yu. E. Veltishev; Professor of the Department of Pediatrics with a Course in Pediatric Surgical Diseases

1, Ostrovityanova, Moscow, 125412

Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно- медицинская академия имени С. М. Кирова Министерства обороны Российской ФедерацииРоссияMilitary Medical Academy named after S. M. KirovRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Московский государственный медикостоматологический университет имени А. И. Евдокимова Министерства здравоохранения Российской ФедерацииРоссияA. I. Yevdokimov Moscow State University of Medicine and DentistryRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Иркутский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияIrkutsk State Medical UniversityRussian FederationФедеральное государственное бюджетное учреждение Северо- Западный окружной научно- клинический центр имени Л. Г. Соколова Федерального медико- биологического агентстваРоссияNorth-West District Scientifi c and Clinical Center named after L. G. Sokolov Federal Medical and Biological AgencyRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Северо-Западный государственный медицинский университет им. И. И. Мечникова Министерства здравоохранения Российской Федерации Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России)РоссияNorth-Western state medical University named after I. I. Mechnikov; Almazov National Medical Research CentreRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Осетинская государственная медицинская академия» Министерства здравоохранения Российской Федерации (ФГБОУ ВО СОГМА Минздрава России)РоссияNorth Ossetian State Medical AcademyRussian FederationФедеральное государственное бюджетное учреждение высшего образования Волгоградский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияVolgograd State Medical UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Казанский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияKazan State Medical UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Северо-Западный государственный медицинский университет им. И. И. Мечникова Министерства здравоохранения Российской ФедерацииРоссияNorth-Western state medical University named after I. I. MechnikovRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Воронежский государственный медицинский университет им. Н. Н. Бурденко Министерства здравоохранения Российской ФедерацииРоссияVoronezh State Medical University named after N. N. BurdenkoRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Чувашский государственный университет имени И. Н. Ульянова, Чувашская РеспубликаРоссияChuvash State University n. a. I. N. Ulyanov”Russian FederationГосударственное бюджетное учреждение здравоохранения Московской области Московский областной научно- исследовательский клинический институт им.М.Ф.ВладимирскогоРоссияMoscow Regional Research Clinical Institute n. a. M. F. Vladimirsky”Russian FederationНаучно-исследовательский институт медицины труда имени академика Н. Ф. ИзмероваРоссияScientifi c Research Institute of labour medicine named after academician N. F. IzmerovRussian FederationНаучно-исследовательский институт медицины труда имени академика Н. Ф. Измерова; Федеральное государственное бюджетное образовательное учреждение высшего образования Первый московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)РоссияScientifi c Research Institute of labour medicine named after academician N. F. Izmerov; I. M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Российский университет дружбы народовРоссияPeoples' Friendship University of RussiaRussian FederationФГБОУ ВО «Санкт- Петербургский государственный педиатрический медицинский университет» Минздрава Российской ФедерацииРоссияSt. Petersburg State Pediatric Medical UniversityRussian FederationНаучно- исследовательский клинический институт педиатрии им. Ю. Е. Вельтищева ФГБАУ ВО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова МЗ РФРоссияRussian National Research Medical University named after N. I. PirogovRussian Federation202220052023012468Copyright © Гриневич В.Б., Лазебник Л.Б., Кравчук Ю.А., Радченко В.Г., Ткаченко Е.И., Першко А.М., Селивёрстов П.В., Саликова С.П., Жданов К.В., Козлов К.В., Макиенко В.В., Потапова И.В., Иванюк Е.С., Егоров Д.В., Сас Е.И., Коржева М.Д., Козлова Н.М., Ратникова А.К., Ратников В.А., Ситкин С.И., Болиева Л.З., Туркина С.В., Абдулганиева Д.И., Ермолова Т.В., Кожевникова С.А., Тарасова Л.В., Мязин Р.Г., Хомерики Н.М., Пилат Т.Л., Кузьмина Л.П., Ханферьян Р.А., Новикова В.П., Полунина А.В., Хавкин А.И., 20232023Гриневич В.Б., Лазебник Л.Б., Кравчук Ю.А., Радченко В.Г., Ткаченко Е.И., Першко А.М., Селивёрстов П.В., Саликова С.П., Жданов К.В., Козлов К.В., Макиенко В.В., Потапова И.В., Иванюк Е.С., Егоров Д.В., Сас Е.И., Коржева М.Д., Козлова Н.М., Ратникова А.К., Ратников В.А., Ситкин С.И., Болиева Л.З., Туркина С.В., Абдулганиева Д.И., Ермолова Т.В., Кожевникова С.А., Тарасова Л.В., Мязин Р.Г., Хомерики Н.М., Пилат Т.Л., Кузьмина Л.П., Ханферьян Р.А., Новикова В.П., Полунина А.В., Хавкин А.И.Grinevich V.B., Lazebnik L.B., Kravchuk Y.A., Radchenko V.G., Tkachenko E.I., Pershko A.M., Seliverstov P.V., Salikova C.P., Zhdanov K.V., Kozlov K.V., Makienko v.V., Potapova I.V., Ivanyuk E.S., Egorov D.V., Sas E.I., Korzheva M.D., Kozlova N.M., Ratnikova A.K., Ratnikov V.A., Sitkin S.I., Bolieva L.Z., Turkina C.V., Abdulganieva D.I., Ermolova T.V., Kozhevnikova S.A., Tarasova L.V., Myazin R.G., Khomeriki N.M., Pilat T.L., Kuzmina L.P., Khanferyan R.A., Novikova V.P., Polunina A.V., Khavkin A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2253

Термин «постковидный синдром» используется для обозначения долгосрочных последствий перенесенной новой коронавирусной инфекции COVID-19, включающих совокупность симптомов, развивающихся или сохраняющихся после перенесенного COVID-19. Симптомы поражения органов пищеварения при постковидном синдроме, обусловленные стойким хроническим воспалением, последствиями повреждения органов, продолжительной госпитализацией, социальной изоляцией и другими причинами, могут иметь стойкий характер и требуют мультидисциплинарного подхода. В представленных клинических рекомендациях рассмотрены основные профилактические и лечебно- диагностические подходы к ведению пациентов с гастроэнтерологическими проявлениями постковидного синдрома. Рекомендации утверждены 17-м Национальным конгрессом терапевтов и 25-м съездом Научного общества гастроэнтерологов России.

Summary Post- COVID syndrome refers to the long-term consequences of a new coronavirus infection COVID-19, which includes a set of symptoms that develop or persist after COVID-19. Symptoms of gastrointestinal disorders in post- COVID syndrome, due to chronic infl ammation, the consequences of organ damage, prolonged hospitalization, social isolation, and other causes, can be persistent and require a multidisciplinary approach. The presented clinical practice guidelines consider the main preventive and therapeutic and diagnostic approaches to the management of patients with gastroenterological manifestations of postCOVID syndrome. The Guidelines were approved by the 17th National Congress of Internal Medicine and the 25th Congress of Gastroenterological Scientifi c Society of Russia.

постковидный синдромрекомендацииCOVID-19поражения органов пищеваренияSARS-CoV-2post-COVID syndromeguidelinesCOVID-19gastrointestinal disordersSARS-CoV-2ReferencesМеждународная классификация болезней 10-го пересмотра (МКБ-10) URL: https://mkb-10.com, Доступ 05 мая 2021.International Statistical Classifi cation of Diseases and Related Health Problems 10th Revision (ICD-10) (https://mkb-10.com, Accessed 05 may 2021).Методические рекомендации «Особенности течения Long- COVID-инфекции. Терапевтические и реабилитационные мероприятия». Терапия. 2022; 1 (Приложение): 1–147. doi: 10.18565/therapy.2022.1suppl.1–147.Guidelines “Peculiarities of the course of Long- COVID infection. Th erapeutic and rehabilitation measures". Th erapy. 2022; 1 (Appendix): 1–147. (in Russ.) doi: 10.18565/therapy.2022.1suppl.1–147.Kelly BD, Gulati G. Long COVID: the elephant in the room. QJM. 2022 Jan 21;115(1):5–6. doi: 10.1093/qjmed/hcab299.Kelly BD, Gulati G. Long COVID: the elephant in the room. QJM. 2022 Jan 21;115(1):5–6. doi: 10.1093/qjmed/hcab299.Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022 Sep;10(9):863–876. doi: 10.1016/S2213–2600(22)00126–6.Huang L, Li X, Gu X, et al. Health outcomes in people 2 years aft er surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022 Sep;10(9):863–876. doi: 10.1016/S2213–2600(22)00126–6.Joan B Soriano (Senior Consultant), Maya Allan, Carine Alsokhn, Nisreen A Alwan, Lisa Askie, Hannah E Davis, Janet V Diaz, Tarun Dua, Wouter de Groote, Robert Jakob, Marta Lado, John Marshall, Srin Murthy, Jacobus Preller, Pryanka Relan, Nicoline Schiess, Archana Seahwag; World Health Organization. A clinical case defi nition of post COVID-19 condition by a Delphi consensus, 6 October 2021. (WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1 accessed 31 August 2022).Joan B Soriano (Senior Consultant), Maya Allan, Carine Alsokhn, Nisreen A Alwan, Lisa Askie, Hannah E Davis, Janet V Diaz, Tarun Dua, Wouter de Groote, Robert Jakob, Marta Lado, John Marshall, Srin Murthy, Jacobus Preller, Pryanka Relan, Nicoline Schiess, Archana Seahwag; World Health Organization. A clinical case defi nition of post COVID-19 condition by a Delphi consensus, 6 October 2021. (WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1 accessed 31 August 2022).COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline [NG188] Published date:18 December 2020]. Available at: https://www.nice.org.uk/guidance/ng188 (Access: 01.10.2022)COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline [NG188] Published date:18 December 2020]. Available at: https://www.nice.org.uk/guidance/ng188 (Access: 01.10.2022)Antoniou KM, Vasarmidi E, Russell AM, Andrejak C, et al. European Respiratory Society Statement on Long COVID-19 Follow- Up. Eur Respir J. 2022 Feb 10:2102174. doi: 10.1183/13993003.02174–2021.Antoniou KM, Vasarmidi E, Russell AM, Andrejak C, et al. European Respiratory Society Statement on Long COVID-19 Follow- Up. Eur Respir J. 2022 Feb 10:2102174. doi: 10.1183/13993003.02174–2021.Jin B, Singh R, Ha SE, Zogg H, Park PJ, Ro S. Patho physiological mechanisms underlying gastrointestinal symptoms in patients with COVID-19. World J Gastroenterol. 2021 May 21;27(19):2341–2352. doi: 10.3748/wjg.v27.i19.2341.Jin B, Singh R, Ha SE, Zogg H, Park PJ, Ro S. Patho physiological mechanisms underlying gastrointestinal symptoms in patients with COVID-19. World J Gastroenterol. 2021 May 21;27(19):2341–2352. doi: 10.3748/wjg.v27.i19.2341.de- Madaria E, Capurso G. COVID-19 and acute pancreatitis: examining the causality. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):3–4. doi: 10.1038/s41575–020–00389-y.de- Madaria E, Capurso G. COVID-19 and acute pancreatitis: examining the causality. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):3–4. doi: 10.1038/s41575–020–00389-y.Xiaoqiang Chai, Longfei Hu, Yan Zhang, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage Aft er 2019-nCoV Infection. bioRxiv. 2020.02.03.931766. doi: 10.1101/2020.02.03.931766.Xiaoqiang Chai, Longfei Hu, Yan Zhang, et al. Specifi c ACE2 Expression in Cholangiocytes May Cause Liver Damage Aft er 2019-nCoV Infection. bioRxiv. 2020.02.03.931766. doi: 10.1101/2020.02.03.931766.Garg M, Angus PW, Burrell LM, Herath C, Gibson PR, Lubel JS. Review article: the pathophysiological roles of the reninangiotensin system in the gastrointestinal tract. Aliment Pharmacol Th er. 2012 Feb;35(4):414–28. doi: 10.1111/j.1365–2036.2011.04971.x.Garg M, Angus PW, Burrell LM, Herath C, Gibson PR, Lubel JS. Review article: the pathophysiological roles of the renin- angiotensin system in the gastrointestinal tract. Aliment Pharmacol Th er. 2012 Feb;35(4):414–28. doi: 10.1111/j.1365–2036.2011.04971.x.Fändriks L. The angiotensin II type 2 receptor and the gastrointestinal tract. J Renin Angiotensin Aldosterone Syst. 2010 Mar;11(1):43–8. doi: 10.1177/1470320309347788.Fändriks L. Th e angiotensin II type 2 receptor and the gastrointestinal tract. J Renin Angiotensin Aldosterone Syst. 2010 Mar;11(1):43–8. doi: 10.1177/1470320309347788.Hashimoto T, Perlot T, Rehman A, Trichereau J, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012 Jul 25;487(7408):477– 81. doi: 10.1038/nature11228.Hashimoto T, Perlot T, Rehman A, Trichereau J, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal infl ammation. Nature. 2012 Jul 25;487(7408):477– 81. doi: 10.1038/nature11228.Wang GD, Wang XY, Hu HZ, Fang XC, Liu S, Gao N, Xia Y, Wood JD. Angiotensin receptors and actions in guinea pig enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3): G614–26. doi: 10.1152/ajpgi.00119.2005.Wang GD, Wang XY, Hu HZ, Fang XC, Liu S, Gao N, Xia Y, Wood JD. Angiotensin receptors and actions in guinea pig enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3): G614–26. doi: 10.1152/ajpgi.00119.2005.Azer SA. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect. 2020 Sep;37:100738. doi: 10.1016/j.nmni.2020.100738.Azer SA. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect. 2020 Sep;37:100738. doi: 10.1016/j.nmni.2020.100738.Zhang H, Li HB, Lyu JR, Lei XM, Li W, Wu G, Lyu J, Dai ZM. Specifi c ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury aft er 2019-nCoV infection. Int J Infect Dis. 2020 Jul;96:19–24. doi: 10.1016/j.ijid.2020.04.027.Zhang H, Li HB, Lyu JR, Lei XM, Li W, Wu G, Lyu J, Dai ZM. Specifi c ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury aft er 2019-nCoV infection. Int J Infect Dis. 2020 Jul;96:19–24. doi: 10.1016/j.ijid.2020.04.027.Zang R, Gomez Castro MF, McCune BT, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020 May 13;5(47): eabc3582. doi: 10.1126/sciimmunol.abc3582.Zang R, Gomez Castro MF, McCune BT, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020 May 13;5(47): eabc3582. doi: 10.1126/sciimmunol.abc3582.Sen A, Rothenberg ME, Mukherjee G, Feng N, Kalisky T, Nair N, Johnstone IM, Clarke MF, Greenberg HB. Innate immune response to homologous rotavirus infection in the small intestinal villous epithelium at single-cell resolution. Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20667–72. doi: 10.1073/pnas.1212188109.Sen A, Rothenberg ME, Mukherjee G, Feng N, Kalisky T, Nair N, Johnstone IM, Clarke MF, Greenberg HB. Innate immune response to homologous rotavirus infection in the small intestinal villous epithelium at single-cell resolution. Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20667–72. doi: 10.1073/pnas.1212188109.Ding S, Zhu S, Ren L, Feng N, Song Y, Ge X, Li B, Flavell RA, Greenberg HB. Rotavirus VP3 targets MAVS for degradation to inhibit type III interferon expression in intestinal epithelial cells. Elife. 2018 Nov 21;7: e39494. doi: 10.7554/eLife.39494.Ding S, Zhu S, Ren L, Feng N, Song Y, Ge X, Li B, Flavell RA, Greenberg HB. Rotavirus VP3 targets MAVS for degradation to inhibit type III interferon expression in intestinal epithelial cells. Elife. 2018 Nov 21;7: e39494. doi: 10.7554/eLife.39494.Yong S. J. Long- Haul COVID-19: Putative Patho physio logy, Risk Factors, and Treatments. Preprints. 2020, 2020120242. doi: 10.20944/preprints202012.0242.v1.Yong S. J. Long- Haul COVID-19: Putative Patho physio logy, Risk Factors, and Treatments. Preprints. 2020, 2020120242. doi: 10.20944/preprints202012.0242.v1.Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022 Feb;23(2):210–216. doi: 10.1038/s41590–021–01113-x.Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022 Feb;23(2):210–216. doi: 10.1038/s41590–021–01113-x.Lopez- Leon S, Wegman- Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint]. 2021 Jan 30:2021.01.27.21250617. doi: 10.1101/2021.01.27.21250617.Lopez- Leon S, Wegman- Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint]. 2021 Jan 30:2021.01.27.21250617. doi: 10.1101/2021.01.27.21250617.Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Th er. 2020 Jun 4;12(1):69. doi: 10.1186/s13195–020–00640–3.Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Th er. 2020 Jun 4;12(1):69. doi: 10.1186/s13195–020–00640–3.Muccioli L, Pensato U, Cani I, Guarino M, Cortelli P, Bisulli F. COVID-19-Associated Encephalopathy and Cytokine- Mediated Neuroinfl ammation. Ann Neurol. 2020 Oct;88(4):860–861. doi: 10.1002/ana.25855.Muccioli L, Pensato U, Cani I, Guarino M, Cortelli P, Bisulli F. COVID-19-Associated Encephalopathy and Cytokine- Mediated Neuroinfl ammation. Ann Neurol. 2020 Oct;88(4):860–861. doi: 10.1002/ana.25855.South K, McCulloch L, McColl BW, Elkind MS, Allan SM, Smith CJ. Preceding infection and risk of stroke: An old concept revived by the COVID-19 pandemic. Int J Stroke. 2020 Oct;15(7):722–732. doi: 10.1177/1747493020943815.South K, McCulloch L, McColl BW, Elkind MS, Allan SM, Smith CJ. Preceding infection and risk of stroke: An old concept revived by the COVID-19 pandemic. Int J Stroke. 2020 Oct;15(7):722–732. doi: 10.1177/1747493020943815.Bortolato B, Carvalho AF, Soczynska JK, Perini GI, McIntyre RS. The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specifi c Treatments. Curr Neuropharmacol. 2015;13(5):558–76. doi: 10.2174/1570159x13666150630171433.Bortolato B, Carvalho AF, Soczynska JK, Perini GI, McIntyre RS. Th e Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specifi c Treatments. Curr Neuropharmacol. 2015;13(5):558–76. doi: 10.2174/1570159x13666150630171433.Kaseda ET, Levine AJ. Post-traumatic stress disorder: A differential diagnostic consideration for COVID-19 survivors. Clin Neuropsychol. 2020 Oct- Nov;34(7–8):1498–1514. doi: 10.1080/13854046.2020.1811894.Kaseda ET, Levine AJ. Post-traumatic stress disorder: A differential diagnostic consideration for COVID-19 survivors. Clin Neuropsychol. 2020 Oct- Nov;34(7–8):1498–1514. doi: 10.1080/13854046.2020.1811894.Salabei JK, Fishman TJ, Asnake ZT, Ali A, Iyer UG. COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart Lung. 2021 MarApr;50(2):357–360. doi: 10.1016/j.hrtlng.2021.01.011.Salabei JK, Fishman TJ, Asnake ZT, Ali A, Iyer UG. COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart Lung. 2021 MarApr;50(2):357–360. doi: 10.1016/j.hrtlng.2021.01.011.Ramlall V, Thangaraj PM, Meydan C, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020 Oct;26(10):1609–1615. doi: 10.1038/s41591–020–1021–2.Ramlall V, Thangaraj PM, Meydan C, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020 Oct;26(10):1609–1615. doi: 10.1038/s41591–020–1021–2.Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factor- enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020 Nov 2;130(11):6151–6157. doi: 10.1172/JCI141374.Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factor- enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020 Nov 2;130(11):6151–6157. doi: 10.1172/JCI141374.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601–615. doi: 10.1038/s41591–021–01283-z.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601–615. doi: 10.1038/s41591–021–01283-z.Deidda S, Tora L, Firinu D, Del Giacco S, et al. Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management. Expert Rev Gastroenterol Hepatol. 2021 Jan;15(1):41– 50. doi: 10.1080/17474124.2020.1821653.Deidda S, Tora L, Firinu D, Del Giacco S, et al. Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management. Expert Rev Gastroenterol Hepatol. 2021 Jan;15(1):41– 50. doi: 10.1080/17474124.2020.1821653.Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020 Dec 3;383(23):2291–2293. doi: 10.1056/NEJMc2031364.Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020 Dec 3;383(23):2291–2293. doi: 10.1056/NEJMc2031364.Choi HM, Moon SY, Yang HI, Kim KS. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. Int J Mol Sci. 2021 Feb 9;22(4):1737. doi: 10.3390/ijms22041737.Choi HM, Moon SY, Yang HI, Kim KS. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Th erapeutics. Int J Mol Sci. 2021 Feb 9;22(4):1737. doi: 10.3390/ijms22041737.Hu F, Chen F, Ou Z, Fan Q, et al. A compromised specific humoral immune response against the SARS-CoV-2 receptor- binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell Mol Immunol. 2020 Nov;17(11):1119–1125. doi: 10.1038/s41423–020–00550–2.Hu F, Chen F, Ou Z, Fan Q, et al. A compromised specific humoral immune response against the SARS-CoV-2 receptor- binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell Mol Immunol. 2020 Nov;17(11):1119–1125. doi: 10.1038/s41423–020–00550–2.Pagano N., Laurent- Rolle M., Hsu J. C. et al. Detection of long SARS-CoV-2 nucleocapsid sequences in peripheral blood monocytes collected soon after hospital admission. bioRxiv. 2020;12(16):423113; doi: 10.1101/2020.12.16.423113.Pagano N., Laurent- Rolle M., Hsu J. C. et al. Detection of long SARS-CoV-2 nucleocapsid sequences in peripheral blood monocytes collected soon after hospital admission. bioRxiv. 2020;12(16):423113; doi: 10.1101/2020.12.16.423113.Boumaza A., Gay L., Mezouar S. et al. Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis. bioRxiv. 2020.09.17.300996. doi: 10.1101/2020.09.17.300996.Boumaza A., Gay L., Mezouar S. et al. Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis. bioRxiv. 2020.09.17.300996. doi: 10.1101/2020.09.17.300996.Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, Primus-de Jong C, Cleemput I, Van den Heede K. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022 Dec;54(1):1473–1487. doi: 10.1080/07853890.2022.2076901.Castanares- Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, Primus-de Jong C, Cleemput I, Van den Heede K. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022 Dec;54(1):1473–1487. doi: 10.1080/07853890.2022.2076901.Kopel J, Perisetti A, Gajendran M, Boregowda U, Goyal H. Clinical Insights into the Gastrointestinal Manifestations of COVID-19. Dig Dis Sci. 2020 Jul;65(7):1932–1939. doi: 10.1007/s10620–020–06362–8.Kopel J, Perisetti A, Gajendran M, Boregowda U, Goyal H. Clinical Insights into the Gastrointestinal Manifestations of COVID-19. Dig Dis Sci. 2020 Jul;65(7):1932–1939. doi: 10.1007/s10620–020–06362–8.van Doorn AS, Meijer B, Frampton CMA, Barclay ML, de Boer NKH. Systematic review with meta-analysis: SARSCoV-2 stool testing and the potential for faecal-oral transmission. Aliment Pharmacol Th er. 2020 Oct;52(8):1276– 1288. doi: 10.1111/apt.16036. Epub 2020 Aug 27. PMID: 32852082; PMCID: PMC7461227van Doorn AS, Meijer B, Frampton CMA, Barclay ML, de Boer NKH. Systematic review with meta-analysis: SARSCoV-2 stool testing and the potential for faecal-oral transmission. Aliment Pharmacol Th er. 2020 Oct;52(8):1276– 1288. doi: 10.1111/apt.16036. Epub 2020 Aug 27. PMID: 32852082; PMCID: PMC7461227Morone G, Palomba A, Iosa M, Caporaso T, De Angelis D, Venturiero V, Savo A, Coiro P, Carbone D, Gimigliano F, Iolascon G, Paolucci S. Incidence and Persistence of Viral Shedding in COVID-19 Post-acute Patients With Negativized Pharyngeal Swab: A Systematic Review. Front Med (Lausanne). 2020 Aug 28;7:562. doi: 10.3389/fmed.2020.00562.Morone G, Palomba A, Iosa M, Caporaso T, De Angelis D, Venturiero V, Savo A, Coiro P, Carbone D, Gimigliano F, Iolascon G, Paolucci S. Incidence and Persistence of Viral Shedding in COVID-19 Post-acute Patients With Negativized Pharyngeal Swab: A Systematic Review. Front Med (Lausanne). 2020 Aug 28;7:562. doi: 10.3389/fmed.2020.00562.Zollner A, Koch R, Jukic A, Pfi ster A, Meyer M, Rössler A, Kimpel J, Adolph TE, Tilg H. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology. 2022 Aug;163(2):495–506.e8. doi: 10.1053/j.gastro.2022.04.037.Zollner A, Koch R, Jukic A, Pfi ster A, Meyer M, Rössler A, Kimpel J, Adolph TE, Tilg H. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology. 2022 Aug;163(2):495–506.e8. doi: 10.1053/j.gastro.2022.04.037.Kumar V. How could we forget immunometabolism in SARS-CoV2 infection or COVID-19? Int Rev Immunol. 2021;40(1–2):72–107. doi: 10.1080/08830185.2020.1840567.Kumar V. How could we forget immunometabolism in SARS-CoV2 infection or COVID-19? Int Rev Immunol. 2021;40(1–2):72–107. doi: 10.1080/08830185.2020.1840567.Wang EY, Mao T, Klein J, Dai Y, Huck JD, Liu F, Zheng NS, Zhou T, Israelow B, Wong P, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Fischer S, Campbell M, Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE; Yale IMPACT Team, Cruz CD, Farhadian SF, Schulz WL, Grubaugh ND, Ko AI, Iwasaki A, Ring AM. Diverse Functional Autoantibodies in Patients with COVID-19. medRxiv [Preprint]. 2021 Feb 1:2020.12.10.20247205. doi: 10.1101/2020.12.10.20247205.Wang EY, Mao T, Klein J, Dai Y, Huck JD, Liu F, Zheng NS, Zhou T, Israelow B, Wong P, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Fischer S, Campbell M, Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE; Yale IMPACT Team, Cruz CD, Farhadian SF, Schulz WL, Grubaugh ND, Ko AI, Iwasaki A, Ring AM. Diverse Functional Autoantibodies in Patients with COVID-19. medRxiv [Preprint]. 2021 Feb 1:2020.12.10.20247205. doi: 10.1101/2020.12.10.20247205.Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020 Jul 7;9: e59177. doi: 10.7554/eLife.59177.Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020 Jul 7;9: e59177. doi: 10.7554/eLife.59177.Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinfl ammation and post- Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020 Nov;100:327–332. doi: 10.1016/j.ijid.2020.09.016.Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinfl ammation and post- Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020 Nov;100:327–332. doi: 10.1016/j.ijid.2020.09.016.Meringer H, Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol. 2022 Jun;19(6):345–346. doi: 10.1038/s41575–022–00611-z.Meringer H, Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol. 2022 Jun;19(6):345–346. doi: 10.1038/s41575–022–00611-z.Settanni CR, Ianiro G, Ponziani FR, Bibbò S, Segal JP, Cammarota G, Gasbarrini A. COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. World J Gastroenterol. 2021 Nov 21;27(43):7433–7445. doi: 10.3748/wjg.v27.i43.7433.Settanni CR, Ianiro G, Ponziani FR, Bibbò S, Segal JP, Cammarota G, Gasbarrini A. COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. World J Gastroenterol. 2021 Nov 21;27(43):7433–7445. doi: 10.3748/wjg.v27.i43.7433.Gu S, Chen Y, Wu Z, et al. Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Infl uenza. Clin Infect Dis. 2020 Dec 17;71(10): 2669–2678. doi: 10.1093/cid/ciaa709.Gu S, Chen Y, Wu Z, et al. Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Infl uenza. Clin Infect Dis. 2020 Dec 17;71(10): 2669–2678. doi: 10.1093/cid/ciaa709.Zuo T, Zhang F, Lui GCY, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020 Sep;159(3):944– 955.e8. doi: 10.1053/j.gastro.2020.05.048.Zuo T, Zhang F, Lui GCY, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020 Sep;159(3):944– 955.e8. doi: 10.1053/j.gastro.2020.05.048.Din AU, Mazhar M, Waseem M, et al. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role. Biomed Pharmacother. 2021 Jan;133:110947. doi: 10.1016/j.biopha.2020.110947.Din AU, Mazhar M, Waseem M, et al. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role. Biomed Pharmacother. 2021 Jan;133:110947. doi: 10.1016/j.biopha.2020.110947.Effenberger M, Grabherr F, Mayr L, et al. Faecal calprotectin indicates intestinal infl ammation in COVID-19. Gut. 2020 Aug;69(8):1543–1544. doi: 10.1136/gutjnl-2020–321388.Effenberger M, Grabherr F, Mayr L, et al. Faecal calprotectin indicates intestinal infl ammation in COVID-19. Gut. 2020 Aug;69(8):1543–1544. doi: 10.1136/gutjnl-2020–321388.Fuglsang A, Rattray FP, Nilsson D, Nyborg NC. Lactic acid bacteria: inhibition of angiotensin converting enzyme in vitro and in vivo. Antonie Van Leeuwenhoek. 2003;83(1):27–34. doi: 10.1023/a:1022993905778.Fuglsang A, Rattray FP, Nilsson D, Nyborg NC. Lactic acid bacteria: inhibition of angiotensin converting enzyme in vitro and in vivo. Antonie Van Leeuwenhoek. 2003;83(1):27–34. doi: 10.1023/a:1022993905778.Barla F, Koyanagi T, Tokuda N, Matsui H, Katayama T, Kumagai H, Michihata T, Sasaki T, Tsuji A, Enomoto T. Th e γ-aminobutyric acid-producing ability under low pH conditions of lactic acid bacteria isolated from traditional fermented foods of Ishikawa Prefecture, Japan, with a strong ability to produce ACE-inhibitory peptides. Biotechnol Rep (Amst). 2016 Apr 9;10:105–110. doi: 10.1016/j.btre.2016.04.002.Barla F, Koyanagi T, Tokuda N, Matsui H, Katayama T, Kumagai H, Michihata T, Sasaki T, Tsuji A, Enomoto T. Th e γ-aminobutyric acid-producing ability under low pH conditions of lactic acid bacteria isolated from traditional fermented foods of Ishikawa Prefecture, Japan, with a strong ability to produce ACE-inhibitory peptides. Biotechnol Rep (Amst). 2016 Apr 9;10:105–110. doi: 10.1016/j.btre.2016.04.002.Lv L, Jiang H, Chen Y, Gu S, Xia J, Zhang H, Lu Y, Yan R, Li L. Th e faecal metabolome in COVID-19 patients is altered and associated with clinical features and gut microbes. Anal Chim Acta. 2021 Apr 1;1152:338267. doi: 10.1016/j.aca.2021.338267.Lv L, Jiang H, Chen Y, Gu S, Xia J, Zhang H, Lu Y, Yan R, Li L. Th e faecal metabolome in COVID-19 patients is altered and associated with clinical features and gut microbes. Anal Chim Acta. 2021 Apr 1;1152:338267. doi: 10.1016/j.aca.2021.338267.Francino MP. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. Front Microbiol. 2016 Jan 12;6:1543. doi: 10.3389/fmicb.2015.01543.Francino MP. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. Front Microbiol. 2016 Jan 12;6:1543. doi: 10.3389/fmicb.2015.01543.Feng Y, Huang Y, Wang Y, Wang P, Song H, Wang F. Antibiotics induced intestinal tight junction barrier dysfunction is associated with microbiota dysbiosis, activated NLRP3 inflammasome and autophagy. PLoS One. 2019 Jun 18;14(6): e0218384. doi: 10.1371/journal.pone.0218384.Feng Y, Huang Y, Wang Y, Wang P, Song H, Wang F. Antibiotics induced intestinal tight junction barrier dysfunction is associated with microbiota dysbiosis, activated NLRP3 inflammasome and autophagy. PLoS One. 2019 Jun 18;14(6): e0218384. doi: 10.1371/journal.pone.0218384.Donati Zeppa S, Agostini D, Piccoli G, Stocchi V, Sestili P. Gut Microbiota Status in COVID-19: An Unrecognized Player? Front Cell Infect Microbiol. 2020 Nov 26;10:576551. doi: 10.3389/fcimb.2020.576551.Donati Zeppa S, Agostini D, Piccoli G, Stocchi V, Sestili P. Gut Microbiota Status in COVID-19: An Unrecognized Player? Front Cell Infect Microbiol. 2020 Nov 26;10:576551. doi: 10.3389/fcimb.2020.576551.Parker EPK, Praharaj I, John J, Kaliappan SP, Kamp mann B, Kang G, Grassly NC. Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo- controlled trial among infants in south India. Sci Rep. 2017 Aug 23;7(1):9168. doi: 10.1038/s41598–017–06862–0.Parker EPK, Praharaj I, John J, Kaliappan SP, Kamp mann B, Kang G, Grassly NC. Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo- controlled trial among infants in south India. Sci Rep. 2017 Aug 23;7(1):9168. doi: 10.1038/s41598–017–06862–0.Fanos V., Pintus M. C., Pintus R., Marcialis M. A. Lung Microbiota in the Acute Respiratory Disease: From Coronavirus to Metabolomics. Journal of Pediatric and Neonatal Individualized Medicine (JPNIM). 2020;9(1): e090139. doi: 10.7363/090139.Fanos V., Pintus M. C., Pintus R., Marcialis M. A. Lung Microbiota in the Acute Respiratory Disease: From Coronavirus to Metabolomics. Journal of Pediatric and Neonatal Individualized Medicine (JPNIM). 2020;9(1): e090139. doi: 10.7363/090139.Mishra GP, Mulani J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. Lancet Respir Med. 2021 Jan;9(1): e8. doi: 10.1016/S2213–2600(20)30530–0.Mishra GP, Mulani J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. Lancet Respir Med. 2021 Jan;9(1): e8. doi: 10.1016/S2213–2600(20)30530–0.Qiu D, Xia Z, Deng J, Jiao X, Liu L, Li J. Glucorticoidinduced obesity individuals have distinct signatures of the gut microbiome. Biofactors. 2019 Nov;45(6):892–901. doi: 10.1002/biof.1565.Qiu D, Xia Z, Deng J, Jiao X, Liu L, Li J. Glucorticoidinduced obesity individuals have distinct signatures of the gut microbiome. Biofactors. 2019 Nov;45(6):892–901. doi: 10.1002/biof.1565.Pinto- Cardoso S, Klatt NR, Reyes- Terán G. Impact of antiretroviral drugs on the microbiome: unknown answers to important questions. Curr Opin HIV AIDS. 2018 Jan;13(1):53–60. doi: 10.1097/COH.0000000000000428.Pinto- Cardoso S, Klatt NR, Reyes- Terán G. Impact of antiretroviral drugs on the microbiome: unknown answers to important questions. Curr Opin HIV AIDS. 2018 Jan;13(1):53–60. doi: 10.1097/COH.0000000000000428.Lozupone CA, Rhodes ME, Neff CP, Fontenot AP, Campbell TB, Palmer BE. HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy. Gut Microbes. 2014 Jul 1;5(4):562– 70. doi: 10.4161/gmic.32132.Lozupone CA, Rhodes ME, Neff CP, Fontenot AP, Campbell TB, Palmer BE. HIV-induced alteration in gut microbiota: driving factors, consequences, and eff ects of antiretroviral therapy. Gut Microbes. 2014 Jul 1;5(4):562– 70. doi: 10.4161/gmic.32132.Balmant BD, Torrinhas RS, Rocha IM, Fonseca DC, Formiga FFC, Bonfá ESDO, Borba EF, Waitzberg DL. SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapyIs there a link? Nutrition. 2021 May;85:111115. doi: 10.1016/j.nut.2020.111115.Balmant BD, Torrinhas RS, Rocha IM, Fonseca DC, Formiga FFC, Bonfá ESDO, Borba EF, Waitzberg DL. SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy- Is there a link? Nutrition. 2021 May;85:111115. doi: 10.1016/j.nut.2020.111115.Maeda Y., Matsushita M., Yura A., et al. OP0191 The Fecal Microbiota of Rheumatoid Arthritis Patients Differs from that of Healthy Volunteers and is Considerably Altered by Treatment with Biologics. Ann Rheum Dis. 2013;72: A117 LP–A117. doi: 10.1136/annrheumdis-2013-eular.396.Maeda Y., Matsushita M., Yura A., et al. OP0191 Th e Fecal Microbiota of Rheumatoid Arthritis Patients Diff ers from that of Healthy Volunteers and is Considerably Altered by Treatment with Biologics. Ann Rheum Dis. 2013;72: A117 LP–A117. doi: 10.1136/annrheumdis-2013-eular.396.Janiri D, Kotzalidis GD, Giuseppin G, Molinaro M, Modica M, Montanari S, Terenzi B, Carfì A, Landi F, Sani G; Gemelli Against COVID-19 Post-acute Care Study Group. Psychological Distress Aft er Covid-19 Recovery: Reciprocal Eff ects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service. Front Psychiatry. 2020 Nov 12;11:590135. doi: 10.3389/fpsyt.2020.590135.Janiri D, Kotzalidis GD, Giuseppin G, Molinaro M, Modica M, Montanari S, Terenzi B, Carfì A, Landi F, Sani G; Gemelli Against COVID-19 Post-acute Care Study Group. Psychological Distress Aft er Covid-19 Recovery: Reciprocal Eff ects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service. Front Psychiatry. 2020 Nov 12;11:590135. doi: 10.3389/fpsyt.2020.590135.Ju Y, Chen W, Liu J, Yang A, Shu K, Zhou Y, Wang M, Huang M, Liao M, Liu J, Liu B, Zhang Y. Effects of centralized isolation vs. home isolation on psychological distress in patients with COVID-19. J Psychosom Res. 2021 Apr;143:110365. doi: 10.1016/j.jpsychores.2021.110365.Ju Y, Chen W, Liu J, Yang A, Shu K, Zhou Y, Wang M, Huang M, Liao M, Liu J, Liu B, Zhang Y. Eff ects of centralized isolation vs. home isolation on psychological distress in patients with COVID-19. J Psychosom Res. 2021 Apr;143:110365. doi: 10.1016/j.jpsychores.2021.110365.Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, Zhang F, Li AYL, Lu W, Hui DS, Chan PK, Chan FKL, Ng SC. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022 Mar;71(3):544–552. doi: 10.1136/gutjnl-2021–325989.Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, Zhang F, Li AYL, Lu W, Hui DS, Chan PK, Chan FKL, Ng SC. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022 Mar;71(3):544–552. doi: 10.1136/gutjnl-2021–325989.Haran JP, Bradley E, Zeamer AL, Cincotta L, Salive MC, Dutta P, Mutaawe S, Anya O, Meza- Segura M, Moormann AM, Ward DV, McCormick BA, Bucci V. Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight. 2021 Oct 22;6(20): e152346. doi: 10.1172/jci.insight.152346.Haran JP, Bradley E, Zeamer AL, Cincotta L, Salive MC, Dutta P, Mutaawe S, Anya O, Meza- Segura M, Moormann AM, Ward DV, McCormick BA, Bucci V. Infl ammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight. 2021 Oct 22;6(20): e152346. doi: 10.1172/jci.insight.152346.Howell MC, Green R, McGill AR, Dutta R, Mohapatra S, Mohapatra SS. SARS-CoV-2-Induced Gut Microbiome Dysbiosis: Implications for Colorectal Cancer. Cancers (Basel). 2021 May 28;13(11):2676. doi: 10.3390/cancers13112676.Howell MC, Green R, McGill AR, Dutta R, Mohapatra S, Mohapatra SS. SARS-CoV-2-Induced Gut Microbiome Dysbiosis: Implications for Colorectal Cancer. Cancers (Basel). 2021 May 28;13(11):2676. doi: 10.3390/cancers13112676.Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020 Jul;77:18–24. doi: 10.1016/j.ejim.2020.05.03.Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020 Jul;77:18–24. doi: 10.1016/j.ejim.2020.05.03.Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 Apr 16;181(2):281–292.e6. doi: 10.1016/j.cell.2020.02.058.Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 Apr 16;181(2):281–292.e6. doi: 10.1016/j.cell.2020.02.058.Al Mahmeed W, Al- Rasadi K, Banerjee Y, Ceriello A, Cosentino F, Galia M, Goh SY, Kempler P, Lessan N, Papanas N, Rizvi AA, Santos RD, Stoian AP, Toth PP, Rizzo M; CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Front Cardiovasc Med. 2021 Dec 15;8:787761. doi: 10.3389/fcvm.2021.787761.Al Mahmeed W, Al- Rasadi K, Banerjee Y, Ceriello A, Cosentino F, Galia M, Goh SY, Kempler P, Lessan N, Papanas N, Rizvi AA, Santos RD, Stoian AP, Toth PP, Rizzo M; CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Front Cardiovasc Med. 2021 Dec 15;8:787761. doi: 10.3389/fcvm.2021.787761.Ugwueze C. V., Ezeokpo B. C., Nnolim B. I., Agim E. A., Anikpo N. C., Onyekachi K. E. COVID-19 and Diabetes Mellitus: The Link and Clinical Implications. Dubai Diabetes Endocrinol. J. 2020;26:69–77. doi: 10.1159/000511354.Ugwueze C. V., Ezeokpo B. C., Nnolim B. I., Agim E. A., Anikpo N. C., Onyekachi K. E. COVID-19 and Diabetes Mellitus: Th e Link and Clinical Implications. Dubai Diabetes Endocrinol. J. 2020;26:69–77. doi: 10.1159/000511354.Abramczyk U, Nowaczyński M, Słomczyński A, Wojnicz P, Zatyka P, Kuzan A. Consequences of COVID-19 for the Pancreas. Int J Mol Sci. 2022 Jan 13;23(2):864. doi: 10.3390/ijms23020864.Abramczyk U, Nowaczyński M, Słomczyński A, Wojnicz P, Zatyka P, Kuzan A. Consequences of COVID-19 for the Pancreas. Int J Mol Sci. 2022 Jan 13;23(2):864. doi: 10.3390/ijms23020864.Abdel- Gawad M, Zaghloul MS, Abd- Elsalam S, et al. Post- COVID-19 Syndrome Clinical Manifestations: A Systematic Review. Antiinfl amm Antiallergy Agents Med Chem. 2022;21(2):115–120. doi: 10.2174/1871523021666220328115818.Abdel- Gawad M, Zaghloul MS, Abd- Elsalam S, et al. Post- COVID-19 Syndrome Clinical Manifestations: A Systematic Review. Antiinfl amm Antiallergy Agents Med Chem. 2022;21(2):115–120. doi: 10.2174/1871523021666220328115818.Sylvester SV, Rusu R, Chan B, Bellows M, O'Keefe C, Nicholson S. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin. 2022 Aug;38(8):1391–1399. doi: 10.1080/03007995.2022.2081454.Sylvester SV, Rusu R, Chan B, Bellows M, O'Keefe C, Nicholson S. Sex diff erences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin. 2022 Aug;38(8):1391–1399. doi: 10.1080/03007995.2022.2081454.Иванов Д. О., Чернова Т. М., Павлова Е. Б., Тим ченко В. Н., Баракина Е. В. Коронавирусная инфекция. Педиатр. 2020; 11 (3):109–117. doi: 10.17816/PED113109–117.Ivanov D. O., Chernova T. M., Pavlova E. B., Tim chenko V. N., Barakina E. V. Coronaviral infection. Pediatrician (St. Petersburg). 2020;11(3):109–117. (in Russ.) doi: 10.17816/PED113109–117.Горелов А. В., Николаева С. В., Акимкин В. Г. Новая коронавирусная инфекция COVID-19: особенности течения у детей в Российской Федерации. Педиатрия. Журн. им. Г. Н. Сперанского. 2020; 99 (66): 57–62. doi: 10.24110/0031–403X-2020–99–6–57–62.Gorelov A. V., Nikolaeva S. V., Akimkin V. G. New coronavirus infection COVID-19: features of the course in children in the Russian Federation. Pediatria n. a. G. N. Speransky. 2020; 99 (6): 57–62. (in Russ.) doi: 10.24110/0031–403X-2020–99–6–57–62.Александрович Ю. С., Алексеева Е. И., Бакрадзе М. Д., и др. Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19), у детей. Версия 2. Педиатрическая фармакология. 2020;17(3):187–212. doi: 10.15690/pf.v17i3.2123.Alexandrovich Yu.S., Alekseeva E. I., Bakradze M. D., et al. Clinical Features and Management of the Disease Caused by New Coronaviral Infection (COVID-19) in Children. Version 2. Pediatric pharmacology. 2020;17(3):187–212. (In Russ.) doi: 10.15690/pf.v17i3.2123.Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020 Jun;109(6):1088–1095. doi: 10.1111/apa.15270.Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020 Jun;109(6):1088–1095. doi: 10.1111/apa.15270.Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, Vidal E, Cogo P. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020 Jul;179(7):1029–1046. doi: 10.1007/s00431–020–03684–7.Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, Vidal E, Cogo P. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020 Jul;179(7):1029–1046. doi: 10.1007/s00431–020–03684–7.Новикова В. П., Хавкин А. И., Горелов А. В., Полунина А. В. Ось «легкие–кишечник» и COVID-инфекция. Инфекционные болезни. 2021; 19(1): 91–96. doi: 10.20953/1729–9225–2021–1–91–96.Novikova V. P., Khavkin A. I., Gorelov A. V., Polu nina A. V. The lung-gut axis and COVID-19. Infekc. bolezni = Infectious diseases. 2021; 19(1): 91–96. (in Russ.) doi: 10.20953/1729–9225–2021–1–91–96.Maglietta G, Diodati F, Puntoni M, Lazzarelli S, Marcomini B, Patrizi L, Caminiti C. Prognostic Factors for PostCOVID-19 Syndrome: A Systematic Review and MetaAnalysis. J Clin Med. 2022 Mar 11;11(6):1541. doi: 10.3390/jcm11061541.Maglietta G, Diodati F, Puntoni M, Lazzarelli S, Marcomini B, Patrizi L, Caminiti C. Prognostic Factors for PostCOVID-19 Syndrome: A Systematic Review and MetaAnalysis. J Clin Med. 2022 Mar 11;11(6):1541. doi: 10.3390/jcm11061541.Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes aft er hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Th orax. 2021 Apr;76(4):399–401. doi: 10.1136/thoraxjnl-2020–216086.Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes aft er hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Th orax. 2021 Apr;76(4):399–401. doi: 10.1136/thoraxjnl-2020–216086.O'Mahoney L. L., Routen A., Gillies C., et al. Th e prevalence and long-term health eff ects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.O'Mahoney L. L., Routen A., Gillies C., et al. Th e prevalence and long-term health eff ects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.Yusuf F, Fahriani M, Mamada SS, et al. Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: A systematic review and meta-analysis. F1000Res. 2021 Apr 19;10:301. doi: 10.12688/f1000research.52216.1.Yusuf F, Fahriani M, Mamada SS, et al. Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: A systematic review and meta-analysis. F1000Res. 2021 Apr 19;10:301. doi: 10.12688/f1000research.52216.1.Samanta J, Singh S, Kumar S, Sharma M, Kochhar R. Gastrointestinal sequelae among COVID-19 patients aft er discharge and their predictors. Dig Liver Dis. 2022 May;54(5):580–582. doi: 10.1016/j.dld.2022.02.002. Epub 2022 Feb 14. PMID: 35216903; PMCID: PMC8841162.Samanta J, Singh S, Kumar S, Sharma M, Kochhar R. Gastrointestinal sequelae among COVID-19 patients aft er discharge and their predictors. Dig Liver Dis. 2022 May;54(5):580–582. doi: 10.1016/j.dld.2022.02.002. Epub 2022 Feb 14. PMID: 35216903; PMCID: PMC8841162.Rizvi A, Patel Z, Liu Y, Satapathy SK, Sultan K, Trinda de AJ; Northwell Health COVID-19 Research Consortium. Gastrointestinal Sequelae 3 and 6 Months Aft er Hospitalization for Coronavirus Disease 2019. Clin Gastroenterol Hepatol. 2021 Nov;19(11):2438–2440.e1. doi: 10.1016/j.cgh.2021.06.046.Rizvi A, Patel Z, Liu Y, Satapathy SK, Sultan K, Trinda de AJ; Northwell Health COVID-19 Research Consortium. Gastrointestinal Sequelae 3 and 6 Months Aft er Hospitalization for Coronavirus Disease 2019. Clin Gastroenterol Hepatol. 2021 Nov;19(11):2438–2440.e1. doi: 10.1016/j.cgh.2021.06.046.Blackett JW, Wainberg M, Elkind MSV, Freedberg DE. Potential Long Coronavirus Disease 2019 Gastro intestinal Symptoms 6 Months Aft er Coronavirus Infection Are Associated With Mental Health Symptoms. Gastroenterology. 2022 Feb;162(2):648–650.e2. doi: 10.1053/j.gastro.2021.10.040.Blackett JW, Wainberg M, Elkind MSV, Freedberg DE. Potential Long Coronavirus Disease 2019 Gastro intestinal Symptoms 6 Months Aft er Coronavirus Infection Are Associated With Mental Health Symptoms. Gastroenterology. 2022 Feb;162(2):648–650.e2. doi: 10.1053/j.gastro.2021.10.040.Al- Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021 Jun;594(7862):259–264. doi: 10.1038/s41586–021–03553–9.Al- Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021 Jun;594(7862):259–264. doi: 10.1038/s41586–021–03553–9.Полунина А. В., Шакмаева М. А., Иванов Д. О., и др. Гастроэнтерологические симптомы при новой коронавирусной инфекции у детей зависят от цитокинового статуса. В сборнике: Актуальные проблемы абдоминальной патологии у детей. Под общей редакцией проф. С. В. Бельмера и проф. Л. И. Ильенко. 2022:66–68Polunina A. V., Shakmaeva M. A., Ivanov D. O., et al. [Gastroenterological symptoms in a new coronavirus infection in children depend on the cytokine status. In the collection: Actual problems of abdominal pathology in children]. edd. S. V. Belmer and prof. L. I. Ilyenko. 2022, pp. 66–68. (in Russ.)Попова Р. В., Руженцова Т. А., Хавкина Д. А., Чухляев П. В., Гарбузов А. А., Мешкова Н. А. Нарушения функции желудочно- кишечного тракта при COVID-19 у детей. Проблемы особо опасных инфекций. 2020;(3):154–157. doi: 10.21055/0370–1069–2020–3–154–157.Popova R. V., Ruzhentsova T. A., Khavkina D. A., Chukhlyaev P. V., Garbuzov A. A., Meshkova N. A. Gastrointestinal Tract Disorders in COVID-19 Infected Children. Problems of Particularly Dangerous Infections. 2020;(3):154–157. (In Russ.) doi: 10.21055/0370–1069–2020–3–154–157.Gupta R, Beg S, Jain A, Bhatnagar S. Paediatric COVID-19 and the GUT. Indian J Med Microbiol. 2020 Jul- Dec;38(3 & 4): 261–264. doi: 10.4103/ijmm.IJMM_20_331.Gupta R, Beg S, Jain A, Bhatnagar S. Paediatric COVID-19 and the GUT. Indian J Med Microbiol. 2020 Jul- Dec;38(3 & 4): 261–264. doi: 10.4103/ijmm.IJMM_20_331.Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr. 2021 MayJun;15(3):869–875. doi: 10.1016/j.dsx.2021.04.007.Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr. 2021 MayJun;15(3):869–875. doi: 10.1016/j.dsx.2021.04.007.Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, Bontempo G, Marrella F, Tommasini A, Fabris M, Curcio F, Isola M, Tascini C. Post- COVID-19 symptoms 6 months aft er acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021 Oct;27(10):1507–1513. doi: 10.1016/j.cmi.2021.05.033.Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, Bontempo G, Marrella F, Tommasini A, Fabris M, Curcio F, Isola M, Tascini C. Post- COVID-19 symptoms 6 months aft er acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021 Oct;27(10):1507–1513. doi: 10.1016/j.cmi.2021.05.033.Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post- Acute Care Study Group. Persistent Symptoms in Patients Aft er Acute COVID-19. JAMA. 2020 Aug 11;324(6):603–605. doi: 10.1001/jama.2020.12603.Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post- Acute Care Study Group. Persistent Symptoms in Patients Aft er Acute COVID-19. JAMA. 2020 Aug 11;324(6):603–605. doi: 10.1001/jama.2020.12603.Иванова О. Н. Постковидный синдром у детей. Международный научно- исследовательский журнал. 2021; 9 (111). – 35–39. doi: 10.23670/IRJ.2021.9.111.040.Ivanova O. N. Post-covid syndrome in children. International Research Journal. 2021; 9 (111):35–39. (in Russ.) doi: 10.23670/IRJ.2021.9.111.040.EDN: HQBQXQ. Налетов А. В., Свистунова Н. А., Мацынина Н. И., Сердюкова Д. А. Функциональные гастроинтестинальные расстройства у детей школьного возраста, перенесших COVID-19. Forcipe. 2022; 5(S2):370. EDN: HQBQXQ.Naletov A. V., Svistunova N. A., Macynina N. I., Serdyukova D. A. [Functional gastrointestinal disorders in school-age children survived COVID-19]. FORCIPE, 2022;5(S2): 370. (in Russ.)Mehandru S, Merad M. Pathological sequelae of longhaul COVID. Nat Immunol. 2022 Feb;23(2):194–202. doi: 10.1038/s41590–021–01104-y.Mehandru S, Merad M. Pathological sequelae of longhaul COVID. Nat Immunol. 2022 Feb;23(2):194–202. doi: 10.1038/s41590–021–01104-y.Bogariu AM, Dumitrascu DL. Digestive involvement in the Long- COVID syndrome. Med Pharm Rep. 2022 Jan;95(1):5–10. doi: 10.15386/mpr-2340.Bogariu AM, Dumitrascu DL. Digestive involvement in the Long- COVID syndrome. Med Pharm Rep. 2022 Jan;95(1):5–10. doi: 10.15386/mpr-2340.Joshee S, Vatti N, Chang C. Long- Term Effects of COVID-19. Mayo Clin Proc. 2022 Mar;97(3):579–599. doi: 10.1016/j.mayocp.2021.12.017.Joshee S, Vatti N, Chang C. Long- Term Effects of COVID-19. Mayo Clin Proc. 2022 Mar;97(3):579–599. doi: 10.1016/j.mayocp.2021.12.017.Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M, Rodríguez- Jiménez M, Montoya N, Zapata E; Post- COVID study group, Monsalve DM, AcostaAmpudia Y, Ramírez- Santana C. Post- COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021 Nov;20(11):102947. doi: 10.1016/j.autrev.2021.102947.Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M, Rodríguez- Jiménez M, Montoya N, Zapata E; Post- COVID study group, Monsalve DM, AcostaAmpudia Y, Ramírez- Santana C. Post- COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021 Nov;20(11):102947. doi: 10.1016/j.autrev.2021.102947.Sisó- Almirall A, Brito- Zerón P, Conangla Ferrín L, Kostov B, Moragas Moreno A, Mestres J, Sellarès J, Galindo G, Morera R, Basora J, Trilla A, RamosCasals M, On Behalf Of Th e CAMFiC Long Covid- Study Group. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int J Environ Res Public Health. 2021 Apr 20;18(8):4350. doi: 10.3390/ijerph18084350.Sisó- Almirall A, Brito- Zerón P, Conangla Ferrín L, Kostov B, Moragas Moreno A, Mestres J, Sellarès J, Galindo G, Morera R, Basora J, Trilla A, RamosCasals M, On Behalf Of Th e CAMFiC Long Covid- Study Group. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int J Environ Res Public Health. 2021 Apr 20;18(8):4350. doi: 10.3390/ijerph18084350.Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, Ma WL, Wang X. Th ree-month Follow-up Study of Survivors of Coronavirus Disease 2019 aft er Discharge. J Korean Med Sci. 2020 Dec 7;35(47): e418. doi: 10.3346/jkms.2020.35.e418.Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, Ma WL, Wang X. Th ree-month Follow-up Study of Survivors of Coronavirus Disease 2019 aft er Discharge. J Korean Med Sci. 2020 Dec 7;35(47): e418. doi: 10.3346/jkms.2020.35.e418.Vorobyev P., Vorobiev A., Darmodekhina D. Report on postcovid syndrome in the CIS *and other countries with a Russian speaking population. 2020. (Available at: https://drive.google.com/file/d/1Z9LY72WbuYOtS4zmwQrdXpbXKplHRafU/view Accessed: 05.05.2022.)Vorobyev P., Vorobiev A., Darmodekhina D. Report on postcovid syndrome in the CIS *and other countries with a Russian speaking population. 2020. (Available at: https://drive.google.com/file/d/1Z9LY72WbuYOtS4zmwQrdXpbXKplHRafU/view Accessed: 05.05.2022.)Шилов С. Н. Постковидный синдром: поражения системы пищеварения и возможности профилактики. Материалы Всероссийской научно- практической конференции «Наука и социум», no. XIX, 2022, pp. 157–160. doi: 10.38163/978–5–6046740–7–9_2022_157.Shilov S. N. Post-covid syndrome: digestive system defects and opportunities for prevention. Science and society. 2022;(XIX):157–160. (in Russ.) doi: 10.38163/978–5–6046740–7–9_2022_157.Турчина М. С., Мишина А. С., Веремейчик А. Л., Резников Р. Г. Клинические особенности поражения желудочно- кишечного тракта у больных с новой коронавирусной инфекцией COVID-19. Актуальные проблемы медицины. 2020;44 (1): 5–15. doi: 10.18413/2687–0940–2021–44–1–5–15.Turchina M. S., Mishina A. S., Veremeichik A. L., Reznikov R. G. Clinical features of gastrointestinal tract damage in pations with new coronaviral infection COVID-19. Challenges in modern medicine. 2020;44 (1): 5–15 (in Russ.). doi: 10.18413/2687–0940–2021–44–1–5–15.Сахоненко Л. В., Мокшина М. В. Клинические особенности поражения желудочно- кишечного тракта при новой коронавирусной инфекции (COVID-19). Тихоокеанский медицинский журнал. 2021;(2):99–100. doi: 10.34215/1609–1175–2021–2–99–100.Sakhonenko L. V., Mokshina M. V. Clinical features of the gastrointestinal tract lesion in patients with a new coronavirus infection (COVID-19). Pacifi c Medical Journal. 2021;(2):99–100. (In Russ.) doi: 10.34215/1609–1175–2021–2–99–100.Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020 May;5(5):428–430. doi: 10.1016/S2468–1253(20)30057–1.Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020 May;5(5):428–430. doi: 10.1016/S2468–1253(20)30057–1.Fierro NA. COVID-19 and the liver: What do we know aft er six months of the pandemic? Ann Hepatol. 2020 NovDec;19(6):590–591. doi: 10.1016/j.aohep.2020.09.001.Fierro NA. COVID-19 and the liver: What do we know aft er six months of the pandemic? Ann Hepatol. 2020 NovDec;19(6):590–591. doi: 10.1016/j.aohep.2020.09.001.Ridruejo E, Soza A. Th e liver in times of COVID-19: What hepatologists should know. Ann Hepatol. 2020 JulAug;19(4):353–358. doi: 10.1016/j.aohep.2020.05.001.Ridruejo E, Soza A. Th e liver in times of COVID-19: What hepatologists should know. Ann Hepatol. 2020 JulAug;19(4):353–358. doi: 10.1016/j.aohep.2020.05.001.Полунина А. В., Дудурич В. В., Данилов Л. Г., Блинов А. Е., Варламова О. Н., Баннова С. Л., Балашов А. Л., Новикова В. П. Особенности кишечного микробиома у детей при новой коронавирусной инфекции. Медицина.Теория и практика.2022; 4:- 63–67. doi: 10.56871/MTP.2022.97.91.007.Polunina A. V., Dudurich V. V., Danilov L. G., et al. Features of the intestinal microbiome in children with a new coronavirus infection. Medicine: theory and practice. 2022;(4):63–67. (in Russ.) doi: 10.56871/MTP.2022.97.91.007.Полунина А. В., Новикова В. П., Блинов А. Е., и др. Уровень зонулина при инфекции Сovid-19 у детей. Пилотное исследование. Инфекционные болезни.2022; 3: 56–6112.Polunina A. V., Novikova V. P., Blinov A. E., et al. Zonulin levels in children with Covid-19 infection. Pilot study. Infectious diseases.2022; 3:56–6112.Jiang G, Cai Y, Yi X, Li Y, Lin Y, Li Q, Xu J, Ke M, Xue K. Th e impact of laryngopharyngeal refl ux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: A retrospective study. J Med Virol. 2020 Oct;92(10):2124– 2129. doi: 10.1002/jmv.25998.Jiang G, Cai Y, Yi X, Li Y, Lin Y, Li Q, Xu J, Ke M, Xue K. Th e impact of laryngopharyngeal refl ux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: A retrospective study. J Med Virol. 2020 Oct;92(10):2124– 2129. doi: 10.1002/jmv.25998.Weng J, Li Y, Li J, Shen L, Zhu L, Liang Y, Lin X, Jiao N, Cheng S, Huang Y, Zou Y, Yan G, Zhu R, Lan P. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol Hepatol. 2021 May;- 6(5): 344–346. doi: 10.1016/S2468–1253(21)00076–5.Weng J, Li Y, Li J, Shen L, Zhu L, Liang Y, Lin X, Jiao N, Cheng S, Huang Y, Zou Y, Yan G, Zhu R, Lan P. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol Hepatol. 2021 May;- 6(5): 344–346. doi: 10.1016/S2468–1253(21)00076–5.Пахомова И. Г. Пациент с ГЭРБ после перенесенной новой коронавирусной инфекции. Рациональная фармакотерапия на клиническом примере. РМЖ. 2021;6:18–22.Pakhomova I. G. Patient with GERD aft er a new coronavirus infection. Rational pharmacotherapy in clinical case. RMJ. 2021;6:18–22 (in Russ.)Marasco G, Lenti MV, Cremon C, Barbaro MR, Stanghellini V, Di Sabatino A, Barbara G. Implications of SARS-CoV-2 infection for neurogastroenterology. Neurogastroenterol Motil. 2021 Mar;33(3): e14104. doi: 10.1111/nmo.14104.Marasco G, Lenti MV, Cremon C, Barbaro MR, Stanghellini V, Di Sabatino A, Barbara G. Implications of SARS-CoV-2 infection for neurogastroenterology. Neurogastroenterol Motil. 2021 Mar;33(3): e14104. doi: 10.1111/nmo.14104.Oshima T, Siah KTH, Yoshimoto T, Miura K, Tomita T, Fukui H, Miwa H. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population- based survey. J Gastroenterol Hepatol. 2021 Jul;36(7):1820–1827. doi: 10.1111/jgh.15346.Oshima T, Siah KTH, Yoshimoto T, Miura K, Tomita T, Fukui H, Miwa H. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population- based survey. J Gastroenterol Hepatol. 2021 Jul;36(7):1820–1827. doi: 10.1111/jgh.15346.Kamp KJ, Levy RL, Munson SA, Heitkemper MM. Impact of COVID-19 on Individuals With Irritable Bowel Syndrome and Comorbid Anxiety and/or Depression. J Clin Gastroenterol. 2022 Feb 1;56(2): e149-e152. doi: 10.1097/MCG.0000000000001515.Kamp KJ, Levy RL, Munson SA, Heitkemper MM. Impact of COVID-19 on Individuals With Irritable Bowel Syndrome and Comorbid Anxiety and/or Depression. J Clin Gastroenterol. 2022 Feb 1;56(2): e149-e152. doi: 10.1097/MCG.0000000000001515.Pérez Roldán F, Malik Javed Z, Yagüe Compadre JL, Navarro López MDC, Rodríguez- Bobada Caraballo D, Fernández Visier I, Burgos Andeliz M, González Carro PS. Gastric ulcers with upper gastrointestinal bleeding in patients with severe SARS-CoV-2. Rev Esp Enferm Dig. 2021 Feb;113(2):122–124. doi: 10.17235/reed.2021.7759/2020.Pérez Roldán F, Malik Javed Z, Yagüe Compadre JL, Navarro López MDC, Rodríguez- Bobada Caraballo D, Fernández Visier I, Burgos Andeliz M, González Carro PS. Gastric ulcers with upper gastrointestinal bleeding in patients with severe SARS-CoV-2. Rev Esp Enferm Dig. 2021 Feb;113(2):122–124. doi: 10.17235/reed.2021.7759/2020.Shih AR, Misdraji J. COVID-19: gastrointestinal and hepatobiliary manifestations. Hum Pathol. 2022 Jul 16: S0046– 8177(22)00179–4. doi: 10.1016/j.humpath.2022.07.006.Shih AR, Misdraji J. COVID-19: gastrointestinal and hepatobiliary manifestations. Hum Pathol. 2022 Jul 16: S0046– 8177(22)00179–4. doi: 10.1016/j.humpath.2022.07.006.Khanna S, Pardi DS, Aronson SL, Kammer PP, Oren stein R, St Sauver JL, Harmsen WS, Zinsmeister AR. Th e epidemiology of community- acquired Clostridium diffi cile infection: a population- based study. Am J Gastroenterol. 2012 Jan;107(1):89–95. doi: 10.1038/ajg.2011.398.Khanna S, Pardi DS, Aronson SL, Kammer PP, Oren stein R, St Sauver JL, Harmsen WS, Zinsmeister AR. Th e epidemiology of community- acquired Clostridium diffi cile infection: a population- based study. Am J Gastroenterol. 2012 Jan;107(1):89–95. doi: 10.1038/ajg.2011.398.Issa I, Moucari R. Probiotics for antibiotic- associated diarrhea: do we have a verdict? World J Gastroenterol. 2014 Dec 21;20(47):17788–95. doi: 10.3748/wjg.v20.i47.17788.Issa I, Moucari R. Probiotics for antibiotic- associated diarrhea: do we have a verdict? World J Gastroenterol. 2014 Dec 21;20(47):17788–95. doi: 10.3748/wjg.v20.i47.17788.Шляпников С. А., Насер Н. Р., Батыршин И. М., Боро дина М. А., Склизков Д. С., Остроумова Ю. С., Рязанова Е. П. Антибиотик- ассоциированный колит – новая проблема в хирургии. Вестник НМХЦ им. Н. И. Пирогова. 2020;15(2):138–143. doi: 10.25881/BPNMSC.2020.62.96.024.Shlyapnikov S. A., Naser N. R., Batyrshin I. M., Borodina M. A., Sklizkov D. S., Ostroumova Yu.S., Ryazanova E. P. The Antibiotic- associated Colitis is a new problem in surgery. Bulletin of Pirogov National Medical & Surgical Center. 2020;15(2):138–143. (In Russ.) doi: 10.25881/BPNMSC.2020.62.96.024.Ивашкин В. Т., Ющук Н. Д., Маев И. В., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению Clostridium diffi cileассоциированной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(5):56–65. doi: 10.22416/1382–4376–2016–26–5–56–65.Ivashkin V. T., Yushchuk N. D., Mayev I. V., et al. Diagnostics and treatment of Clostridium difficileassociated disease: Guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5):56–65. (In Russ.) doi: 10.22416/1382–4376–2016–26–5–56–65.Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. doi: 10.1016/S0140–6736(20)30566–3.Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. doi: 10.1016/S0140–6736(20)30566–3.Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3;71(9):2459–2468. doi: 10.1093/cid/ciaa530.Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3;71(9):2459–2468. doi: 10.1093/cid/ciaa530.Ding Q, Lu P, Fan Y, Xia Y, Liu M. Th e clinical characteristics of pneumonia patients coinfected with 2019 novel corona virus and infl uenza virus in Wuhan, China. J Med Virol. 2020 Sep;92(9):1549–1555. doi: 10.1002/jmv.25781.Ding Q, Lu P, Fan Y, Xia Y, Liu M. Th e clinical characteristics of pneumonia patients coinfected with 2019 novel corona virus and infl uenza virus in Wuhan, China. J Med Virol. 2020 Sep;92(9):1549–1555. doi: 10.1002/jmv.25781.Sandhu A, Tillotson G, Polistico J, Salimnia H, Cranis M, Moshos J, Cullen L, Jabbo L, Diebel L, Chopra T. Clostridioides diffi cile in COVID-19 Patients, Detroit, Michigan, USA, March- April 2020. Emerg Infect Dis. 2020 Sep; 26(9):2272–4. doi: 10.3201/eid2609.202126.Sandhu A, Tillotson G, Polistico J, Salimnia H, Cranis M, Moshos J, Cullen L, Jabbo L, Diebel L, Chopra T. Clostridioides diffi cile in COVID-19 Patients, Detroit, Michigan, USA, March- April 2020. Emerg Infect Dis. 2020 Sep; 26(9):2272–4. doi: 10.3201/eid2609.202126.Maslennikov R, Ivashkin V, Ufi mtseva A, Poluektova E, Ulyanin A. Clostridioides diffi cile co-infection in patients with COVID-19. Future Microbiol. 2022 Jun;17:653–663. doi: 10.2217/fmb-2021–0145.Maslennikov R, Ivashkin V, Ufi mtseva A, Poluektova E, Ulyanin A. Clostridioides diffi cile co-infection in patients with COVID-19. Future Microbiol. 2022 Jun;17:653–663. doi: 10.2217/fmb-2021–0145.Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, Khare S, Srivastava A. Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis. Indian J Gastroenterol. 2020 Jun;39(3):268–284. doi: 10.1007/s12664–020–01058–3.Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, Khare S, Srivastava A. Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis. Indian J Gastroenterol. 2020 Jun;39(3):268–284. doi: 10.1007/s12664–020–01058–3.Dong ZY, Xiang BJ, Jiang M, Sun MJ, Dai C. Th e Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta- Analysis. J Clin Gastroenterol. 2021 Jan;55(1):67–76. doi: 10.1097/MCG.0000000000001424.Dong ZY, Xiang BJ, Jiang M, Sun MJ, Dai C. Th e Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta- Analysis. J Clin Gastroenterol. 2021 Jan;55(1):67–76. doi: 10.1097/MCG.0000000000001424.Wang H, Qiu P, Liu J, Wang F, Zhao Q. Th e liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2020 Oct;44(5):653–661. doi: 10.1016/j.clinre.2020.04.012.Wang H, Qiu P, Liu J, Wang F, Zhao Q. Th e liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2020 Oct;44(5):653–661. doi: 10.1016/j.clinre.2020.04.012.Wong YJ, Tan M, Zheng Q, Li JW, Kumar R, Fock KM, Teo EK, Ang TL. A systematic review and meta-analysis of the COVID-19 associated liver injury. Ann Hepatol. 2020 Nov- Dec;19(6):627–634. doi: 10.1016/j.aohep.2020.08.064.Wong YJ, Tan M, Zheng Q, Li JW, Kumar R, Fock KM, Teo EK, Ang TL. A systematic review and meta-analysis of the COVID-19 associated liver injury. Ann Hepatol. 2020 Nov- Dec;19(6):627–634. doi: 10.1016/j.aohep.2020.08.064.Wu Y, Li H, Guo X, Yoshida EM, Mendez- Sanchez N, Levi Sandri GB, Teschke R, Romeiro FG, Shukla A, Qi X. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):621–637. doi: 10.1007/s12072–020–10074–6.Wu Y, Li H, Guo X, Yoshida EM, Mendez- Sanchez N, Levi Sandri GB, Teschke R, Romeiro FG, Shukla A, Qi X. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):621–637. doi: 10.1007/s12072–020–10074–6.Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, Talukdar R, Sharma M, Qi X, Rao PN, Reddy DN. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Th er. 2020 Aug;52(4):584–599. doi: 10.1111/apt.15916.Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, Talukdar R, Sharma M, Qi X, Rao PN, Reddy DN. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Th er. 2020 Aug;52(4):584–599. doi: 10.1111/apt.15916.Лазебник Л. Б., Тарасова Л. В., Комарова Е. А., Цыга нова Ю. В., Бусалаева Е. И., Барсукова Е. В., Орешникова С. Ф., Орешников А. В. Изменение концентрации аммиака и других биохимических показателей у пациентов с новой коронавирусной инфекцией. Экспериментальная и клиническая гастроэнтерология. 2021;(4):76–83. doi: 10.31146/1682–8658-ecg-188–4–76–83.Lazebnik L. B., Tarasova L. V., Komarova E. A., Tsyga nova Yu. V., Busalaeva E. I., Вarsukova E. V., Oreshnikova.F., Oreshnikov A. V. Change in concentration of ammonia and other biochemical indicators in patients with new coronaviral infection. Experimental and Clinical Gastroenterology. 2021;(4):76–83. (In Russ.) doi: 10.31146/1682–8658-ecg-188–4–76–83.Лазебник Л. Б., Голованова Е. В., Алексеенко С. А., и др. Российский консенсус «Гипераммониемии у взрослых». Экспериментальная и клиническая гастроэнтерология. 2019;172(12): 4–23. doi: 10.31146/1682–8658-ecg-172–12–4–23.Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Russian Consensus “Hyperammonemia in Adults”. Experimen tal and Clinical Gastroenterology. 2019;(12):4–23. (In Russ.) doi: 10.31146/1682–8658-ecg-172–12–4–23.Гриневич В. Б., Кравчук Ю. А., Педь В. И., и др. Ведение пациентов с заболеваниями органов пищеварения в период пандемии COVID-19.Клинические рекомендации Российского научного медицинского общества терапевтов и Научного общества гастроэнтерологов России (2-е издание). Экспериментальная и клиническая гастроэнтерология. 2021;(3):5–82. doi: 10.31146/1682–8658-ecg-187–3–5–82.Grinevich V. B., Kravchuk Yu.A., Ped V. I., et al. Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientific medical society of internal medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (2nd edition). Experimental and Clinical Gastroenterology. 2021;(3):5–82. (In Russ.) doi: 10.31146/1682–8658-ecg-187–3–5–82.Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy Aft er Severe COVID-19: Clinical Features and Prognostic Implications. Am J Gastroenterol. 2021 Jul 1;116(7):1414– 1425. doi: 10.14309/ajg.0000000000001264.Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy Aft er Severe COVID-19: Clinical Features and Prognostic Implications. Am J Gastroenterol. 2021 Jul 1;116(7):1414– 1425. doi: 10.14309/ajg.0000000000001264.Liao X, Li D, Ma Z, Zhang L, Zheng B, Li Z, Li G, Liu L, Zhang Z. 12-Month Post- Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single- Center Prospective Cohort Study. Front Cell Infect Microbiol. 2022 Apr 14;12:864933. doi: 10.3389/fcimb.2022.864933.Liao X, Li D, Ma Z, Zhang L, Zheng B, Li Z, Li G, Liu L, Zhang Z. 12-Month Post- Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single- Center Prospective Cohort Study. Front Cell Infect Microbiol. 2022 Apr 14;12:864933. doi: 10.3389/fcimb.2022.864933.Radzina M, Putrins DS, Micena A, Vanaga I, Kolesova O, Platkajis A, Viksna L. Post- COVID-19 Liver Injury: Comprehensive Imaging With Multiparametric Ultrasound. J Ultrasound Med. 2022 Apr;41(4):935–949. doi: 10.1002/jum.15778.Radzina M, Putrins DS, Micena A, Vanaga I, Kolesova O, Platkajis A, Viksna L. Post- COVID-19 Liver Injury: Comprehensive Imaging With Multiparametric Ultrasound. J Ultrasound Med. 2022 Apr;41(4):935–949. doi: 10.1002/jum.15778.Milic J, Barbieri S, Gozzi L, et al. Metabolic- Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis. 2022 Jan 10;9(3): ofac003. doi: 10.1093/ofid/ofac003.Milic J, Barbieri S, Gozzi L, et al. Metabolic- Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis. 2022 Jan 10;9(3): ofac003. doi: 10.1093/ofid/ofac003.Bobermin LD, Quincozes- Santos A. COVID-19 and hyperammonemia: Potential interplay between liver and brain dysfunctions. Brain Behav Immun Health. 2021 Jul;14:100257. doi: 10.1016/j.bbih.2021.100257.Bobermin LD, Quincozes- Santos A. COVID-19 and hyperammonemia: Potential interplay between liver and brain dysfunctions. Brain Behav Immun Health. 2021 Jul;14:100257. doi: 10.1016/j.bbih.2021.100257.Nersesjan V, Fonsmark L, Christensen RHB, Amiri M, Merie C, Lebech AM, Katzenstein T, Bang LE, Kjærgaard J, Kondziella D, Benros ME. Neuropsychiatric and Cognitive Outcomes in Patients 6 Months Aft er COVID-19 Requiring Hospitalization Compared With Matched Control Patients Hospitalized for Non- COVID-19 Illness. JAMA Psychiatry. 2022 May 1;79(5):486–497. doi: 10.1001/jamapsychiatry.2022.0284.Nersesjan V, Fonsmark L, Christensen RHB, Amiri M, Merie C, Lebech AM, Katzenstein T, Bang LE, Kjærgaard J, Kondziella D, Benros ME. Neuropsychiatric and Cognitive Outcomes in Patients 6 Months Aft er COVID-19 Requiring Hospitalization Compared With Matched Control Patients Hospitalized for Non- COVID-19 Illness. JAMA Psychiatry. 2022 May 1;79(5):486–497. doi: 10.1001/jamapsychiatry.2022.0284.Pistarini C, Fiabane E, Houdayer E, Vassallo C, Manera MR, Alemanno F. Cognitive and Emotional Disturbances Due to COVID-19: An Exploratory Study in the Rehabilitation Setting. Front Neurol. 2021 May 17;12:643646. doi: 10.3389/fneur.2021.643646.Pistarini C, Fiabane E, Houdayer E, Vassallo C, Manera MR, Alemanno F. Cognitive and Emotional Disturbances Due to COVID-19: An Exploratory Study in the Rehabilitation Setting. Front Neurol. 2021 May 17;12:643646. doi: 10.3389/fneur.2021.643646.Rass V, Beer R, Schiefecker AJ, et al. Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. Eur J Neurol. 2021 Oct;28(10):3348–3359. doi: 10.1111/ene.14803Rass V, Beer R, Schiefecker AJ, et al. Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. Eur J Neurol. 2021 Oct;28(10):3348–3359. doi: 10.1111/ene.14803Лазебник Л. Б., Туркина С. В., Мязин Р. Г., Тарасова Л. В., Ермолова Т. В., Кожевникова С. А., Абдулгани ева Д. И. Эффективность L-орнитин L-аспартата (LOLA) для коррекции когнитивных и гепатотропных расстройств в постковидном периоде: результаты многоцентрового проспективного наблюдательного исследования «Клиническое значение гипераммониемии у пациентов с постковидным синдромом (ЛИРА – COVID)». Экспериментальная и клиническая гастроэнтерология. 2022;207(11): 5–16. doi: 10.31146/1682–8658-ecg-207–11–5–16.Lazebnik L. B., Turkina S. V., Myazin R. G., Tarasova L. V., Ermolova T. V., Kozhevnikova S. A., Abdulganieva D. I. Results of a multicenter prospective observational study “Clinical signifi cance of hyperammonemia in patients with post- Covid syndrome (LIRA – COVID)”: effi cacy of L-ornithine L-aspartate. Experimental and Clinical Gastroenterology. 2022;207(11):5–16. (In Russ.) doi: 10.31146/1682–8658-ecg-207–11–5–16.Roth NC, Kim A, Vitkovski T, Xia J, Ramirez G, Bernstein D, Crawford JM. Post- COVID-19 Cholangiopathy: A Novel Entity. Am J Gastroenterol. 2021 May 1;116(5):1077–1082. doi: 10.14309/ajg.0000000000001154.Roth NC, Kim A, Vitkovski T, Xia J, Ramirez G, Bernstein D, Crawford JM. Post- COVID-19 Cholangiopathy: A Novel Entity. Am J Gastroenterol. 2021 May 1;116(5):1077–1082. doi: 10.14309/ajg.0000000000001154.Rojas M, Rodríguez Y, Zapata E, Hernández JC, Anaya JM. Cholangiopathy as part of post- COVID syndrome. J Transl Autoimmun. 2021;4:100116. doi: 10.1016/j.jtauto.2021.100116.Rojas M, Rodríguez Y, Zapata E, Hernández JC, Anaya JM. Cholangiopathy as part of post- COVID syndrome. J Transl Autoimmun. 2021;4:100116. doi: 10.1016/j.jtauto.2021.100116.Bethineedi LD, Suvvari TK. Post COVID-19 cholangiopathy –A deep dive. Dig Liver Dis. 2021 Oct;53(10):1235– 1236. doi: 10.1016/j.dld.2021.08.001.Bethineedi LD, Suvvari TK. Post COVID-19 cholangiopathy –A deep dive. Dig Liver Dis. 2021 Oct;53(10):1235– 1236. doi: 10.1016/j.dld.2021.08.001.Kulkarni AV, Khelgi A, Sekaran A, et al. Post- COVID-19 Cholestasis: A Case Series and Review of Literature. J Clin Exp Hepatol. 2022 Nov- Dec;12(6):1580–1590. doi: 10.1016/j.jceh.2022.06.004.Kulkarni AV, Khelgi A, Sekaran A, et al. Post- COVID-19 Cholestasis: A Case Series and Review of Literature. J Clin Exp Hepatol. 2022 Nov- Dec;12(6):1580–1590. doi: 10.1016/j.jceh.2022.06.004.Fiore V, Beretta R, De Vito A, Barac A, Maida I, Joeseph Kelvin DD, Piu C, Lai V, Madeddu G, Rubino S, Stevanovic G, Korica S, Babudieri S. Emerging Clinical Features of COVID-19 Related Pancreatitis: Case Reports and Review of the Literature. Front Med (Lausanne). 2022 Jan 18;8:779118. doi: 10.3389/fmed.2021.779118.Fiore V, Beretta R, De Vito A, Barac A, Maida I, Joeseph Kelvin DD, Piu C, Lai V, Madeddu G, Rubino S, Stevanovic G, Korica S, Babudieri S. Emerging Clinical Features of COVID-19 Related Pancreatitis: Case Reports and Review of the Literature. Front Med (Lausanne). 2022 Jan 18;8:779118. doi: 10.3389/fmed.2021.779118.Zhang J, Liu P, Wang M, et al. Th e clinical data from 19 critically ill patients with coronavirus disease 2019: a single- centered, retrospective, observational study. Z Gesundh Wiss. 2022;30(2):361–364. doi: 10.1007/s10389–020–01291–2.Zhang J, Liu P, Wang M, et al. Th e clinical data from 19 critically ill patients with coronavirus disease 2019: a single- centered, retrospective, observational study. Z Gesundh Wiss. 2022;30(2):361–364. doi: 10.1007/s10389–020–01291–2.Inamdar S, Benias PC, Liu Y, Sejpal DV, Satapathy SK, Trindade AJ; Northwell COVID-19 Research Consor tium. Prevalence, Risk Factors, and Outcomes of Hospitalized Patients With Coronavirus Disease 2019 Presenting as Acute Pancreatitis. Gastroenterology. 2020 Dec;159(6):2226–2228.e2. doi: 10.1053/j.gastro.2020.08.044.Inamdar S, Benias PC, Liu Y, Sejpal DV, Satapathy SK, Trindade AJ; Northwell COVID-19 Research Consor tium. Prevalence, Risk Factors, and Outcomes of Hospitalized Patients With Coronavirus Disease 2019 Presenting as Acute Pancreatitis. Gastroenterology. 2020 Dec;159(6):2226–2228.e2. doi: 10.1053/j.gastro.2020.08.044.Dirweesh A, Li Y, Trikudanathan G, Mallery JS, Freeman ML, Amateau SK. Clinical Outcomes of Acute Pancreatitis in Patients With Coronavirus Disease 2019. Gastro enterology. 2020 Nov;159(5):1972–1974. doi: 10.1053/j.gastro.2020.07.038.Dirweesh A, Li Y, Trikudanathan G, Mallery JS, Freeman ML, Amateau SK. Clinical Outcomes of Acute Pancreatitis in Patients With Coronavirus Disease 2019. Gastro enterology. 2020 Nov;159(5):1972–1974. doi: 10.1053/j.gastro.2020.07.038.Wang K, Luo J, Tan F, Liu J, Ni Z, Liu D, Tian P, Li W. Acute Pancreatitis as the Initial Manifestation in 2 Cases of COVID-19 in Wuhan, China. Open Forum Infect Dis. 2020 Aug 7;7(9): ofaa324. doi: 10.1093/ofid/ofaa324.Wang K, Luo J, Tan F, Liu J, Ni Z, Liu D, Tian P, Li W. Acute Pancreatitis as the Initial Manifestation in 2 Cases of COVID-19 in Wuhan, China. Open Forum Infect Dis. 2020 Aug 7;7(9): ofaa324. doi: 10.1093/ofid/ofaa324.Kumaran NK, Karmakar BK, Taylor OM. Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP). BMJ Case Rep. 2020 Sep 7;13(9): e237903. doi: 10.1136/bcr-2020–237903.Kumaran NK, Karmakar BK, Taylor OM. Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP). BMJ Case Rep. 2020 Sep 7;13(9): e237903. doi: 10.1136/bcr-2020–237903.Alves AM, Yvamoto EY, Marzinotto MAN, Teixeira ACS, Carrilho FJ. SARS-CoV-2 leading to acute pancreatitis: an unusual presentation. Braz J Infect Dis. 2020 NovDec;24(6):561–564. doi: 10.1016/j.bjid.2020.08.011.Alves AM, Yvamoto EY, Marzinotto MAN, Teixeira ACS, Carrilho FJ. SARS-CoV-2 leading to acute pancreatitis: an unusual presentation. Braz J Infect Dis. 2020 NovDec;24(6):561–564. doi: 10.1016/j.bjid.2020.08.011.Маев И. В., Шпектор А. В., Васильева Е. Ю., Манчуров В. Н., Андреев Д. Н. Новая коронавирусная инфекция COVID-19: экстрапульмональные проявления. Терапевтический архив. 2020;92(8):4–11. doi: 10.26442/00403660.2020.08.000767.Maev I. V., Shpektor A. V., Vasilyeva E. Y., Manchurov V. N., Andreev D. N. Novel coronavirus infection COVID-19: extrapulmonary manifestations. Tera pev ticheskii arkhiv. 2020;92(8):4–11. (in Russ.) doi: 10.26442/00403660.2020.08.000767.Balthazar JA, Chehter EZ. Acute pancreatitis and COVID-19: a new target for infection? Einstein (Sao Paulo). 2022 Feb 21;20: eRW6667. doi: 10.31744/einstein_journal/2022RW6667.Balthazar JA, Chehter EZ. Acute pancreatitis and COVID-19: a new target for infection? Einstein (Sao Paulo). 2022 Feb 21;20: eRW6667. doi: 10.31744/einstein_journal/2022RW6667.Szatmary P, Arora A, Thomas Raraty MG, Joseph Dunne DF, Baron RD, Halloran CM. Emerging Phenotype of Severe Acute Respiratory Syndrome- Coronavirus 2-associated Pancreatitis. Gastroenterology. 2020 Oct;159(4):1551–1554. doi: 10.1053/j.gastro.2020.05.069.Szatmary P, Arora A, Thomas Raraty MG, Joseph Dunne DF, Baron RD, Halloran CM. Emerging Phenotype of Severe Acute Respiratory Syndrome- Coronavirus 2-associated Pancreatitis. Gastroenterology. 2020 Oct;159(4):1551–1554. doi: 10.1053/j.gastro.2020.05.069.Bruno G, Fabrizio C, Santoro CR, Buccoliero GB. Pancreatic injury in the course of coronavirus disease 2019: A not-so-rare occurrence. J Med Virol. 2021 Jan;93(1):74–75. doi: 10.1002/jmv.26134.Bruno G, Fabrizio C, Santoro CR, Buccoliero GB. Pancreatic injury in the course of coronavirus disease 2019: A not-so-rare occurrence. J Med Virol. 2021 Jan;93(1):74–75. doi: 10.1002/jmv.26134.Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage Aft er SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020 Aug;18(9):2128–2130.e2. doi: 10.1016/j.cgh.2020.04.040.Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage Aft er SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020 Aug;18(9):2128–2130.e2. doi: 10.1016/j.cgh.2020.04.040.Bacaksız F, Ebik B, Ekin N, Kılıc J. Pancreatic damage in COVID-19: Why? How? Int J Clin Pract. 2021 Oct;75(10): e14692. doi: 10.1111/ijcp.14692.Bacaksız F, Ebik B, Ekin N, Kılıc J. Pancreatic damage in COVID-19: Why? How? Int J Clin Pract. 2021 Oct;75(10): e14692. doi: 10.1111/ijcp.14692.Almutairi F, Rabeie N, Awais A, Samannodi M, Aljehani N, Tayeb S, Elsayad W. COVID-19 induced acute pancreatitis aft er resolution of the infection. J Infect Public Health. 2022 Mar;15(3):282–284. doi: 10.1016/j.jiph.2022.01.003.Almutairi F, Rabeie N, Awais A, Samannodi M, Aljehani N, Tayeb S, Elsayad W. COVID-19 induced acute pancreatitis aft er resolution of the infection. J Infect Public Health. 2022 Mar;15(3):282–284. doi: 10.1016/j.jiph.2022.01.003.Abdel- Moneim A. COVID-19-associated pancreatic dysfunction. Hong Kong Med J. 2021 Apr;27(2):157–159. doi: 10.12809/hkmj209056.Abdel- Moneim A. COVID-19-associated pancreatic dysfunction. Hong Kong Med J. 2021 Apr;27(2):157–159. doi: 10.12809/hkmj209056.McNabb- Baltar J, Jin DX, Grover AS, Redd WD, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Shen L, Chan WW. Lipase Elevation in Patients With COVID-19. Am J Gastroenterol. 2020 Aug;115(8):1286–1288. doi: 10.14309/ajg.0000000000000732.McNabb- Baltar J, Jin DX, Grover AS, Redd WD, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Shen L, Chan WW. Lipase Elevation in Patients With COVID-19. Am J Gastroenterol. 2020 Aug;115(8):1286–1288. doi: 10.14309/ajg.0000000000000732.de- Madaria E, Siau K, Cárdenas- Jaén K. Increased Amylase and Lipase in Patients With COVID-19 Pneumonia: Don't Blame the Pancreas Just Yet! Gastroenterology. 2021 Apr;160(5):1871. doi:10.1053/j.gastro.2020.04.044.de- Madaria E, Siau K, Cárdenas- Jaén K. Increased Amylase and Lipase in Patients With COVID-19 Pneumonia: Don't Blame the Pancreas Just Yet! Gastroenterology. 2021 Apr;160(5):1871. doi: 10.1053/j.gastro.2020.04.044.Tositti G, Fabris P, Barnes E, et al. Pancreatic hyperamylasemia during acute gastroenteritis: incidence and clinical relevance. BMC Infect Dis. 2001;1:18. doi: 10.1186/1471–2334–1–18.Tositti G, Fabris P, Barnes E, et al. Pancreatic hyperamylasemia during acute gastroenteritis: incidence and clinical relevance. BMC Infect Dis. 2001;1:18. doi: 10.1186/1471–2334–1–18.Pieper- Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am. 1990 Dec;19(4):793–810. PMID: 1702756.Pieper- Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am. 1990 Dec;19(4):793–810. PMID: 1702756.Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence- based guidelines for the management of acute pancreatitis. Pancreatology. 2013 Jul- Aug;13 (4 Suppl 2): e1–15. doi: 10.1016/j.pan.2013.07.063.Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence- based guidelines for the management of acute pancreatitis. Pancreatology. 2013 Jul- Aug;13 (4 Suppl 2): e1–15. doi: 10.1016/j.pan.2013.07.063.Lamprecht B. Gibt es ein Post- COVID-Syndrom? [Is there a post- COVID syndrome?]. Pneumologe (Berl). 2020;17(6):398–405. German. doi: 10.1007/s10405–020–00347–0.Lamprecht B. Gibt es ein Post- COVID-Syndrom? [Is there a post- COVID syndrome?]. Pneumologe (Berl). 2020;17(6):398–405. German. doi: 10.1007/s10405–020–00347–0.Sisó- Almirall A, Brito- Zerón P, Conangla Ferrín L, Kostov B, Moragas Moreno A, Mestres J, Sellarès J, Galindo G, Morera R, Basora J, Trilla A, RamosCasals M, On Behalf Of Th e CAMFiC Long Covid- Study Group. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int J Environ Res Public Health. 2021 Apr 20;18(8):4350. doi: 10.3390/ijerph18084350.Sisó- Almirall A, Brito- Zerón P, Conangla Ferrín L, Kostov B, Moragas Moreno A, Mestres J, Sellarès J, Galindo G, Morera R, Basora J, Trilla A, RamosCasals M, On Behalf Of Th e CAMFiC Long Covid- Study Group. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int J Environ Res Public Health. 2021 Apr 20;18(8):4350. doi: 10.3390/ijerph18084350.Гриневич В. Б., Кравчук Ю. А., Ткаченко Е. И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19. Экспериментальная и клиническая гастроэнтерология. 2020;176 (4).3–18. doi: 10.31146/1682–8658ecg-176–4–3–18.Grinevich V. B., Kravchuk Yu. A., et al. Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic. Experimental and Clinical Gastroenterology. 2020; 174(4): 3–18. (In Russ.) doi:10.31146/1682–8658ecg-176–4–3–18.Matysiak- Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Th er. 2003 Jul;18 Suppl 1:55–62. doi: 10.1046/j.1365–2036.18.s1.6.x.Matysiak- Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Th er. 2003 Jul;18 Suppl 1:55–62. doi: 10.1046/j.1365–2036.18.s1.6.x.Shim S, Jang HS, Myung HW, Myung JK, Kang JK, Kim MJ, Lee SB, Jang WS, Lee SJ, Jin YW, Lee SS, Park S. Rebamipide ameliorates radiation- induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017 Aug 15;329:40–47. doi: 10.1016/j.taap.2017.05.012.Shim S, Jang HS, Myung HW, Myung JK, Kang JK, Kim MJ, Lee SB, Jang WS, Lee SJ, Jin YW, Lee SS, Park S. Rebamipide ameliorates radiation- induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017 Aug 15;329:40–47. doi: 10.1016/j.taap.2017.05.012.Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta- Analysis. Dig Dis Sci. 2018 May;63(5):1250–1260. doi: 10.1007/s10620–017–4871–9.Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta- Analysis. Dig Dis Sci. 2018 May;63(5):1250–1260. doi: 10.1007/s10620–017–4871–9.Zhou Q, Verne ML, Fields JZ, Lefante JJ, Basra S, Salameh H, Verne GN. Randomised placebo- controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019 Jun;68(6):996–1002. doi: 10.1136/gutjnl-2017–315136.Zhou Q, Verne ML, Fields JZ, Lefante JJ, Basra S, Salameh H, Verne GN. Randomised placebo- controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019 Jun;68(6):996–1002. doi: 10.1136/gutjnl-2017–315136.Wen X, Chen X, Zhou X. [Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 May;34(5):457–160. Chinese. PMID: 19483297.Wen X, Chen X, Zhou X. [Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 May;34(5):457–160. Chinese. PMID: 19483297.Yasuda T, Chiba H, Satomi T, Matsuo A, Kaneko T, Chikazu D, Miyamatsu H. Preventive eff ect of rebamipide gargle on chemoradiotherpy- induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res. 2012 Jan 1;2(4): e3. doi: 10.5037/jomr.2011.2403.Yasuda T, Chiba H, Satomi T, Matsuo A, Kaneko T, Chikazu D, Miyamatsu H. Preventive eff ect of rebamipide gargle on chemoradiotherpy- induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res. 2012 Jan 1;2(4): e3. doi: 10.5037/jomr.2011.2403.Akagi S, Fujiwara T, Nishida M, Okuda A, Nagao Y, Okuda T, Tokuda H, Takayanagi K. Th e eff ectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy- induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019 Jul 25;5:16. doi: 10.1186/s40780–019–0146–2.Akagi S, Fujiwara T, Nishida M, Okuda A, Nagao Y, Okuda T, Tokuda H, Takayanagi K. Th e eff ectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy- induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019 Jul 25;5:16. doi: 10.1186/s40780–019–0146–2.Hong SJ, Park SH, Moon JS, et al. The Benefits of Combination Th erapy with Esomeprazole and Rebamipide in Symptom Improvement in Refl ux Esophagitis: An International Multicenter Study. Gut Liver. 2016 Nov 15; 10(6): 910–916. doi: 10.5009/gnl15537.Hong SJ, Park SH, Moon JS, et al. The Benefits of Combination Th erapy with Esomeprazole and Rebamipide in Symptom Improvement in Refl ux Esophagitis: An International Multicenter Study. Gut Liver. 2016 Nov 15; 10(6): 910–916. doi: 10.5009/gnl15537.Takeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012 Jun;28(3):259–63. doi: 10.1089/jop.2011.0142.Takeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012 Jun;28(3):259–63. doi: 10.1089/jop.2011.0142.Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Effi cacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double- blind, placebocontrolled study. Drugs R D. 2003;4(1):19–28. doi: 10.2165/00126839–200304010–00002.Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Effi cacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double- blind, placebocontrolled study. Drugs R D. 2003;4(1):19–28. doi: 10.2165/00126839–200304010–00002.Kim GH, Lee HL, Joo MK, et al. Effi cacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, DoubleBlind, Active Control, Noninferiority, Multicenter, Phase 3 Study. Gut Liver. 2021 Nov 15;15(6):841–850. doi: 10.5009/gnl20338.Kim GH, Lee HL, Joo MK, et al. Effi cacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, DoubleBlind, Active Control, Noninferiority, Multicenter, Phase 3 Study. Gut Liver. 2021 Nov 15;15(6):841–850. doi: 10.5009/gnl20338.Ратникова А. К., Гриневич В. Б., Ратников В. А., Козлов К. В., Горелов В. П., Кравчук Ю. А. Значение показателей кишечной проницаемости, состояния микробиоты в развитии гастроэнтерологических проявлений при лечении больных новой коронавирусной инфекцией (COVID-19). Врач, 2022; (1): 80–88. doi: 10.29296/25877305–2022–01–14.Ratnikova A. K., Grinevich V. B., Ratnikov V. A., Kozlov K. V., Gorelov V. P., Kravchuk Yu. A. Signifi cance of indicators of intestinal permeability, the state of the microbiota in the development of gastroenterological manifestations in the treatment of patients with a new coronavirus infection (COVID-19). Vrach (Th e Doctor). 2022;(1):80–88. (in Russ.) doi: 10.29296/25877305–2022–01–14.Asha D. Patel, N. K. Prajapati. Review on Biochemical Importance of Vitamin- U. Journal of Chemical and Pharmaceutical Research. 2012;4(1):209–215.Asha D. Patel, N. K. Prajapati. Review on Biochemical Importance of Vitamin- U. Journal of Chemical and Pharmaceutical Research. 2012;4(1):209–215.Ichikawa T, Ito Y, Saegusa Y, Iwai T, Goso Y, Ikezawa T, Ishihara K. Eff ects of combination treatment with famotidine and methylmethionine sulfonium chloride on the mucus barrier of rat gastric mucosa. J Gastroenterol Hepatol. 2009 Mar;24(3):488–92. doi: 10.1111/j.1440–1746.2008.05667.x.Ichikawa T, Ito Y, Saegusa Y, Iwai T, Goso Y, Ikezawa T, Ishihara K. Eff ects of combination treatment with famotidine and methylmethionine sulfonium chloride on the mucus barrier of rat gastric mucosa. J Gastroenterol Hepatol. 2009 Mar;24(3):488–92. doi: 10.1111/j.1440–1746.2008.05667.x.Харкевич Д. А. Фармакология. ГЭОТАР-МЕДИА, Москва, 10-е издание, 2010. с. 475.Kharkevich D. A. Pharmacology. 10th edition. Moscow, GEOTAR-MEDIA, 2010. 475 P. (in Russ.)Kim WS, Seo HM, Kim WK, Choi JS, Kim I, Sung JH. Th e Photoprotective Eff ect of S-Methylmethionine Sulfonium in Skin. Int J Mol Sci. 2015 Jul 28;16(8):17088–100. doi: 10.3390/ijms160817088.Kim WS, Seo HM, Kim WK, Choi JS, Kim I, Sung JH. Th e Photoprotective Eff ect of S-Methylmethionine Sulfonium in Skin. Int J Mol Sci. 2015 Jul 28;16(8):17088–100. doi: 10.3390/ijms160817088.Ивашкин В. Т., Маев И. В., Трухманов А. С., Ла пина Т. Л., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. doi: 10.22416/1382–4376–2020–30–4–70–97.Ivashkin V. T., Maev I. V., Trukhmanov A. S., et al. Re commen dations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Refl ux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020; 30(4):70–97. (In Russ.) doi: 10.22416/1382–4376–2020–30–4–70–97.Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019 May 8;14(5): e0216750. doi: 10.1371/journal.pone.0216750.Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019 May 8;14(5): e0216750. doi: 10.1371/journal.pone.0216750.Zhou J, Li C, Zhao G, Chu H, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017 Nov 15;3(11): eaao4966. doi: 10.1126/sciadv.aao4966.Zhou J, Li C, Zhao G, Chu H, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017 Nov 15;3(11): eaao4966. doi: 10.1126/sciadv.aao4966.Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol. 2020 Oct;115(10):1707–1715. doi: 10.14309/ajg.0000000000000798.Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol. 2020 Oct;115(10):1707–1715. doi: 10.14309/ajg.0000000000000798.Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021 Jan;70(1):76–84. doi: 10.1136/gutjnl-2020–322248.Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021 Jan;70(1):76–84. doi: 10.1136/gutjnl-2020–322248.Kow CS, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Intern Med. 2021 Jan;289(1):125–128. doi: 10.1111/joim.13183.Kow CS, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Intern Med. 2021 Jan;289(1):125–128. doi: 10.1111/joim.13183.Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, Tuveson D. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut. 2020 Sep;69(9):1592–1597. doi: 10.1136/gutjnl-2020–321852.Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, Tuveson D. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut. 2020 Sep;69(9):1592–1597. doi: 10.1136/gutjnl-2020–321852.Мороз Е. В., Каратеев А. Е. Ингибиторы протонной помпы и риск развития пневмонии: насколько опасно использовать эти препараты в период пандемии. Терапия. 2021; 1: 78–82. doi: 10.18565/therapy.2021.1.78–82.Moroz E. V., Karateev A. E. Proton pump inhibitors and the risk of pneumonia: how dangerous is it to use these drugs during the COVID-19 pandemic? Th erapy. 2021; 1: 78–82. (in Russ.) doi: 10.18565/therapy.2021.1.78–82.Patel P, Sengupta N. PPIs and Beyond: A Framework for Managing Anticoagulation- Related Gastrointestinal Bleeding in the Era of COVID-19. Dig Dis Sci. 2020 Aug;65(8):2181–2186. doi: 10.1007/s10620–020–06408-x.Patel P, Sengupta N. PPIs and Beyond: A Framework for Managing Anticoagulation- Related Gastrointestinal Bleeding in the Era of COVID-19. Dig Dis Sci. 2020 Aug;65(8):2181–2186. doi: 10.1007/s10620–020–06408-x.Gadiparthi C, Perisetti A, Sayana H, Tharian B, Inamdar S, Korman A. Gastrointestinal Bleeding in Patients with Severe SARS-CoV-2. Am J Gastroenterol. 2020 Aug;115(8):1283–1285. doi: 10.14309/ajg.0000000000000719.Gadiparthi C, Perisetti A, Sayana H, Tharian B, Inamdar S, Korman A. Gastrointestinal Bleeding in Patients with Severe SARS-CoV-2. Am J Gastroenterol. 2020 Aug;115(8):1283–1285. doi: 10.14309/ajg.0000000000000719.Lo CH, Ni P, Yan Y, Ma W, Joshi AD, Nguyen LH, Mehta RS, Lochhead P, Song M, Curhan GC, Cao Y, Chan AT. Association of Proton Pump Inhibitor Use With All- Cause and Cause- Specifi c Mortality. Gastroenterology. 2022 Oct;163(4):852–861.e2. doi:10.1053/j.gastro.2022.06.067.Lo CH, Ni P, Yan Y, Ma W, Joshi AD, Nguyen LH, Mehta RS, Lochhead P, Song M, Curhan GC, Cao Y, Chan AT. Association of Proton Pump Inhibitor Use With All- Cause and Cause- Specifi c Mortality. Gastroenterology. 2022 Oct;163(4):852–861.e2. doi: 10.1053/j.gastro.2022.06.067.Ивашкин В. Т., Трухманов А. С., Гоник М. И. Применение ребамипида в лечении гастроэзофагеальной рефлюксной болезни Терапевтический архив 4, 2020 doi: 10.26442/00403660.2020.04.000568.Ivashkin VT, Trukhmanov AS, Gonik MI. [Rebamipide using in gastroesophageal refl ux disease treatment]. Ter Arkh. 2020 May 19;92(4):98–104. Russian. doi: 10.26442/00403660.2020.04.000568.Soon Man Yoon et al. The Effect of Rebamipide in Patients with Gastroesophageal Refl ux Disease, Including NonErosive Refl ux Disease: A Multi- Center, Randomized, Single- Blind, Placebo- Controlled Study. AGA Abstracts. 2019;156(6, S1): S-5.Soon Man Yoon et al. The Effect of Rebamipide in Patients with Gastroesophageal Refl ux Disease, Including NonErosive Refl ux Disease: A Multi- Center, Randomized, Single- Blind, Placebo- Controlled Study. AGA Abstracts. 2019;156(6, S1): S-5.Gweon TG, Park JH, Kim BW, Choi YK, Kim JS, Park SM, Kim CW, Kim HG, Chung JW; Incheon and Western Kyonggi Gastrointestinal Study. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro- Esophageal Refl ux Disease. Gut Liver. 2018 Jan 15;12(1):46–50. doi: 10.5009/gnl17078.Gweon TG, Park JH, Kim BW, Choi YK, Kim JS, Park SM, Kim CW, Kim HG, Chung JW; Incheon and Western Kyonggi Gastrointestinal Study. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro- Esophageal Refl ux Disease. Gut Liver. 2018 Jan 15;12(1):46–50. doi: 10.5009/gnl17078.Kim JW, Jeong Y, Park SJ, Jin H, Lee J, Ju JH, Ji GE, Park SH. Infl uence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatology (Oxford). 2021 Feb 1;60(2):708–716. doi: 10.1093/rheumatology/keaa316.Kim JW, Jeong Y, Park SJ, Jin H, Lee J, Ju JH, Ji GE, Park SH. Infl uence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatology (Oxford). 2021 Feb 1;60(2):708–716. doi: 10.1093/rheumatology/keaa316.Yoshida N, Kamada K, Tomatsuri N, Suzuki T, Takagi T, Ichikawa H, Yoshikawa T. Management of recurrence of symptoms of gastroesophageal refl ux disease: synergistic eff ect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010 Dec;55(12):3393–8. doi: 10.1007/s10620–010–1166–9.Yoshida N, Kamada K, Tomatsuri N, Suzuki T, Takagi T, Ichikawa H, Yoshikawa T. Management of recurrence of symptoms of gastroesophageal refl ux disease: synergistic eff ect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010 Dec;55(12):3393–8. doi: 10.1007/s10620–010–1166–9.Гриневич В. Б. Пребиотическая коррекция микробнотканевого комплекса кишечника, как базовая составляющая современной патогенетической терапии метаболического синдрома и ассоциированных кардиоваскулярных и цереброваскулярных заболеваний. Учебно- методическое пособие / В. Б. Гриневич, Е. И. Сас, В. Е. Кон [и др.]. – СПб., 2012. – 20 с.Grinevich VB, Sas VE, Kon, et al. [Prebiotic correction of the intestinal microbial- tissue complex as a basic component of modern pathogenetic therapy of metabolic syndrome and associated cardiovascular and cerebrovascular diseases]. SPb., 2012, 20 P. (in Russ.)Ивашкин В. Т., Маев И. В., Каприн А. Д. и др. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Рос журн гастроэнтерол гепатол колопроктол. – 2019. – Т. 29, № 5. – С. 53–74. doi: 10.22416/13824376–2019–29–5–53–74.Ivashkin V. T., Mayev I. V., Kaprin A. D., et al. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(5):53–74. (In Russ.) doi: 10.22416/13824376–2019–29–5–53–74.World Gastroenterology Organisation Global Guidelines ‘Probiotics and Prebiotics’. 2017 Feb. Available at: http://www.worldgastroenterology.org/guidelines/globalguidelines/probiotics-and-prebiotics/probiotics-andprebiotics-english (Accessed 10 August 2020).World Gastroenterology Organisation Global Guidelines ‘Probiotics and Prebiotics’. 2017 Feb. Available at: http://www.worldgastroenterology.org/guidelines/globalguidelines/probiotics-and-prebiotics/probiotics-andprebiotics-english (Accessed 10 August 2020).Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клини ческие рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол колопроктол. –2018.–Т. 28, № 1.– С. 55–70. doi: 10.22416/1382–4376–2018–28–1–55–70.Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55–70. (In Russ.) doi: 10.22416/1382–4376–2018–28–1–55–70.Ивашкин В. Т., Маев И. В., Лапина Т. Л., Федоров Е. Д., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):70–99. doi: 10.22416/1382–4376–2021–31–4–70–99.Ivashkin V. T., Maev I. V., Lapina T. L., Fedorov E. D., et al. Clinical Recommendations of Russian Gastroentero logical Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70–99. (In Russ.) doi:10.22416/1382–4376–2021–31–4–70–99.Simadibrata M. et al. Anti free radical &anti infl ammatory eff ect of rebamipide in chronic gastritis. Open Journal of Gastroenterology. 2013;(3):72–77. doi: 10.4236/ojgas.2013.31011.Simadibrata M. et al. Anti free radical &anti infl ammatory eff ect of rebamipide in chronic gastritis. Open Journal of Gastroenterology. 2013;(3):72–77. doi: 10.4236/ojgas.2013.31011.Otani K, Tanigawa T, Watanabe T, Shimada S, Nadatani Y, Nagami Y, Tanaka F, Kamata N, Yamagami H, Shiba M, Tominaga K, Fujiwara Y, Arakawa T. Microbiota Plays a Key Role in Non- Steroidal Anti- Infl ammatory DrugInduced Small Intestinal Damage. Digestion. 2017;- 95(1):22–28. doi: 10.1159/000452356.Otani K, Tanigawa T, Watanabe T, Shimada S, Nadatani Y, Nagami Y, Tanaka F, Kamata N, Yamagami H, Shiba M, Tominaga K, Fujiwara Y, Arakawa T. Microbiota Plays a Key Role in Non- Steroidal Anti- Infl ammatory DrugInduced Small Intestinal Damage. Digestion. 2017;- 95(1):22–28. doi: 10.1159/000452356.Симаненков В. И., Бакулина Н. В., Филь Т. С., Хубиева А. Х. Оценка эффективности эрадикации Н. Pylori при добавлении к схеме лечения цитопротективного препарата ребамипид: результаты исследования Бастион. Фарматека. – 2017. – S5. – C. 65–70.Simanenkov V. I., Bakulina N. V., Fil Т. S., Khu bi e va A. Kh. Evaluation of effi ciency of H. Pylori eradication in case of addition of cytoprotective preparation rebamipide to the treatment: results of the bastion trial. Farmateka. 2017: S5;65–70. (in Russ.)Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Th erapy for Helicobacter pylori Infection: Meta- Analysis of Randomized Controlled Studies. J Clin Med. 2019 Sep 19; 8(9): 1498. doi: 10.3390/jcm8091498.Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Th erapy for Helicobacter pylori Infection: Meta- Analysis of Randomized Controlled Studies. J Clin Med. 2019 Sep 19; 8(9): 1498. doi: 10.3390/jcm8091498.Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Лечение инфекции Helicobacter pylori: мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Рос журн гастроэнтерол гепатол колопроктол. – 2017. – Т. 27, № 4. – С. 4–21. doi: 10.22416/1382–4376–2017–27–4–4–21.Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):4–21. (In Russ.) doi: 10.22416/1382–4376–2017–27–4–4–21.Каратеев А. Е., Насонов Е. Л., Ивашкин В. Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно- практическая ревматология. – 2018. – № 56. – С. 1–29. doi: 10.14412/19954484–2018–1–29.Karateev A. E., Nasonov E. L., Ivashkin V. T., et al. Rational use of nonsteroidal anti-infl ammatory drugs. Clinical guide lines. Rheumatology Science and Practice. 2018;- 56:1–29. (In Russ.) doi: 10.14412/19954484–2018–1–29.Лазебник Л. Б., Голованова Е. В., Алексеенко С. А. и др. Рекомендации по профилактике и лечению эзофагогастро- энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами. Экспериментальная и клиническая гастроэнтерология. – 2018. – № 151(03). – С. 04–18.Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Recommendations for the prevention and treatment of esophago- gastro-entero- colopathy induced by nonsteroidal antiinfl ammatory drugs “NSAID”. Experimental and Clinical Gastroenterology. 2018;(3):4–18. (In Russ.)Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):261–70. doi: 10.1586/egh.10.25.Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):261–70. doi: 10.1586/egh.10.25.Song DU, Ryu MH, Chay KO, Jung YD, Yang SY, Cha SH, Lee MW, Ahn BW. Eff ect of rebamipide on the glycos aminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol. 1998;12(5):546–52. doi: 10.1111/j.1472–8206.1998.tb00984.x.Song DU, Ryu MH, Chay KO, Jung YD, Yang SY, Cha SH, Lee MW, Ahn BW. Eff ect of rebamipide on the glycos aminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol. 1998;12(5):546–52. doi: 10.1111/j.1472–8206.1998.tb00984.x.Suzuki T, Yoshida N, Nakabe N, Isozaki Y, Kajikawa H, Takagi T, Handa O, Kokura S, Ichikawa H, Naito Y, Matsui H, Yoshikawa T. Prophylactic eff ect of rebamipide on aspirin- induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008 Mar;106(3):469–77. doi:10.1254/jphs.fp0071422.Suzuki T, Yoshida N, Nakabe N, Isozaki Y, Kajikawa H, Takagi T, Handa O, Kokura S, Ichikawa H, Naito Y, Matsui H, Yoshikawa T. Prophylactic eff ect of rebamipide on aspirin- induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008 Mar;106(3):469–77. doi: 10.1254/jphs.fp0071422.Ивашкин В. Т., Шелыгин Ю. А., Баранская Е. К., Ачкасов С. И., и др. Синдром раздраженного кишечника. Колопроктология. 2022;21(1):10–25. doi: 10.33878/2073–7556–2022–21–1–10–25.Ivashkin V. T., Shelygin Y. A., Baranskaya E. K., Achkasov S. I., et al. Irritable bowel syndrome. Koloproktologia. 2022;21(1):10–25. doi: 10.33878/2073–7556–2022–21–1–10–25.Гриневич В. Б., Кравчук Ю. А., Сас Е. И. Эволюция понятия микробно- тканевого комплекса кишечника. Экспериментальная и клиническая гастроэнтерология. 2020;183(11):4–10. doi: 10.31146/1682–8658-ecg-183–11–4–10.Grinevich V. B., Kravchuk Yu.A., Sas E. I. The evolution of the concept of the intestinal microbial- tissue complex. Experimental and Clinical Gastroenterology. 2020;183(11):4–10. (In Russ.) doi: 10.31146/1682–8658-ecg-183–11–4–10.Monsour HP Jr, Quigley EM. Th e Microbiome: What Will the Future Hold? Semin Liver Dis. 2016 Sep;36(4):354– 359. doi: 10.1055/s-0036–1594009.Monsour HP Jr, Quigley EM. Th e Microbiome: What Will the Future Hold? Semin Liver Dis. 2016 Sep;36(4):354– 359. doi: 10.1055/s-0036–1594009.Андреев Н. Г. Коррекция изменений кишечной микробиоты как компонент терапии заболеваний желудочно- кишечного тракта. Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2018; 2: 29–32. doi: 10.26442/26583739.2018.2.000002.Andreev N. G. Correction of the intestinal microbiota changes as a component of gastrointestinal diseases treatment. Gastroenterology. Surgery. Intensive care. Consilium Medicum. 2018; 2: 29–32. doi: 10.26442/26583739.2018.2.000002. (In Russ.)Ивашкин В. Т., Маев И. В., Абдулганиева Д. И., и др. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков, пребиотиков, синбиотиков и обогащенных ими функциональных пищевых продуктов для лечения и профилактики заболеваний гастроэнтерологического профиля у детей и взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(2):65–91. doi: 10.22416/1382–4376–2021–31–2–65–91.Ivashkin V. T., Maev I. V., Abdulganieva D. I., et al. Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(2):65–91. (In Russ.) doi: 10.22416/1382–4376–2021–31–2–65–91.Hu J, Zhang L, Lin W, Tang W, Chan FKL, Ng SC. Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic. Trends Food Sci Technol. 2021 Feb;108:187–196. doi: 10.1016/j.tifs.2020.12.009.Hu J, Zhang L, Lin W, Tang W, Chan FKL, Ng SC. Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic. Trends Food Sci Technol. 2021 Feb;108:187–196. doi: 10.1016/j.tifs.2020.12.009.Wang Y, Wu G, Zhao L, Wang W. Nutritional Modulation of Gut Microbiota Alleviates Severe Gastrointestinal Symptoms in a Patient with Post- Acute COVID-19 Syndrome. mBio. 2022 Apr 26;13(2): e0380121. doi: 10.1128/mbio.03801–21. Epub 2022 Mar 7. PMID: 35254129; PMCID: PMC9040862.Wang Y, Wu G, Zhao L, Wang W. Nutritional Modulation of Gut Microbiota Alleviates Severe Gastrointestinal Symptoms in a Patient with Post- Acute COVID-19 Syndrome. mBio. 2022 Apr 26;13(2): e0380121. doi: 10.1128/mbio.03801–21. Epub 2022 Mar 7. PMID: 35254129; PMCID: PMC9040862.Devaux CA, Lagier JC, Raoult D. New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness. Front Med (Lausanne). 2021 Feb 18;8:640073. doi: 10.3389/fmed.2021.640073.Devaux CA, Lagier JC, Raoult D. New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness. Front Med (Lausanne). 2021 Feb 18;8:640073. doi: 10.3389/fmed.2021.640073.Chakraborty M, Munshi SK. Th e prospects of employing probiotics in combating COVID-19. Tzu Chi Med J. 2021 Oct 5;34(2):148–159. doi: 10.4103/tcmj.tcmj_104_21.Chakraborty M, Munshi SK. Th e prospects of employing probiotics in combating COVID-19. Tzu Chi Med J. 2021 Oct 5;34(2):148–159. doi: 10.4103/tcmj.tcmj_104_21.Alharbi KS, Singh Y, Hassan Almalki W, Rawat S, Afzal O, Alfawaz Altamimi AS, Kazmi I, Al- Abbasi FA, Alzarea SI, Singh SK, Bhatt S, Chellappan DK, Dua K, Gupta G. Gut Microbiota Disruption in COVID-19 or Post- COVID Illness Association with severity biomarkers: A Possible Role of Pre / Pro-biotics in manipulating microfl ora. Chem Biol Interact. 2022 May 1;358:109898. doi: 10.1016/j.cbi.2022.109898.Alharbi KS, Singh Y, Hassan Almalki W, Rawat S, Afzal O, Alfawaz Altamimi AS, Kazmi I, Al- Abbasi FA, Alzarea SI, Singh SK, Bhatt S, Chellappan DK, Dua K, Gupta G. Gut Microbiota Disruption in COVID-19 or Post- COVID Illness Association with severity biomarkers: A Possible Role of Pre / Pro-biotics in manipulating microfl ora. Chem Biol Interact. 2022 May 1;358:109898. doi: 10.1016/j.cbi.2022.109898.Monteagudo- Mera A, Rastall RA, Gibson GR, Cha ralam popoulos D, Chatzifragkou A. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. Appl Microbiol Biotechnol. 2019 Aug;103(16):6463–6472. doi: 10.1007/s00253–019–09978–7.Monteagudo- Mera A, Rastall RA, Gibson GR, Cha ralam popoulos D, Chatzifragkou A. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. Appl Microbiol Biotechnol. 2019 Aug;103(16):6463–6472. doi: 10.1007/s00253–019–09978–7.Lebeer S, Bron PA, Marco ML, Van Pijkeren JP, O'Connell Motherway M, Hill C, Pot B, Roos S, Klaenhammer T. Identifi cation of probiotic eff ector molecules: present state and future perspectives. Curr Opin Biotechnol. 2018 Feb;49:217–223. doi: 10.1016/j.copbio.2017.10.007.Lebeer S, Bron PA, Marco ML, Van Pijkeren JP, O'Connell Motherway M, Hill C, Pot B, Roos S, Klaenhammer T. Identifi cation of probiotic eff ector molecules: present state and future perspectives. Curr Opin Biotechnol. 2018 Feb;49:217–223. doi: 10.1016/j.copbio.2017.10.007.Plaza- Diaz J, Ruiz- Ojeda FJ, Gil- Campos M, Gil A. Mechanisms of Action of Probiotics. Adv Nutr. 2019 Jan 1; 10(suppl_1): S49-S66. doi: 10.1093/advances/nmy063.Plaza- Diaz J, Ruiz- Ojeda FJ, Gil- Campos M, Gil A. Mechanisms of Action of Probiotics. Adv Nutr. 2019 Jan 1; 10(suppl_1): S49-S66. doi: 10.1093/advances/nmy063.Biliavska L, Pankivska Y, Povnitsa O, Zagorodnya S. Antiviral Activity of Exopolysaccharides Produced by Lactic Acid Bacteria of the Genera Pediococcus, Leuconostoc and Lactobacillus against Human Adenovirus Type 5. Medicina (Kaunas). 2019 Aug 22;55(9):519. doi: 10.3390/medicina55090519.Biliavska L, Pankivska Y, Povnitsa O, Zagorodnya S. Antiviral Activity of Exopolysaccharides Produced by Lactic Acid Bacteria of the Genera Pediococcus, Leuconostoc and Lactobacillus against Human Adenovirus Type 5. Medicina (Kaunas). 2019 Aug 22;55(9):519. doi: 10.3390/medicina55090519.Mousavi E, Makvandi M, Teimoori A, Ataei A, Ghafari S, Samarbaf- Zadeh A. Antiviral eff ects of Lactobacillus crispatus against HSV-2 in mammalian cell lines. J Chin Med Assoc. 2018 Mar;81(3):262–267. doi: 10.1016/j.jcma.2017.07.010.Mousavi E, Makvandi M, Teimoori A, Ataei A, Ghafari S, Samarbaf- Zadeh A. Antiviral eff ects of Lactobacillus crispatus against HSV-2 in mammalian cell lines. J Chin Med Assoc. 2018 Mar;81(3):262–267. doi: 10.1016/j.jcma.2017.07.010.Kleerebezem M, Binda S, Bron PA, Gross G, Hill C, van Hylckama Vlieg JE, Lebeer S, Satokari R, Ouwehand AC. Understanding mode of action can drive the translational pipeline towards more reliable health benefi ts for probiotics. Curr Opin Biotechnol. 2019 Apr;56:55–60. doi:10.1016/j.copbio.2018.09.007.Kleerebezem M, Binda S, Bron PA, Gross G, Hill C, van Hylckama Vlieg JE, Lebeer S, Satokari R, Ouwehand AC. Understanding mode of action can drive the translational pipeline towards more reliable health benefi ts for probiotics. Curr Opin Biotechnol. 2019 Apr;56:55–60. doi: 10.1016/j.copbio.2018.09.007.Villena J, Vizoso- Pinto MG, Kitazawa H. Intestinal Innate Antiviral Immunity and Immunobiotics: Beneficial Eff ects against Rotavirus Infection. Front Immunol. 2016 Dec 5; 7: 563. doi: 10.3389/fimmu.2016.00563.Villena J, Vizoso- Pinto MG, Kitazawa H. Intestinal Innate Antiviral Immunity and Immunobiotics: Beneficial Eff ects against Rotavirus Infection. Front Immunol. 2016 Dec 5; 7: 563. doi: 10.3389/fimmu.2016.00563.Arena MP, Capozzi V, Russo P, Drider D, Spano G, Fiocco D. Immunobiosis and probiosis: antimicrobial activity of lactic acid bacteria with a focus on their antiviral and antifungal properties. Appl Microbiol Biotechnol. 2018 Dec; 102(23):9949–9958. doi: 10.1007/s00253–018–9403–9.Arena MP, Capozzi V, Russo P, Drider D, Spano G, Fiocco D. Immunobiosis and probiosis: antimicrobial activity of lactic acid bacteria with a focus on their antiviral and antifungal properties. Appl Microbiol Biotechnol. 2018 Dec; 102(23):9949–9958. doi: 10.1007/s00253–018–9403–9.Eguchi K, Fujitani N, Nakagawa H, Miyazaki T. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055. Sci Rep. 2019 Mar 18;9(1):4812. doi: 10.1038/s41598–019–39602–7.Eguchi K, Fujitani N, Nakagawa H, Miyazaki T. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055. Sci Rep. 2019 Mar 18;9(1):4812. doi: 10.1038/s41598–019–39602–7.Kageyama Y, Nishizaki Y, Aida K, Yayama K, Ebisui T, Akiyama T, Nakamura T. Lactobacillus plantarum induces innate cytokine responses that potentially provide a protective benefi t against COVID-19: A single-arm, double- blind, prospective trial combined with an in vitro cytokine response assay. Exp Th er Med. 2022 Jan;23(1):20. doi: 10.3892/etm.2021.10942.Kageyama Y, Nishizaki Y, Aida K, Yayama K, Ebisui T, Akiyama T, Nakamura T. Lactobacillus plantarum induces innate cytokine responses that potentially provide a protective benefi t against COVID-19: A single-arm, double- blind, prospective trial combined with an in vitro cytokine response assay. Exp Th er Med. 2022 Jan;23(1):20. doi: 10.3892/etm.2021.10942.Ivashkin V, Fomin V, Moiseev S, Brovko M, Maslennikov R, Ulyanin A, Sholomova V, Vasilyeva M, Trush E, Shifrin O, Poluektova E. Efficacy of a Probiotic Con si sting of Lacticaseibacillus rhamnosus PDV 1705, Bifi dobacterium bifi dum PDV 0903, Bifi dobacterium longum subsp. infantis PDV 1911, and Bifi dobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial. Probiotics Antimicrob Proteins. 2021 Oct 13:1–9. doi: 10.1007/s12602–021–09858–5.Ivashkin V, Fomin V, Moiseev S, Brovko M, Maslennikov R, Ulyanin A, Sholomova V, Vasilyeva M, Trush E, Shifrin O, Poluektova E. Efficacy of a Probiotic Con si sting of Lacticaseibacillus rhamnosus PDV 1705, Bifi dobacterium bifi dum PDV 0903, Bifi dobacterium longum subsp. infantis PDV 1911, and Bifi dobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial. Probiotics Antimicrob Proteins. 2021 Oct 13:1–9. doi: 10.1007/s12602–021–09858–5.Angurana SK, Bansal A. Probiotics and Coronavirus disease 2019: think about the link. Br J Nutr. 2021 Nov 28;126(10):1564–1570. doi: 10.1017/S000711452000361X.Angurana SK, Bansal A. Probiotics and Coronavirus disease 2019: think about the link. Br J Nutr. 2021 Nov 28;126(10):1564–1570. doi: 10.1017/S000711452000361X.Tao W, Zhang G, Wang X, Guo M, Zeng W, Xu Z, Cao D, Pan A, Wang Y, Zhang K, Ma X, Chen Z, Jin T, Liu L, Weng J, Zhu S. Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the infl ammatory factor IL-18. Med Microecol. 2020 Sep;5:100023. doi:10.1016/j.medmic.2020.100023.Tao W, Zhang G, Wang X, Guo M, Zeng W, Xu Z, Cao D, Pan A, Wang Y, Zhang K, Ma X, Chen Z, Jin T, Liu L, Weng J, Zhu S. Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the infl ammatory factor IL-18. Med Microecol. 2020 Sep;5:100023. doi: 10.1016/j.medmic.2020.100023.Morais AHA, Passos TS, Maciel BLL, da Silva- Maia JK. Can Probiotics and Diet Promote Benefi cial Immune Modulation and Purine Control in Coronavirus Infection? Nutrients. 2020 Jun 10;12(6):1737. doi: 10.3390/nu12061737.Morais AHA, Passos TS, Maciel BLL, da Silva- Maia JK. Can Probiotics and Diet Promote Benefi cial Immune Modulation and Purine Control in Coronavirus Infection? Nutrients. 2020 Jun 10;12(6):1737. doi: 10.3390/nu12061737.Wunderlich PF, Braun L, Fumagalli I, D'Apuzzo V, Heim F, Karly M, Lodi R, Politta G, Vonbank F, Zeltner L. Double- blind report on the effi cacy of lactic acid-producing Enterococcus SF68 in the prevention of antibioticassociated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res. 1989 Jul- Aug;17(4):333–8. doi: 10.1177/030006058901700405.Wunderlich PF, Braun L, Fumagalli I, D'Apuzzo V, Heim F, Karly M, Lodi R, Politta G, Vonbank F, Zeltner L. Double- blind report on the effi cacy of lactic acid-producing Enterococcus SF68 in the prevention of antibioticassociated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res. 1989 Jul- Aug;17(4):333–8. doi: 10.1177/030006058901700405.Ахмедов В. А., Гаус О. В. Возможности современной пробиотической терапии в лечении пациентов с постинфекционным синдромом раздраженного кишечника. Лечащий Врач. 2022; 2 (25): 32–35. doi:10.51793/OS.2022.25.2.005.Akhmedov V. A., Gaus O. V. Possibilities of modern probiotic therapy in the treatment of patients with post-infectious irritable bowel syndrome. Lechaschi Vrach. 2022; 2 (25): 32–35. (in Russ.) doi: 10.51793/OS.2022.25.2.005.Яковенко Э. П., Строкова Т. В., Яковенко А. В., Иванов А. Н., Солуянова И. П., Васильев Н. Н. Эффективность и безопасность двухнедельной висмутсодержащей квадротерапии Helicobacter рylori- инфекции с включением пробиотика, содержащего Bifi dobacterium longum BB-46 и Enterococcus faecium ENCfa-68. Проспективное рандомизированное сравнительное многоцентровое исследование. Терапевтический архив. 2021; 93 (8): 916–922. doi: 10.26442/00403660.2021.08.200996.Yakovenko EP, Strokova TV, Iakovenko AV, Ivanov AN, Soluyanova IP, Vasilyev NN. A prospective randomized comparative study of the effi cacy and safety of a twoweek bismuth- based quadrotherapy of Helicobacter pylori infection with the inclusion of the probiotic containing Bifi dobacterium longum BB-46 and Enterococcus faecium ENCfa-68. Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (8): 916–922. (in Russ.) doi: 10.26442/00403660.2021.08.200996.Инструкция по медицинскому применению препарата Бифиформ, № ПN013677/01 от 18.08.2017. Министерство здравоохранения Российской Федерации[Instructions for the medical use of the drug Bifi form]. No. PN013677/01 of 08/18/2017. Ministry of Health of the Russian Federation. Moscow. 2017. (in Russ.)Storr M, Stengel A. Klinische Evidenz zu Probiotika in der Prävention einer Antibiotika- assoziierten Diarrhö: Systematischer Review [Systematic review: clinical evidence of probiotics in the prevention of antibioticassociated diarrhoea]. MMW Fortschr Med. 2021 Apr;163(Suppl 4):19–26. German. doi: 10.1007/s15006–021–9762–5.Storr M, Stengel A. Klinische Evidenz zu Probiotika in der Prävention einer Antibiotika- assoziierten Diarrhö: Systematischer Review [Systematic review: clinical evidence of probiotics in the prevention of antibioticassociated diarrhoea]. MMW Fortschr Med. 2021 Apr;163(Suppl 4):19–26. German. doi: 10.1007/s15006–021–9762–5.Kazemian N, Kao D, Pakpour S. Fecal Microbiota Transplantation during and Post- COVID-19 Pandemic. Int J Mol Sci. 2021 Mar 16;22(6):3004. doi: 10.3390/ijms22063004.Kazemian N, Kao D, Pakpour S. Fecal Microbiota Transplantation during and Post- COVID-19 Pandemic. Int J Mol Sci. 2021 Mar 16;22(6):3004. doi: 10.3390/ijms22063004.Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011 Aug 10;2011(8): CD003460. doi: 10.1002/14651858.CD003460.pub3.Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011 Aug 10;2011(8): CD003460. doi: 10.1002/14651858.CD003460.pub3.Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soff er EE, Spiegel BM, Quigley EM; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug;109 Suppl 1: S2–26; quiz S27. doi: 10.1038/ajg.2014.187.Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soff er EE, Spiegel BM, Quigley EM; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug;109 Suppl 1: S2–26; quiz S27. doi: 10.1038/ajg.2014.187.Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure aft er 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014 Nov;34(11):783–93. doi: 10.1007/s40261–014–0233-y.Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure aft er 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014 Nov;34(11):783–93. doi: 10.1007/s40261–014–0233-y.Boisson J, Coudert Ph, Dupuis J, Laverdant Ch, Toulet J. Tolerance de la mebeverine a long terme. Act Ther. 1987;16(4):289–92.Boisson J, Coudert Ph, Dupuis J, Laverdant Ch, Toulet J. Tolerance de la mebeverine a long terme. Act Ther. 1987;16(4):289–92.Danne O., Pospai D., Mignon M. Effi cacité comparée du citrate d'alvérine (nouvelle formule) et de la mébévérine chez les adultes atteints de troubles fonctionnels intestinaux. Concours mé dical. 1996;118(36–37): I–VIII.Danne O., Pospai D., Mignon M. Effi cacité comparée du citrate d'alvérine (nouvelle formule) et de la mébévérine chez les adultes atteints de troubles fonctionnels intestinaux. Concours mé dical. 1996;118(36–37): I–VIII.Barthet, M., Mambrini, P., Salducci, J., Bouvier M., Chiarelli, P., Grimaud J. C., et al. Effi cacité de l’association citrate d’alvérine+siméthicone dans le traitement du syndrome de l’intestin irritable. Les Actualités en Gastroentérologie. 1996;10, S1-S7.Barthet, M., Mambrini, P., Salducci, J., Bouvier M., Chiarelli, P., Grimaud J. C., et al. Effi cacité de l’association citrate d’alvérine+siméthicone dans le traitement du syndrome de l’intestin irritable. Les Actualités en Gastroentérologie. 1996;10, S1-S7.Ducrotte P, Grimaud JC, Dapoigny M, Personnic S, O'Mahony V, Andro- Delestrain MC. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract. 2014 Feb;68(2):245–54. doi: 10.1111/ijcp.12333.Ducrotte P, Grimaud JC, Dapoigny M, Personnic S, O'Mahony V, Andro- Delestrain MC. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract. 2014 Feb;68(2):245–54. doi: 10.1111/ijcp.12333.Chang FY, Lu CL, Chen CY, Luo JC. Efficacy of dioctahedral smectite in treating patients of diarrheapredominant irritable bowel syndrome. J Gastroenterol Hepatol. 2007 Dec;22(12):2266–72. doi: 10.1111/j.1440–1746.2007.04895.x.Chang FY, Lu CL, Chen CY, Luo JC. Efficacy of dioctahedral smectite in treating patients of diarrheapredominant irritable bowel syndrome. J Gastroenterol Hepatol. 2007 Dec;22(12):2266–72. doi: 10.1111/j.1440–1746.2007.04895.x.Menees SB, Maneerattannaporn M, Kim HM, Chey WD. Th e effi cacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan;107(1):28–35; quiz 36. doi: 10.1038/ajg.2011.355.Menees SB, Maneerattannaporn M, Kim HM, Chey WD. Th e effi cacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan;107(1):28–35; quiz 36. doi: 10.1038/ajg.2011.355.Lorenzo- Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome- related quality of life. World J Gastroenterol. 2014 Jul 14;20(26):8709–16. doi: 10.3748/wjg.v20.i26.8709.Lorenzo- Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome- related quality of life. World J Gastroenterol. 2014 Jul 14;20(26):8709–16. doi: 10.3748/wjg.v20.i26.8709.Openshaw PJ. Crossing barriers: infections of the lung and the gut. Mucosal Immunol. 2009 Mar;2(2):100–2. doi: 10.1038/mi.2008.79.Openshaw PJ. Crossing barriers: infections of the lung and the gut. Mucosal Immunol. 2009 Mar;2(2):100–2. doi: 10.1038/mi.2008.79.Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soff er EE, Spiegel BM, Moayyedi P. Effi cacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014 Oct;109(10):1547–61; quiz 1546, 1562. doi: 10.1038/ajg.2014.202.Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soff er EE, Spiegel BM, Moayyedi P. Effi cacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014 Oct;109(10):1547–61; quiz 1546, 1562. doi: 10.1038/ajg.2014.202.Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta- analysis. Intern Med. 2015;54(3):243–9. doi: 10.2169/internalmedicine.54.2710.Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta- analysis. Intern Med. 2015;54(3):243–9. doi: 10.2169/internalmedicine.54.2710.В. Т. Ивашкин, О. М. Драпкина, А. А. Шептулин, О. С. Шифрин, Е. А. Полуэктова, С. Ю. Кучумова. Сравнительная эффективность композиции Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus и Sa ccharomy ces boulardii в лечении больных с диарейным вариантом синдрома раздраженного кишечника. РЖГГК. – 2015. – Т. 25. – № 2. – С. 10.Ivashkin V. T., Drapkina O. M., Sheptulin A. A., Shifrin O. S., Poluektova Ye.A., Kuchumova S. Yu. Com pa rative assessment of Bifi dobacterium bifi dum, Bifido bacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus and Saccharomyces boulardii. Ross z gastroenterol gepatol koloproktol. 2016; 25(21):10– 21. (in Russ.)В. Т. Ивашкин, О. М. Драпкина, А. А. Шептулин, О. С. Шифрин, Е. А. Полуэктова, С. Ю. Кучумова. Сравнительная эффективность композиции Bifi dobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus и прукалоприда в лечении больных с обстипационным вариантом синдрома раздраженного кишечника. РЖГГК. – 2015. – Т. 25. – № 3. – С. 21–32.Ivashkin V. T., Drapkina O. M., Sheptulin A. A., Shifrin O. S., Poluektova Ye.A., Kuchumova S. Yu. Comparative efficacy of Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus composition and prucalopride in treatment of constipation variant of irritable bowel syndrome. Ross z gastroenterol gepatol koloproktol. 2016; 25(3):21–32. (in Russ.)Ivashkin V., Drapkina O., Poluektova Ye., Kuchumova S., Sheptulin A. and Shifrin O. Th e Eff ect of a Multi-strain Probiotic on the Symptoms and Small Intestinal Bacterial Overgrowth in Constipation- predominant Irritable Bowel Syndrome: A Randomized, Simple- blind, Placebocontrolled Trial. American Journal of Clinical Medicine Research. 2015; 3(2):18–23. doi: 10.12691/ajcmr-3–2–1Ivashkin V., Drapkina O., Poluektova Ye., Kuchumova S., Sheptulin A. and Shifrin O. Th e Eff ect of a Multi-strain Probiotic on the Symptoms and Small Intestinal Bacterial Overgrowth in Constipation- predominant Irritable Bowel Syndrome: A Randomized, Simple- blind, Placebocontrolled Trial. American Journal of Clinical Medicine Research. 2015; 3(2):18–23. doi: 10.12691/ajcmr-3–2–1Ардатская М. Д., Буторова Л. И., Калашникова М. А., и др. Гастроэнтерологические симптомы у пациентов с COVID-19 легкой тяжести: возможности оптимизации антидиарейной терапии. Терапевтический архив. 2021; 93 (8): 923–931. doi: 10.26442/00403660.2021.08.201020.Ardatskaya M. D., Butorova L. I., Kalashnikova M. A., et al. Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy. Terapevticheskii arkhiv. 2021; 93(8): 923–931. doi: 10.26442/00403660.2021.08.201020. (In Russ.)Минушкин О. Н., Масловский Л. В., Ардатская М. Д. и др. Клинико- метаболические эффекты терапии метапребиотиками некоторых функциональных заболеваний кишечника. Экспериментальная и клиническая гастроэнтерология. 2021; № 194(10): 100–108. doi: 10.31146/1682–8658-ecg-194–10–100–108.Minushkin O. N., Maslovsky L. V., Ardatskaya M. D. et al. Clinical and metabolic eff ects of metaprebiotic therapy for some functional bowel diseases. Experimental and Clinical Gastroenterology. 2021; 194(10): 100–108. (in Russ.) doi: 10.31146/1682–8658-ecg-194–10–100–108.Fleming V, Wade WE. A review of laxative therapies for treatment of chronic constipation in older adults. Am J Geriatr Pharmacother. 2010 Dec;8(6):514–50. doi: 10.1016/S1543–5946(10)80003–0.Fleming V, Wade WE. A review of laxative therapies for treatment of chronic constipation in older adults. Am J Geriatr Pharmacother. 2010 Dec;8(6):514–50. doi: 10.1016/S1543–5946(10)80003–0.Soltanian N, Janghorbani M. Eff ect of fl axseed or psyllium vs. placebo on management of constipation, weight, glycemia, and lipids: A randomized trial in constipated patients with type 2 diabetes. Clin Nutr ESPEN. 2019 Feb;29:41–48. doi: 10.1016/j.clnesp.2018.11.002.Soltanian N, Janghorbani M. Eff ect of fl axseed or psyllium vs. placebo on management of constipation, weight, glycemia, and lipids: A randomized trial in constipated patients with type 2 diabetes. Clin Nutr ESPEN. 2019 Feb;29:41–48. doi: 10.1016/j.clnesp.2018.11.002.Erdogan A, Rao SS, Thiruvaiyaru D, Lee YY, Coss Adame E, Valestin J, O'Banion M. Randomised clinical trial: mixed soluble/insoluble fi bre vs. psyllium for chronic constipation. Aliment Pharmacol Th er. 2016 Jul;44(1):35–44. doi: 10.1111/apt.13647.Erdogan A, Rao SS, Thiruvaiyaru D, Lee YY, Coss Adame E, Valestin J, O'Banion M. Randomised clinical trial: mixed soluble/insoluble fi bre vs. psyllium for chronic constipation. Aliment Pharmacol Th er. 2016 Jul;44(1):35–44. doi: 10.1111/apt.13647.Ивашкин В. Т., Шелыгин Ю. А., Маев И. В., и др. Диагностика и лечение запора у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):69–85. doi: 10.22416/1382–4376–2020–30–6–69–85.Ivashkin V. T., Shelygin Yu.A., Maev I. V., et al. Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia on Diagnosis and Treatment of Constipation in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(6):69–85. (In Russ.) doi: 10.22416/1382–4376–2020–30–6–69–85.Lee- Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus Polyethylene Glycol for Chronic Constipation. Cochrane Database Syst Rev. 2010 Jul 7;(7): CD007570. doi: 10.1002/14651858.CD007570.pub2.Lee- Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus Polyethylene Glycol for Chronic Constipation. Cochrane Database Syst Rev. 2010 Jul 7;(7): CD007570. doi: 10.1002/14651858.CD007570.pub2.Miller LE, Tennilä J, Ouwehand AC. Effi cacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol. 2014 Jul 12;7:241–8. doi: 10.2147/CEG.S58952.Miller LE, Tennilä J, Ouwehand AC. Effi cacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol. 2014 Jul 12;7:241–8. doi: 10.2147/CEG.S58952.Tack J, Müller- Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol. 2009 May;7(5):502–8; quiz 496. doi: 10.1016/j.cgh.2008.12.006.Tack J, Müller- Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol. 2009 May;7(5):502–8; quiz 496. doi: 10.1016/j.cgh.2008.12.006.Petticrew M, Rodgers M, Booth A. Eff ectiveness of laxatives in adults. Qual Health Care. 2001 Dec;10(4):268–73. doi:10.1136/qhc.0100268.Petticrew M, Rodgers M, Booth A. Eff ectiveness of laxatives in adults. Qual Health Care. 2001 Dec;10(4):268–73. doi: 10.1136/qhc.0100268.Dupont C, Leluyer B, Maamri N, et al. Double- blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr. 2005 Nov;41(5):625–33. doi: 10.1097/01.mpg.0000181188.01887.78.Dupont C, Leluyer B, Maamri N, et al. Double- blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr. 2005 Nov;41(5):625–33. doi: 10.1097/01.mpg.0000181188.01887.78.Migeon- Duballet I, Chabin M, Gautier A, Mistoufl et T, Bonnet M, Aubert JM, Halphen M. Long-term effi cacy and cost-eff ectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population. Curr Med Res Opin. 2006 Jun;22(6):1227–35. doi: 10.1185/030079906X112543.Migeon- Duballet I, Chabin M, Gautier A, Mistoufl et T, Bonnet M, Aubert JM, Halphen M. Long-term effi cacy and cost-eff ectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population. Curr Med Res Opin. 2006 Jun;22(6):1227–35. doi: 10.1185/030079906X112543.Corazziari E, Badiali D, Bazzocchi G, Bassotti G, Roselli P, Mastropaolo G, Lucà MG, Galeazzi R, Peruzzi E. Long term effi cacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000 Apr;46(4):522–6. doi: 10.1136/gut.46.4.522.Corazziari E, Badiali D, Bazzocchi G, Bassotti G, Roselli P, Mastropaolo G, Lucà MG, Galeazzi R, Peruzzi E. Long term effi cacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000 Apr;46(4):522–6. doi: 10.1136/gut.46.4.522.Loening- Baucke V, Pashankar DS. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics. 2006 Aug;118(2):528–35. doi: 10.1542/peds.2006–0220.Loening- Baucke V, Pashankar DS. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics. 2006 Aug;118(2):528–35. doi: 10.1542/peds.2006–0220.Denis Ph., Lerebours E. Study of the long-term tolerance of Forlax in 16 patients treated for an average of 17 months for chronic constipation. Medicine & Chirurgie Digestives. 1996; 25 (5): 7–16.Denis Ph., Lerebours E. Study of the long-term tolerance of Forlax in 16 patients treated for an average of 17 months for chronic constipation. Medicine & Chirurgie Digestives. 1996; 25 (5): 7–16.Черемушкин С. В., Кучерявый Ю. А. и др. Ретроспективная оценка эффекта последействия при лечении хронического запора. Врач 2013; № 3: 58–62.Cheremushkin S. V., Kucheryavy Yu.A., et al. [Retrospective evaluation of the aft ereff ect in the treatment of chronic constipation]. Doctor. 2013;(3): 58–62. (in Russ.)Bosshard W., Dreher R., Schnegg J., Bula C. Th e treatment of chronic constipation in elderly people: an update. Drugs Aging. 2004; 21: 911–930. doi: 10.2165/00002512–200421140–00002.Bosshard W., Dreher R., Schnegg J., Bula C. Th e treatment of chronic constipation in elderly people: an update. Drugs Aging. 2004; 21: 911–930. doi: 10.2165/00002512–200421140–00002.Ford A. An evidence- based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol. 2009; 104 (suppl.1): 1–28.Ford A. An evidence- based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol. 2009; 104 (suppl.1): 1–28.Stanghellini V., Vandeplassche L., Kerstens R. Best response distribution of 12-week treatment with prucalopride (RESOLOR) in patients with chronic constipation: combined results of three randomised, double- blind, placebo- controlled phase III trials. Gut. 2011;60: A159-A160. doi: 10.1136/gut.2011.239301.338.Stanghellini V., Vandeplassche L., Kerstens R. Best response distribution of 12-week treatment with prucalopride (RESOLOR) in patients with chronic constipation: combined results of three randomised, double- blind, placebo- controlled phase III trials. Gut. 2011;60: A159-A160. doi: 10.1136/gut.2011.239301.338.Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Clinical trial: the effi cacy of open-label prucalopride treatment in patients with chronic constipation – follow-up of patients from the pivotal studies. Aliment Pharmacol Th er. 2010 Nov;32(9):1113– 23. doi: 10.1111/j.1365–2036.2010.04455.x.Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Clinical trial: the effi cacy of open-label prucalopride treatment in patients with chronic constipation – follow-up of patients from the pivotal studies. Aliment Pharmacol Th er. 2010 Nov;32(9):1113– 23. doi: 10.1111/j.1365–2036.2010.04455.x.Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol. 2022 Oct;77(4):1161– 1197. doi: 10.1016/j.jhep.2022.07.008.Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol. 2022 Oct;77(4):1161– 1197. doi: 10.1016/j.jhep.2022.07.008.Лазебник Л. Б., Голованова Е. В., Хлынова О. В., и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29–54. doi: 10.31146/1682–8658-ecg-174–2–29–54.Lazebnik L. B., Golovanova E. V., Hlynova O. V., et al. Medicinal liver damage in adults. Experimental and Clinical Gastroenterology. 2020;174(2):29–54. (In Russ.) doi: 10.31146/1682–8658-ecg-174–2–29–54.Chandok N, Watt KD. Pain management in the cirrho tic patient: the clinical challenge. Mayo Clin Proc. 2010 May;- 85(5):451–8. doi: 10.4065/mcp.2009.0534.Chandok N, Watt KD. Pain management in the cirrho tic patient: the clinical challenge. Mayo Clin Proc. 2010 May;- 85(5):451–8. doi: 10.4065/mcp.2009.0534.Маевская М. В., Надинская М. Ю., Луньков В. Д., Пирогова И. Ю., Чесноков Е. В., Кодзоева Х. Б., Ивашкин В. Т. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):22–29. doi: 10.22416/1382–4376–2019–29–6–22–29.Mayevskaya M. V., Nadinskaia M. Yu., Lunkov V. D., Pirogova I. Yu., Chesnokov E. V., Kodzoeva K. B., Ivashkin V. T. An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non- Alcoholic Fatty Liver Disease: Results of the USPEH Study. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019; 29(6): 22–29. (In Russ.) doi: 10.22416/1382–4376–2019–29–6–22–29.Mroz M. S., Harvey B. J. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fi brosis bronchial epithelial cells. Steroids. 2019 Nov;151:108461. doi: 10.1016/j.steroids.2019.108461.Mroz M. S., Harvey B. J. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fi brosis bronchial epithelial cells. Steroids. 2019 Nov;151:108461. doi: 10.1016/j.steroids.2019.108461.Schultz F, Hasan A, Alvarez- Laviada A, Miragoli M, Bhogal N, Wells S, Poulet C, Chambers J, Williamson C, Gorelik J. Th e protective eff ect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fi broblasts. Prog Biophys Mol Biol. 2016 Jan;120(1–3):149–63. doi: 10.1016/j.pbiomolbio.2016.01.003.Schultz F, Hasan A, Alvarez- Laviada A, Miragoli M, Bhogal N, Wells S, Poulet C, Chambers J, Williamson C, Gorelik J. Th e protective eff ect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fi broblasts. Prog Biophys Mol Biol. 2016 Jan;120(1–3):149–63. doi: 10.1016/j.pbiomolbio.2016.01.003.Işık S, Karaman M, Çilaker Micili S, Çağlayan- Sözmen Ş, Bağrıyanık HA, Arıkan- Ayyıldız Z, Uzuner N, Karaman Ö. Benefi cial eff ects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th 2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr). 2017 Jul- Aug;45(4):339–349. doi: 10.1016/j.aller.2016.12.003.Işık S, Karaman M, Çilaker Micili S, Çağlayan- Sözmen Ş, Bağrıyanık HA, Arıkan- Ayyıldız Z, Uzuner N, Karaman Ö. Benefi cial eff ects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th 2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr). 2017 Jul- Aug;45(4):339–349. doi: 10.1016/j.aller.2016.12.003.Niu F, Xu X, Zhang R, Sun L, Gan N, Wang A. Ursodeoxy cholic acid stimulates alveolar fl uid clearance in LPS-induced pulmonary edema via ALX/cAMP/PI3K pathway. J Cell Physiol. 2019 Nov;234(11):20057–20065. doi: 10.1002/jcp.28602.Niu F, Xu X, Zhang R, Sun L, Gan N, Wang A. Ursodeoxy cholic acid stimulates alveolar fl uid clearance in LPS-induced pulmonary edema via ALX/cAMP/PI3K pathway. J Cell Physiol. 2019 Nov;234(11):20057–20065. doi: 10.1002/jcp.28602.Subramanian S, Iles T, Ikramuddin S, Steer CJ. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients. Vaccines (Basel). 2020;8(2):320. Published. 2020 Jun 19. doi:10.3390/vaccines8020320Subramanian S, Iles T, Ikramuddin S, Steer CJ. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients. Vaccines (Basel). 2020;8(2):320. Published. 2020 Jun 19. doi:10.3390/vaccines8020320Abdulrab S, Al- Maweri S, Halboub E. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm. Med Hypotheses. 2020 Oct;143:109897. doi:10.1016/j.mehy.2020.109897.Abdulrab S, Al- Maweri S, Halboub E. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm. Med Hypotheses. 2020 Oct;143:109897. doi: 10.1016/j.mehy.2020.109897.Пресс-релиз РГА и РОПИП. Новое заболевание, новые симптомы, новые терапевтические возможности. 2021. https://www.rsls.ru/files/Prz2.pdfRSLS Press release of RGA and ROPIP. New disease, new symptoms, new therapeutic possibilities. 2021. (in Russ.) Available at: https://www.rsls.ru/files/Prz2.pdf (Access. 05.05.2022.)Астраханова Т. А., Щелчкова Н.А, Пчелин П. В., Ведунова М. В., Мухина И. В. Биоэнергетика клетки при нормоксии и гипоксии, Учебно- методическое пособие. Нижний Новгород, 2016, C. 36.Astrakhanova T. A., Shchelchkova N. A., Pchelin P. V., Vedunova M. V., Mukhina I. V. [Bioenergetics of the cell in normoxia and hypoxia, Educational- methodical manual]. Nizhny Novgorod, 2016, 36 P. (in Russ.)Лазебник Л. Б., Голованова Е. В., Тарасова Л. В., Кривошеев А. Б., Сас Е. И., Еремина Е. Ю., Трухан Д. И., Хлынова О. В., Цыганова Ю. В. Алкогольная болезнь печени (АБП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):4–28. doi: 10.31146/1682–8658-ecg-174–2–4–28.Lazebnik L. B., Golovanova E. V., Tarasova L. V., Krivosheev A. B., Sas E. I., Eremina E. Yu., Trukhan D. I., Hlynova O. V., Tsyganova Yu. V. Adult Alcoholic Liver Disease. Experimental and Clinical Gastroenterology. 2020;174(2):4–28. (In Russ.) doi: 10.31146/1682–8658-ecg-174–2–4–28.Ивашкин В. Т., Барановский А. Ю., Райхельсон К. Л., Пальгова Л. К., Маевская М. В., Кондрашина А., Марченко Н. В., Некрасова.П., Никитин И. Г. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):85–115. doi: 10.22416/1382–4376–2019–29–1–101–131.Ivashkin V. T., Baranovsky A. Yu., Raikhelson K. L., Palgova L. K., Maevskaya M. V., Kondrashina E. A., Marchenko N. V., Nekrasova T. P., Nikitin I. G. DrugInduced Liver Injuries (Clinical Guidelines for Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):85–115. (In Russ.) doi: 10.22416/1382–4376–2019–29–1–101–131.Ильченко Л. Ю., Оковитый С. В. Ремаксол: механизмы действия и применение в клинической практике. Часть 1. Архивъ внутренней медицины. 2016; 6(2): 16–21. doi: 10.20514/2226–6704–2016–6–2–16–21Ilchenko L. Yu., Okovity S. B. Remaxol: mechanisms of action and application in real clinical practice. Th e Russian Archives of Internal Medicine. 2016;6(2):16–21. (In Russ.) doi: 10.20514/2226–6704–2016–6–2–16–21.Шаповалов К. Г., Цыденпинов Г. А., Лукьянов С. А., Трусова Ю. С., Коннов В. А. Перспективы применения сукцинатов при тяжелом течении новой коронавирусной инфекции. Экспериментальная и клиническая фармакология, 2020.Том 83 (№ 10), с. 40–43. doi: 10.30906/0869–2092–2020–83–10–40–43.Shapovalov K. G., Tsydenpilov G. A., Luk’yanov S. A., Trusova Yu. S., Konnov V. A. Prospects for the Use of Succinates in Treating Severe Course of New Coronavirus Infection. Experimental and Clinical Pharmacology. 2020;83(10):40–43. (in Russ.) doi: 10.30906/0869–2092–2020–83–10–40–43.Смок А. М., Малкова А. М., Кудлай Д. А., Старшинова А. А. Возможности коррекции гепатотоксических реакций на фоне терапии у больных с COVID-19 (описание клинического случая). Трансляционная медицина. 2020;7(6):65–72. doi: 10.18705/2311–4495–2020–7–6–65–72.Smok A. M., Malkova A. M., Kudlay D. A., Star shi nova A. A. Possibilities for correcting hepatotoxic reactions during therapy in patients with COVID-19 (case report). Translational Medicine. 2020;7(6):65–72. (In Russ.) doi: 10.18705/2311–4495–2020–7–6–65–72.Nardo AD, Schneeweiss- Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021 Jan;41(1):20–32. doi: 10.1111/liv.14730.Nardo AD, Schneeweiss- Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021 Jan;41(1):20–32. doi: 10.1111/liv.14730.Wu J, Song S, Cao HC, Li LJ. Liver diseases in COVID-19: Etiology, treatment and prognosis. World J Gastroenterol. 2020 May 21;26(19):2286–2293. doi: 10.3748/wjg.v26.i19.2286.Wu J, Song S, Cao HC, Li LJ. Liver diseases in COVID-19: Etiology, treatment and prognosis. World J Gastroenterol. 2020 May 21;26(19):2286–2293. doi: 10.3748/wjg.v26.i19.2286.Jalan R, De Chiara F, Balasubramaniyan V, Andreola F, Khetan V, Malago M, Pinzani M, Mookerjee RP, Rombouts K. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. J Hepatol. 2016 Apr;64(4):823–33. doi: 10.1016/j.jhep.2015.11.019.Jalan R, De Chiara F, Balasubramaniyan V, Andreola F, Khetan V, Malago M, Pinzani M, Mookerjee RP, Rombouts K. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. J Hepatol. 2016 Apr;64(4):823–33. doi: 10.1016/j.jhep.2015.11.019.Плотникова Е. Ю. Роль L-орнитин- L-аспартата в комплексном лечении больных с гипераммониемией. Клин. перспективы гастроэнтерологии, гепатологии. 2013. № 2. С. 1–9Plotnikova E. Yu. [Th e role of L-ornithine- L-aspartate in the complex treatment of patients with hyperammonemia]. Clinical perspectives of gastroenterology, hepatology. 2013, No. 2, pp.1–9. (in Russ.)Лазебник Л. Б., Голованова Е. В., Алексеенко С. А., и др. Российский консенсус «Гипераммониемии у взрослых» (Версия 2021). Экспериментальная и клиническая гастроэнтерология. 2021;(3):97–118. doi: 10.31146/1682–8658-ecg-187–3–97–118.Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Russian Consensus “Hyperammonemia in Adults” (Version 2021). Experimental and Clinical Gastroenterology. 2021;(3):97–118. (In Russ.) doi: 10.31146/1682–8658-ecg-187–3–97–118.Butterworth RF, Kircheis G, Hilger N, McPhail MJW. Effi cacy of l- Ornithine l- Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta- Analysis of Randomized Controlled Trials. J Clin Exp Hepatol. 2018 Sep;8(3):301–313. doi: 10.1016/j.jceh.2018.05.004.Butterworth RF, Kircheis G, Hilger N, McPhail MJW. Effi cacy of l- Ornithine l- Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta- Analysis of Randomized Controlled Trials. J Clin Exp Hepatol. 2018 Sep;8(3):301–313. doi: 10.1016/j.jceh.2018.05.004.Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2011 Aug;23(8):725–32. doi: 10.1097/MEG.0b013e32834696f5.Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2011 Aug;23(8):725–32. doi: 10.1097/MEG.0b013e32834696f5.Alvares-da- Silva MR, de Araujo A, Vicenzi JR, da Silva GV, Oliveira FB, Schacher F, Oliboni L, Magnus A, Kruel LP, Prieb R, Fernandes LN. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double- blind, placebo- controlled trial. Hepatol Res. 2014 Sep;44(9):956–63. doi: 10.1111/hepr.12235.Alvares-da- Silva MR, de Araujo A, Vicenzi JR, da Silva GV, Oliveira FB, Schacher F, Oliboni L, Magnus A, Kruel LP, Prieb R, Fernandes LN. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double- blind, placebo- controlled trial. Hepatol Res. 2014 Sep;44(9):956–63. doi: 10.1111/hepr.12235.Poo JL, Góngora J, Sánchez- Avila F, Aguilar- Castillo S, García- Ramos G, Fernández- Zertuche M, RodríguezFragoso L, Uribe M. Efficacy of oral L-ornithine- Laspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose- controlled study. Ann Hepatol. 2006 OctDec;5(4):281–8. PMID: 17151582.Poo JL, Góngora J, Sánchez- Avila F, Aguilar- Castillo S, García- Ramos G, Fernández- Zertuche M, RodríguezFragoso L, Uribe M. Efficacy of oral L-ornithine- Laspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose- controlled study. Ann Hepatol. 2006 OctDec;5(4):281–8. PMID: 17151582.Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. Int J Res Med Sci. 2019;7(6):2482– 93. doi: 10.18203/2320–6012.ijrms20192550.Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. Int J Res Med Sci. 2019;7(6):2482– 93. doi: 10.18203/2320–6012.ijrms20192550.Lieber CS, Packer L. S-Adenosylmethionine: molecular, biological, and clinical aspects – an introduction. Am J Clin Nutr. 2002 Nov;76(5):1148S-50S. doi: 10.1093/ajcn/76/5.1148S.Lieber CS, Packer L. S-Adenosylmethionine: molecular, biological, and clinical aspects – an introduction. Am J Clin Nutr. 2002 Nov;76(5):1148S-50S. doi: 10.1093/ajcn/76/5.1148S.Ou X, Yang H, Ramani K, Ara AI, Chen H, Mato JM, Lu SC. Inhibition of human betaine- homocysteine methyltransferase expression by S-adenosylmethionine and methylthioadenosine. Biochem J. 2007 Jan 1; 401(1):87–96. doi: 10.1042/BJ20061119.Ou X, Yang H, Ramani K, Ara AI, Chen H, Mato JM, Lu SC. Inhibition of human betaine- homocysteine methyltransferase expression by S-adenosylmethionine and methylthioadenosine. Biochem J. 2007 Jan 1; 401(1):87–96. doi: 10.1042/BJ20061119.Gil B, Casado M, Pajares MA, Boscá L, Mato JM, MartínSanz P, Alvarez L. Differential expression pattern of S-adenosylmethionine synthetase isoenzymes during rat liver development. Hepatology. 1996 Oct;24(4):876–81. doi: 10.1002/hep.510240420.Gil B, Casado M, Pajares MA, Boscá L, Mato JM, MartínSanz P, Alvarez L. Differential expression pattern of S-adenosylmethionine synthetase isoenzymes during rat liver development. Hepatology. 1996 Oct;24(4):876–81. doi: 10.1002/hep.510240420.Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adeno sylmethionine: a control switch that regulates liver function. FASEB J. 2002 Jan;16(1):15–26. doi: 10.1096/fj.01–0401rev.Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adeno sylmethionine: a control switch that regulates liver function. FASEB J. 2002 Jan;16(1):15–26. doi: 10.1096/fj.01–0401rev.Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, Carrieri V, Albano O. Eff ects of oral S-adenosyl- L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol. 1989 May;24(4):407–15. doi: 10.3109/00365528909093067.Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, Carrieri V, Albano O. Eff ects of oral S-adenosyl- L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol. 1989 May;24(4):407–15. doi: 10.3109/00365528909093067.Ivashkin VT, Maevskaya MV, Kobalava ZD, et al. Openlabel study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. Minerva Gastroenterol Dietol. 2018 Sep;64(3):208–219. doi: 10.23736/S1121–421X.18.02461–3.Ivashkin VT, Maevskaya MV, Kobalava ZD, et al. Openlabel study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. Minerva Gastroenterol Dietol. 2018 Sep;64(3):208–219. doi: 10.23736/S1121–421X.18.02461–3.Лазебник Л. Б., Голованова Е. В., Туркина С. В., и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение.Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1): 4–52. doi: 10.31146/1682–8658-ecg-185–1–4–52.Lazebnik L. B., Golovanova E. V., Turkina S. V., et al. Nonalcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4– 52. (In Russ.) doi: 10.31146/1682–8658-ecg-185–1–4–52.Райхельсон К. Л., Кондрашина Э. Л. Адеметионин в лечении повышенной утомляемости/слабости при заболеваниях печени: систематический обзор. Терапевтический архив. 2019;91(2):134–142. doi: 10.26442/00403660.2019.02.000130.Raikhelson K. L., Kondrashina E. A. Ademethionine in the treatment of fatigue in liver diseases: a systematic review. Terapevticheskii arkhiv. 2019;91(2):134–142. (in Russ.) doi: 10.26442/00403660.2019.02.000130.Fiorelli G. S-Adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease: A fi eld trial. Curr Th er Res. 1999;60(6):335–48. doi: 10.1016/s0011–393x(99)80010–1.Fiorelli G. S-Adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease: A fi eld trial. Curr Th er Res. 1999;60(6):335–48. doi: 10.1016/s0011–393x(99)80010–1.Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7–14. doi: 10.1111/j.1600–0404.1994.tb05403.x.Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7–14. doi: 10.1111/j.1600–0404.1994.tb05403.x.Максимов В. А., Каримова И. М. Возможности плацентарной медицины в восстановительном лечении. Вестник восстановительной медицины. – 2018. – Т. 83. – № 1 – С. 32–37.Maksimov V. A., Karimova I. M. Possibilities of placentary medicine in restoration treatment. Bulletin of Rehabilitation Medicine. 2018;83(1):32–37. (in Russ.)Торшин И. Ю., Громова О. А., Диброва Е. А. и др. Микронутриенты против коронавирусов / под ред. А. Г. Чучалина.–Москва: ГЭОТАР-Медиа, 2020. –112 с.Torshin I. Yu., Gromova O. A., Dibrova E. A., et al. Micronutrients against coronaviruses. edd. A. G. Chucha lin. Moscow. GEOTAR-Media, 2020. 112 p. (in Russ.)Лазебник Л. Б., Радченко В. Г., Джадхав С. Н., Ситкин С. И., Селиверстов П. В. Системное воспаление и неалкогольная жировая болезнь печени. Экспериментальная и клиническая гастроэнтерология. 2019;(5):29–41. doi:10.31146/1682–8658-ecg-165–5–29–41.Lazebnik L. B., Radchenko V. G., Dzhadhav S. N., Sitkin S. I., Seliverstov P. V. Systemic infl ammation and non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;(5):29–41. (In Russ.) doi: 10.31146/1682–8658-ecg-165–5–29–41.Торшин И. Ю., Громова О. А. Мировой опыт использования гидролизатов плаценты человека в терапии. Экспериментальная и клиническая гастроэнтерология. 2019;1(10):79–89. doi: 10.31146/1682–8658-ecg170–10–79–89.Torshin I. Yu., Gromova O. A. Worldwide experience of the therapeutic use of the human placental hydrolytes. Experimental and Clinical Gastroenterology. 2019;1(10):79–89. (In Russ.) doi: 10.31146/1682–8658-ecg-170–10–79–89.Максимов В. А., Ткачева О. Н., Стражеско И. Д. и др. Гидролизат плаценты человека как препарат, способствующий снижению уровня маркеров воспаления у больных с тяжелыми формами COVID-19. Терапия. – 2020. – № 5. – С. 56–68. doi: 10.18565/therapy.2020.5.56–68.Maksimov V. A., Tkacheva O. N., Strazhesko I. D., Torshin I. Yu., Gromova O. A., Chuchalin A. G., Lazebnik L. B. Human placenta hydrolysate as a drug to reduces markers of infl ammation in patients with severe COVID-19. Terapy. 2020;(5):56–68. (in Russ.) doi: 10.18565/therapy.2020.5.56–68.Громова О. А., Торшин И. Ю. Важность цинка для поддержания активности белков врожденного противовирусного иммунитета: анализ публикаций, посвященных COVID-19. Профилактическая медицина. 2020;23(3):131–139. doi: 10.17116/profmed202023031131.Gromova O. A., Torshin I. Iu. Th e importance of zinc in maintaining the activity of antiviral innate immunity proteins: analysis of publications on COVID-19. Profilakticheskaya Meditsina. 2020;23(3):131–139. (In Russ., In Engl.) doi: 10.17116/profmed202023031131. (in Russ.)Громова О. А. Микронутриенты, поддерживающие врожденный иммунитет против коронавирусов: результаты систематического компьютерного анализа публикаций по COVID-19 и белков противовирусной защиты протеома человека / О. А. Громова, И. Ю. Торшин, В. Ф. Учайкин // Фармакология & Фармакотерапия. – 2020. – № 1. – С. 9–25. doi: 10.46393/2713–2129_2020_1_9Gromova О. А., Torshina Уи., Uchaykin V. F. Micronutrients supporting innate immunity against coronaviruses: results of а systematic computer analysis of puЬlications on C0VID-19 and antiviral proteins of the human proteome. Pharmacology & Pharmaco therapy. 2020;(1):9–25. doi: 10.46393/2713–2129_2020_1_9. (in Russ.)Максимов В. А., Торшин И. Ю., Чучалин А. Г., Лазебник Л. Б., Ткачева О. Н., Стражеско И. Д., Громо ва О. А. Опыт применения препарата Лаеннек у пациентов с высоким риском развития «цитокинового шторма» на фоне COVID-19 и гиперферритинемии. Пульмонология. 2020;30(5):587–598. doi: 10.18093/0869–0189–2020–30–5–587–598.Maksimov V. A., Torshin I. Yu., Chuchalin A. G., Lazeb nik L. B., Tkacheva O. N., Strazhesko I. D., Gro mova O. A. An experience of using Laennec in patients at high risk of a cytokine storm with COVID-19 and hyperferritinemia. PULMONOLOGIYA. 2020;30(5):587–598. (in Russ.) doi: 10.18093/0869–0189–2020–30–5–587–598.Полухина А. В., Винницкая Е. В., Бордин Д. С., Сандлер Ю. Г. Неалкогольная жировая болезнь печени у коморбидных пациентов: опыт терапии с использованием Тиотриазолина. Эффективная фармакотерапия, 2018, № 3. 20–24.Polukhina A. V., Vinnitskaya Ye.V., Bordin D. S., Sandler Yu. G. Non- Alcoholic Fatty Liver Disease in Patients with Comorbidities: the Experience of Th erapy with the Use of Thiotriazolin. Effective pharmacotherapy. 2018;32(3):20–24. (in Russ.)Сандлер Ю. Г., Матвеева Ю. А., Винницкая Е. В., Гендрик сон Л. Н., Кейян В. А. Возможности применения антигипоксантной и антиоксидантной терапии при неалкогольной болезни печени. РМЖ, 2016 № 22.- С.1–4.Sandler Yu.G., Matveeva Yu.A., Vinnitskaya E. V., et al. Anti hypoxants and antioxidants for non-alcoholic liver disease. RMJ. 2016;(26):1815–1818. (in Russ.)Киношенко Е. И., Никонов В. В., Белая И. Е., Ко ло миец В. И. Комплексный подход к терапии инфаркта миокарда, сочетанного с неалкогольной жировой болезнью печени. Медицина неотложных состояний, 2017, 1(80);47–60. doi: 10.22141/2224–0586.1.80.2017.94451.Kinoshenko E. I., Nikonov V. V., Belaya I. E., Ko lo miets V. I. Complex approach to treatment of myocardial infarction combined with non-alcoholic fatty liver disease. Emergency Medicine. 2017, 1(80);47–60. doi: 10.22141/2224–0586.1.80.2017.94451.Савченко С. А., Филиппов А. Е. Симпозиум «Тиотриазолин: кардиопротекция с позиции доказательной медицины» в рамках Российского национального конгресса кардиологов. РМЖ. 2015;27:1638–1643.Savchenko S. A., Filippov A. E. [Symposium "Thiotria zolin: cardioprotection from the standpoint of evidence- based medicine"] Russian National Congress of Cardiology. RMJ. 2015;27:1638–1643. (in Russ.)Кадин Д. В., Чумак Б. А., Филиппов А. Е., Шустов С. Б. Тиотриазолин в комплексной терапии стабильной стенокардии напряжения II–III функционального класса. Кардиология.-2015. -№ 8. – С.72–81. doi: 10.18565/cardio.2015.8.26–29.Kadin D. V., Chumak B. A., Filippov A. E., Shustov S. B. Thiotriazoline in the complex therapy of stable exertional angina II–III functional class. Cardio logy. 2015;(8): 72–81. (in Russ.) doi: 10.18565/cardio.2015.8.26–29.Лазебник Л. Б., Голованова Е. В., Симаненков В. И., Гриневич В. Б., Успенский Ю. П., Бакулин И. Г., Бакулина Н. В., Лутаенко Е. А., Кравчук Ю. А., Бакулова Е. В. Возможности политропной терапии тиотриазолином у пациентов с неалкогольным стеатогепатозом и сердечно- сосудистыми факторами риска. Результаты наблюдательной программы «ТРИГОН –1». Экспериментальная и клиническая гастроэнтерология. 2020;(8):10–18. doi:10.31146/1682–8658-ecg-180–8–10–18.Lazebnik L. B., Golovanova E. V., Simanenkov V. I., Grinevich V. B., Uspensky Yu.P., Bakulin I. G., Bakulina N. V., Lutaenko Е. A., Kravchuk Yu.A., Bakulova E. V. Possibilities of polytropic therapy with thiotriazoline in patients with non-alcoholic steatohepatosis and cardiovascular risk factors. Th e results of the TRIGON-1 observation program. Experimental and Clinical Gastroenterology. 2020;(8):10–18. (In Russ.) doi: 10.31146/1682–8658-ecg-180–8–10–18.Саливончик Д. П., Саливончик Е. И. Энергетический коллапс при COVID–19: новые маркеры диагностики, аспекты лечения. Поликлиника № 1, 2021.С.-78–84.Salivonchyk D. P., Salivonchyk E. I. Energy COVID-19 Collapse: new diagnostic markers, treatment aspects. Policlinic Journal. 2021;(1):78–84. (in Russ.)Приказ Министерства здравоохранения РФ от 17 февраля 2022 г. N 86н "Об утверждении стандарта медицинской помощи взрослым при хроническом панкреатите (диагностика и лечение)"Order of the Ministry of Health of the Russian Federation "On approval of the standard of medical care for adults with chronic pancreatitis (diagnosis and treatment)" of February 17, 2022 N 86n. (in Russ.)Российский консенсус по диагностике и лечению хронического панкреатита. / Хатьков И. Е., Маев И. В., Абдулхаков С. Р. и соавт.// Терапевтический архив. – 2017. – № 2. – С. 105–113. doi: 10.17116/terarkh2017892105–113.Khatkov I. E., Maev I. V., Abdulkhakov S. R., et al. The Russian consensus on the diagnosis and treatment of chronic pancreatitis. Terapevticheskii arkhiv. 2017;89(2):105–113. (in Russ.) doi: 10.17116/terarkh2017892105–113.Ивашкин В. Т., Маев И. В., Охлобыстин А. В., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению экзокринной недостаточности поджелудочной железы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(2):72–100. doi: 10.22416/1382–4376–2018–28–2–72–100.Ivashkin V. T., Mayev I. V., Okhlobystin A. V., et al. Diagnostics and treatment of pancreatic exocrine insuffi ciency: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(2):72–100. (In Russ.) doi: 10.22416/1382–4376–2018–28–2–72–100.Клинические Рекомендации Российской Ассоциации Эндокринологов «Алгоритмы Специализированной Медицинской Помощи больным Сахарным Диабетом» / Под ред. Дедова И. И., Ше ста ко вой М. В., Майрова А. Ю. – М., 2017. – 111 сClinical Recommendations of the Russian Association of Endocrinologists "Algorithms for Specialized Medical Care for Patients with Diabetes Mellitus" / Edd. Dedov I. I., Shestakov M. V., Mayrov A. Yu. Moscow. 2017. 111 p. (in Russ.)Гриневич В. Б., Кравчук Ю. А., Педь В. И. и др. Клиническая эффективность Метеоспазмила в комплексной терапии болевого абдоминального и диспептического синдромов у пациентов с хроническим панкреатитом. Медицинский алфавит. 2019;2(13):5– 12. doi: 10.33667/2078–5631–2019–2–13(388)-5–12.Grinevich V. B., Kravchuk Yu.A., Ped’ V.I., Ro dionov G. G., Shantyr’ I.I., Kuvakin V. I., Svetkina E. V., Arapkhanovа M. M., Medvedko S. A. Clinical effi cacy of Meteospasmyl in treatment of painful abdominal and dyspeptic syndromes in patients with chronic pancreatitis. Medical alphabet. 2019;2(13):5–12. (In Russ.) doi: 10.33667/2078–5631–2019–2–13(388)-5–12.Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Th er. 2020 May;51(9):843–851. doi: 10.1111/apt.15731.Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Th er. 2020 May;51(9):843–851. doi: 10.1111/apt.15731.Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal- Oral Transmission. Gastroenterology. 2020 May;158(6):1518–1519. doi: 10.1053/j.gastro.2020.02.054.Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal- Oral Transmission. Gastroenterology. 2020 May;158(6):1518–1519. doi: 10.1053/j.gastro.2020.02.054.Sunanda V Kane, et al. COVID-19: Issues related to gastrointestinal disease in adults. Th is topic last updated: Jul, 2022. Available at: https://www.uptodate.com/contents/covid-19-issues-related-to-gastrointestinal-disease-inadults (Access: 05.05.2022)Sunanda V Kane, et al. COVID-19: Issues related to gastrointestinal disease in adults. Th is topic last updated: Jul, 2022. Available at: https://www.uptodate.com/contents/covid-19-issues-related-to-gastrointestinal-disease-inadults (Access: 05.05.2022)Bangma A, Voskuil MD, Weersma RK. TNFα- Antagonist Use and Mucosal Infl ammation Are Associated with Increased Intestinal Expression of SARS-CoV-2 Host Protease TMPRSS2 in Patients with Infl ammatory Bowel Disease. Gastroenterology. 2021 Jun;160(7):2621–2622. doi: 10.1053/j.gastro.2020.05.091.Bangma A, Voskuil MD, Weersma RK. TNFα- Antagonist Use and Mucosal Infl ammation Are Associated with Increased Intestinal Expression of SARS-CoV-2 Host Protease TMPRSS2 in Patients with Infl ammatory Bowel Disease. Gastroenterology. 2021 Jun;160(7):2621–2622. doi: 10.1053/j.gastro.2020.05.091.Schettino M, Pellegrini L, Picascia D, et al. Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A SingleCenter Cohort Study. Am J Gastroenterol. 2021 Feb 1;- 116(2):306–310. doi: 10.14309/ajg.0000000000000965.Schettino M, Pellegrini L, Picascia D, et al. Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A SingleCenter Cohort Study. Am J Gastroenterol. 2021 Feb 1;- 116(2):306–310. doi: 10.14309/ajg.0000000000000965.Choudhury A, Tariq R, Jena A, Vesely EK, Singh S, Khanna S, Sharma V. Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis. Th erap Adv Gastroenterol. 2022 Aug 19;15:17562848221118403. doi: 10.1177/17562848221118403.Choudhury A, Tariq R, Jena A, Vesely EK, Singh S, Khanna S, Sharma V. Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis. Th erap Adv Gastroenterol. 2022 Aug 19;15:17562848221118403. doi: 10.1177/17562848221118403.Giuseppe Vanella, Gabriele Capurso, Cesare Burti, Lorella Fanti. Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: An international multicentre study. BMJ Open Gastroenterol .2021;8: e000578. doi: 10.1136/bmjgast-2020–000578.Giuseppe Vanella, Gabriele Capurso, Cesare Burti, Lorella Fanti. Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: An international multicentre study. BMJ Open Gastroenterol .2021;8: e000578. doi: 10.1136/bmjgast-2020–000578.Тутельян В. А., Никитюк Д. Б., Погожева А. В. и др. COVID-19: реабилитация и питание. Руководство для врачей, М., ГЭОТАР-Медиа, 2021.Tutelyan V. A., Nikityuk D. B., Pogozheva A. V., et al. COVID-19: rehabilitation and nutrition. Guide for doctors. Moscow. GEOTAR-Media, 2021. (in Russ.)Handu D, Moloney L, Rozga M, Cheng FW. Malnutrition Care During the COVID-19 Pandemic: Considerations for Registered Dietitian Nutritionists. J Acad Nutr Diet. 2021 May;121(5):979–987. doi: 10.1016/j.jand.2020.05.012.Handu D, Moloney L, Rozga M, Cheng FW. Malnutrition Care During the COVID-19 Pandemic: Considerations for Registered Dietitian Nutritionists. J Acad Nutr Diet. 2021 May;121(5):979–987. doi: 10.1016/j.jand.2020.05.012.Ferguson M, Capra S, Bauer J, Banks M. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition. 1999 Jun;15(6):458–64. doi: 10.1016/s0899–9007(99)00084–2.Ferguson M, Capra S, Bauer J, Banks M. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition. 1999 Jun;15(6):458–64. doi: 10.1016/s0899–9007(99)00084–2.Ochoa JB, Cárdenas D, Goiburu ME, Bermúdez C, Carrasco F, Correia MITD. Lessons Learned in Nutrition Therapy in Patients With Severe COVID-19. JPEN J Parenter Enteral Nutr. 2020 Nov;44(8):1369–1375. doi:10.1002/jpen.2005.Ochoa JB, Cárdenas D, Goiburu ME, Bermúdez C, Carrasco F, Correia MITD. Lessons Learned in Nutrition Therapy in Patients With Severe COVID-19. JPEN J Parenter Enteral Nutr. 2020 Nov;44(8):1369–1375. doi: 10.1002/jpen.2005.Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D, Pirlich M, Singer P; endorsed by the ESPEN Council. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. 2020 Jun;39(6):1631– 1638. doi: 10.1016/j.clnu.2020.03.022.Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D, Pirlich M, Singer P; endorsed by the ESPEN Council. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. 2020 Jun;39(6):1631– 1638. doi: 10.1016/j.clnu.2020.03.022.Metabolic Interaction in Infection. Edited by Ricardo Silvestre and Egidio Torrado. Springer Nature Switzerland AG. 2018. P. 476.Metabolic Interaction in Infection. Edited by Ricardo Silvestre and Egidio Torrado. Springer Nature Switzerland AG. 2018. P. 476.Fernández- Quintela A, Milton- Laskibar I, Trepiana J, Gómez- Zorita S, Kajarabille N, Léniz A, González M, Portillo MP. Key Aspects in Nutritional Management of COVID-19 Patients. J Clin Med. 2020 Aug 10;9(8):2589. doi: 10.3390/jcm9082589.Fernández- Quintela A, Milton- Laskibar I, Trepiana J, Gómez- Zorita S, Kajarabille N, Léniz A, González M, Portillo MP. Key Aspects in Nutritional Management of COVID-19 Patients. J Clin Med. 2020 Aug 10;9(8):2589. doi: 10.3390/jcm9082589.Ивашкин В. Т. Результаты наблюдательного исследования особенностей повреждения ЖКТ и печени при COVID-19 у 460 пациентов. https://omnidoctor.ru/press-center/ 10 марта2021Ivashkin V. T. Th e results of an observational study of the features of damage to the gastrointestinal tract and liver with COVID-19 in 460 patients. (Available at: https://omnidoctor.ru/press-center, Accessed: March 10, 2021).Некоторые аспекты лечения больных с тяжелой формой короновирусной инфекции COVID-19: пособие для врачей / под ред. профессора А. Н. Кондратьева.– СПб. Ассоциация анастезиологов и реаниматологов Северо- Запада, 2021–132 с.Kondratiev A. N. [Some aspects of the treatment of patients with severe coronovirus infection COVID-19: a guide for doctors]. St. Petersburg. Association of Anesthesiologists and Resuscitators of the North- West Publ., 2021, 132 p. (in Russ.)Нутритивная поддержка пациентов с коронавирусной инфекцией COVID-19. Методические рекомендации национальной ассоциации клинического питания и метаболизма. М., Тверь, ООО «Издательство «Триада», 2020, 92 с.Nutritional support for patients with COVID-19. Guidelines from the National Association for Clinical Nutrition and Metabolism. Moscow., Tver, Triada Publishing House LLC, 2020, 92 p. (in Russ.)Гречко А. В., Евдокимов Е. А. Котенко О. Н., и др. Нутритивная поддержка пациентов с коронавирусной инфекцией COVID-19. Клиническое питание и метаболизм. 2020; 1(2):56–91. doi: 10.17816/clinutr42278.Grechko A. V., Evdokimov E. A., Kotenko O. N., et al. Nutritional support for patients with COVID-19 coronavirus infection. Clinical nutrition and metabolism. 2020;1(2):56–91. (in Russ.) doi: 10.17816/clinutr42278.Драпкина О. М., Маев И. В., Бакулин И. Г., и др. Временные методические рекомендации: «Болезни органов пищеварения в условиях пандемии новой коронавирусной инфекции (COVID-19)». Профилактическая медицина. 2020; 23 № 3 (приложение), стр. 120–152.Drapkina O. M., Maev I. V., Bakulin I. G., et al. Temporary guidelines: "Diseases of the digestive system in the context of a pandemic of a new coronavirus infection (COVID-19)". Preventive medicine. 2020;23(3):120–152. (in Russ.)Саидов С. С., Сметнева Н. С., Давыдова С. С., Калинина Н. Н., Чекальников Д. А. Распространенн ость симптомов поражения желудочно- кишечного тракта среди клинических проявлений COVID-19. Вестник медицинского института «Реавиз». Реабилитация, Врач и Здоровье. 2021;3(51):5–12. doi: 10.20340/vmi-rvz.2021.3.COVID.1.Saidov S. S., Smetneva N. S., Davydova S. S., Kalinina N. N., Chekalnikov D. A. Prevalence of symptoms of gastrointestinal tract among clinical manifestations of COVID-19. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2021;(3):5–12. (In Russ.) doi: 10.20340/vmi-rvz.2021.3.COVID.1.Справочник по диетологии /В. А. Тутельян, М. А. Самсонов. – М.: Издательство: Медицина; 2002 г.; С. 544.Tutelyan V. A., Samsonov M. A. [Handbook of dietetics] Moscow. Medicine Publ., 2002, 544. (in Russ.)Руководство по гастроэнтерологии / Под ред. Ф. И. Комарова, С. И. Рапопорта. – М.: Медицинское информационное агентство, 2010. – 864 с., 41Komarov F. I., Rapoport S. I. [Guide to gastroenterology]. Moscow. Medical Information Agency Publ., 2010. 864 P. (in Russ.)Baranovsky A. Yu. Dietology. 5th ed.-St. Petersburg: Peter, 2017. 1104 p. (In Russ.) Барановский А. Ю. Диетология. 5-е изд.-СПб.: Питер, 2017. –1104 с.Baranovsky A. Yu. Dietology. 5th ed.-St. Petersburg: Peter, 2017. 1104 p. (In Russ.)Диетология: Новейший справ.для врачей / Б. Л. Смолян ский, В. Г. Лифляндский. – М.: Эксмо; СПб.: Сова, 2003. – 815 с.Smolyansky B. L., Lifl yandsky V. G. Dietetics: Th e latest guide for physicians. Moscow. Eksmo; SPb. Sova, 2003. 815 p. (in Russ)Тутельян В. А., Гаппаров М. М.Г., Батурин А. К. и соавт. Семидневные меню для основных вариантов стандартных диет с использованием блюд оптимизированного состава, применяемых в лечебном питании в медицинских организациях Российской Федерации. /Практическое руководство для врачейдиетологов, медицинских сестер диетических, специалистов по организации питания в стационарных учреждениях специального обслуживания граждан пожилого возраста и инвалидов, специалистов общественного питания. / Москва, 2014. – 460 с.Tutelyan V. A., Gapparov M. M.G., Baturin A. K. et al. [Seven-day menus for the main variants of standard diets using dishes of an optimized composition used in clinical nutrition in medical organizations of the Russian Federation]. A practical guide for dieticians, dietitian nurses, catering specialists in stationary institutions of special care for the elderly and disabled, catering specialists. Moscow, 2014. 460 p. (in Russ.)Vaillant MF, Agier L, Martineau C, et al. Food intake and weight loss of surviving inpatients in the course of COVID-19 infection: A longitudinal study of the multicenter NutriCoviD30 cohort. Nutrition. 2022 Jan;93:111433. doi: 10.1016/j.nut.2021.111433.Vaillant MF, Agier L, Martineau C, et al. Food intake and weight loss of surviving inpatients in the course of COVID-19 infection: A longitudinal study of the multicenter NutriCoviD30 cohort. Nutrition. 2022 Jan;93:111433. doi: 10.1016/j.nut.2021.111433.Gemelli Against COVID-19 Post- Acute Care Study Group. Post- COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res. 2020 Aug;32(8):1613–1620. doi: 10.1007/s40520–020–01616-x.Gemelli Against COVID-19 Post- Acute Care Study Group. Post- COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res. 2020 Aug;32(8):1613–1620. doi: 10.1007/s40520–020–01616-x.Шкурко Т. В., Веселов А. В., Князев О. В., Пар фенов А. И., Каграманова А. В. Особенности новой коронавирусной инфекции COVID-19 у пациентов с заболеваниями желудочно- кишечного тракта: Временные методические рекомендации № 69. М.: ГБУ «НИИОЗММ ДЗМ», 2020. – 32 сShkurko T. V., Veselov A. V., Knyazev O. V., Parfenov A. I., Kagramanova A. V. Features of the new coronavirus infection COVID-19 in patients with diseases of the gastrointestinal tract: Temporary guidelines No. 69. Moscow. "NIIOZMM DZM" Publ, 2020. 32 p. (in Russ.)Пилат Т. Л., Кузьмина Л. П., Измерова Н. И. Детоксикационное питание/Под ред. Т. Л. Пилат. – М.: ГЭОТАР-Медиа, 2012. – 688 с., 74Pilat T. L., Kuzmina L. P., Izmerova N. I. Detox nutrition. Moscow. GEOTAR-Media, 2012. 688 p.; 74 p. (in Russ.)Парентеральное и энтеральное питание: национальное руководство / под ред. М. Ш. Хубутия, Т. С. Поповой, А. И. Салтыковой. –М.: ГЭОТАР-Медиа., 2014. –800 с.[Parenteral and enteral nutrition: national guidelines]. / edd. M. Sh. Khubutia, T. S. Popova, A. I. Saltykova. Moscow. GEOTAR-Media Publ., 2014. 800 p. (in Russ.)McFarland LV. Diarrhea acquired in the hospital. Gastroenterol Clin North Am. 1993 Sep;22(3):563–77. PMID: 8406731.McFarland LV. Diarrhea acquired in the hospital. Gastroenterol Clin North Am. 1993 Sep;22(3):563–77. PMID: 8406731.Лодягин А. Н., Батоцыренов Б. В., Шикалова И. А., Вознюк И. А. Ацидоз и токсический гемолиз – цели патогенетического лечения полиорганной патологии при COVID-19. Вестник восстановительной медицины, 2020; 97(3):25–30. doi: 10.38025/2078–1962–2020–97–3–25–30.Lodyagin A. N., batotsyrenov b.V., Shi ka lo va I. A., Voznyuk I. A. Acidosis and toxic hemolysis – goals of pathogenetic treatment of polyorgan pathology in Covid-19. Bulletin of rehabilitation medicine. 2020; 97 (3): 25–30. doi: 10.38025/2078–1962–2020–97–3–25–30.Пилат Т. Л., Радыш И. В., Суровцев В. В., Коростелева М. М., Ханферьян Р. А. Возможности специализированной диетической коррекции нарушений желудочно- кишечного тракта у больных с вирусной инфекцией СOVID-19. Лечащий Врач. 2020;(8):11–15. doi: 10.26295/OS.2020.90.44.001.Pilat T. L., Radysh I. V., Surovtsev V. V., Ko ro ste le va M. M., Khanfer’yan R. A. Possibilities of specialized dietary correction of gastrointestinal tract disorders in patients with COVID-19 viral infection. Lechaschi Vrach. 2020;(8):11– 15. (In Russ.) doi: 10.26295/OS.2020.90.44.001.Пилат Т. Л., Ханферьян Р. А. Специализированные диетические продукты как факторы повышения эффективности фармакотерапии желудочно- кишечных заболеваний. Терапия. –№ 6. – 2020. –С. 212–218. doi: 10.18565/therapy.2020.6.212–218.Pilat T. L., Khanferian R. A. Specialized dietary preventive and therapeutic products as a means of increasing the effi ciency of gastrointestinal diseases pharmacotherapy. Th erapy. 2020;(6):212–218. (in Russ.) doi: 10.18565/therapy.2020.6.212–218.Пилат Т. Л., Кузьмина Л. П., Лашина Е. Л., Коляски на М. М., Безрукавникова Л. М., Бессонов В. В., Коростелева M. М., Гуревич К. Г., Лагутина Н. П., Ханферьян Р. А. Опыт применения специализированного пищевого продукта диетического лечебного и диетического профилактического питания при воспалительных заболеваниях желудочно- кишечного тракта. Медицинский Совет. 2020;(4):107–113. doi: 10.21518/2079–701X-2020–4–107–113.Pilat T. L., Kuzmina L. P., Lashina E. L., Ko lya skina M. M., Bezrukavnikova L. M., Bessonov V. V., Korosteleva M. M., Gurevich K. G., Lagutina N. P., Khanferyan R. A. Experience of application of specialized food product of dietary therapeutic and dietary preventive nutrition in case of infl ammatory diseases of gastrointestinal tract. Meditsinskiy sovet = Medical Council. 2020;(4):107– 113. (In Russ.) doi: 10.21518/2079–701X-2020–4–107–113.Пилат Т. Л., Лашина Е. Л., Коляскина М. М., Безрукавникова Л. М., Бессонов В. В., Коростелева М. М., Лагутина Н. П., Радыш И. В., Суровцев В. В., Ханферьян Р. А. Эффективность «ЛЕОВИТ GASTRO» при заболеваниях желудочно- кишечного тракта. Ремедиум Поволжье. 2020;2(179):20–21.Pilat T. L., Lashina E. L., Kolyaskina M. M., Bez ruka vnikova L. M., Bessonov V. V., Korosteleva M. M., La gu ti na N. P., Radysh I. V., Surovtsev V. V., Khanferyan R. A. Th e eff ectiveness of "LEOVIT GASTRO" in diseases of the gastrointestinal tract. Re me dium Volga region. 2020;2(179):20–21. (in Russ.)Пилат Т. Л., Лашина Е. Л., Коляскина М. М., Безрукавникова Л. М., Коростелева М. М., Гуревич К. Г., Лагутина Н. П., Ханферьян Р. А. Влияние специализированного диетического коктейля с растительными компонентами на репаративные процессы при различных заболеваниях желудочно- кишечного тракта // Журнал Поликлиника. 2020– № 1(2). С. 100–110.Pilat T. L., Lashina E. L., Kolyaskina M. M., Bez rukav nikova L. M., Korosteleva M. M., Gurevich K. G., Lagutina N. P., Khanferyan R. A. Th e infl uence of a specialized dietary cocktail with herbal components on reparative processes in various diseases of the gastrointestinal tract. Journal Polyclinic. 2020;1(2):100–110. (in Russ.)Пилат Т. Л., Радыш И. В., Суровцев В. В., Коростелева М. М., Ханферьян Р. А. Диетическая коррекция нарушений пищеварения и функций ЖКТ после длительной самоизоляции и карантина, а также пациентов с SARS-CoV-2 в периоде реабилитации. Медицинский Совет. 2020;(15):146–152. doi: 10.21518/2079–701X-2020–15–146–152.Pilat T. L., Radysh I. V., Surovtsev V. V., Ko ro ste leva M. M., Khanferyan R. A. Dietary management of digestive and gastrointestinal disorders aft er long-term self-isolation and lockdown as well as patients with SARS-CoV-2 during the rehabilitation period. Me di tsin skiy sovet = Medical Council. 2020;(15):146–152. (In Russ.) doi: 10.21518/2079–701X-2020–15–146–152.Т. Л. Пилат, Л. М. Безрукавникова, М. М. Коляскина, В. В. Бессонов, Н. А. Анварул, Р. А. Ханферьян. Исследование эффективности детоксицирующего влияния комплексной программы питания DETOX на функциональные показатели организма. Терапия. 2020. № 2. С. 156–163. doi: 10.18565/therapy.2020.2.156–163.Pilat T. L., Bezrukavnikova L. M., Kolyaskina M. M., Bessonov V. V., Anvarul N. A., Khanferyan R. A. Study of eff ectiveness of detoxing impact of the complex detox nutrition program on functional parameters of the organism. Th erapy. 2020;(2):156–163. (in Russ.) doi: 10.18565/therapy.2020.2.156–163.Lewandowski K, Rosołowski M, Kaniewska M, Kucha P, Meler A, Wierzba W, Rydzewska G. Clostridioides diffi - cile infection in coronavirus disease 2019 (COVID-19): an underestimated problem? Pol Arch Intern Med. 2021 Feb 26;131(2):121–127. doi: 10.20452/pamw.15715.Lewandowski K, Rosołowski M, Kaniewska M, Kucha P, Meler A, Wierzba W, Rydzewska G. Clostridioides diffi - cile infection in coronavirus disease 2019 (COVID-19): an underestimated problem? Pol Arch Intern Med. 2021 Feb 26;131(2):121–127. doi: 10.20452/pamw.15715.Granata G, Bartoloni A, Codeluppi M, Contadini I, Cristini F, Fantoni M, Ferraresi A, Fornabaio C, Grasselli S, Lagi F, Masucci L, Puoti M, Raimondi A, Taddei E, Trapani FF, Viale P, Johnson S, Petrosillo N, On Behalf Of Th e CloVid Study Group. Th e Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case- Control Study in Italian Hospitals (CloVid). J Clin Med. 2020 Nov 27;9(12):3855. doi: 10.3390/jcm9123855.Granata G, Bartoloni A, Codeluppi M, Contadini I, Cristini F, Fantoni M, Ferraresi A, Fornabaio C, Grasselli S, Lagi F, Masucci L, Puoti M, Raimondi A, Taddei E, Trapani FF, Viale P, Johnson S, Petrosillo N, On Behalf Of Th e CloVid Study Group. Th e Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case- Control Study in Italian Hospitals (CloVid). J Clin Med. 2020 Nov 27;9(12):3855. doi: 10.3390/jcm9123855.Временные методические рекомендации Министерства здравоохранения России. «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)» Версия 16 от 18.08.2022. https://remedium.ru/legislation/other/Vmr-profilaktikadiagnostika-lechenie-covid19-v16Temporary guidelines of the Ministry of Health of Russia. "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)" Version 16 of 08/18/2022. (in Russ.) (Available at: https://remedium.ru/legislation/other/Vmr-profilaktika-diagnostika-lecheniecovid19-v16, Accessed: 05.05.2022).Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinfl ammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020 Oct;41(10):2657–2669. doi: 10.1007/s10072–020–04575–3.Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinfl ammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020 Oct;41(10):2657–2669. doi: 10.1007/s10072–020–04575–3.Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831–1833.e3. doi: 10.1053/j.gastro.2020.02.055.Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831–1833.e3. doi: 10.1053/j.gastro.2020.02.055.Баклаушев В. П., Кулемзин С. В., Горчаков А. А., Лесняк В. Н., Юсубалиева Г. М., Сотникова А. Г. COVID-19. Этиология, патогенез, диагностика и лечение. Клиническая практика. – 2020. – Т. 11. – № 1. – C. 7–20. doi: 10.17816/clinpract26339.Baklaushev V. P., Kulemzin S. V., Gorchakov А. А., Lesnyak V. N., Yusubalieva G. M., Sotnikova A. G. COVID-19. Aetiology, pathogenesis, diagnosis and treatment. Journal of Clinical Practice. 2020;11(1):7–20. doi: 10.17816/clinpract26339. (In Russ.)Пилат Т. Л., Виноградов В. В., Решульский С. С., Федорова Е. Б., Ханферьян Р. А. Диетические продукты питания: возможности применения у больных, инфицированных SARS-COV-2, во время болезни и в периоде реабилитации. Поликлиника. 2020. –№ 6– C. 27–32.Pilat T. L., Vinogradov V. V., Reshulsky S. S., Fe do rova E. B., Khanferyan R. A. Dietary food products: possibilities of use in patients infected with SARS-COV-2, during illness and in the rehabilitation period. Polyclinic. 2020;(6):27–32. (in Russ.)Пилат Т. Л., Кузьмина Л. П., Коляскина М. М., Радыш И. В., Ханферьян Р. А. Специализированная нутритивная поддержка пациентов с COVID-19 диетическими лечебными продуктами питания в условиях стационара // Терапия. 2021. –№ 2 (44)–С. 153–159. doi: 10.18565/therapy.2021.2.153–159.Pilat T. L., Kuzmina L. P., Kolyaskina М. М., Radysh I. V., Khanferian R. А. Specialized nutritional support of hospitalized patients with COVID-19 by means of dietary medicinal food products. Th erapy. 2021;2 (44):153–159. (in Russ.) doi: 10.18565/therapy.2021.2.153–159.Пилат Т. Л., Алексеенко С. Н., Крутова В. А., Акимов М. Ю., Радыш И. В., Умнова Т. Н., Истомин А. В., Гордеева Е. А., Коростелева М. М., Ханферьян Р. А. Проблемы питания больных COVID-19- вирусной инфекцией и возможности нутритивной коррекции нарушений. Медицинский Совет. 2021;(4):144–154. doi: 10.21518/2079–701X-2021–4–144–154.Pilat T. L., Alekseenko S. N., Krutova V. A., Akimov M. Yu., Radysh I. V., Umnova T. N., Istomin A. V., Gordeeva E. A., Korosteleva M. M., Khanferyan R. A. Nutritional problems of patients infected with COVID-19 and potential for nutritional management of disorders. Meditsinskiy sovet = Me di cal Council. 2021;(4):144–154. (In Russ.) doi: 10.21518/2079–701X-2021–4–144–154.Пилат Т. Л., Истомин А. В., Гордеева Е. А., Ханферьян Р. А. Может ли детоксикационное питание быть вспомогательным средством при лечении и реабилитации больных, инфицированных вирусом COVID-19? Лечащий Врач. 2021;(4):43–49. doi: 10.51793/OS.2021.99.23.008.Pilat T. L., Istomin A. V., Gordeeva E. A., Khan feryan R. A. Can detox nutrition be an adjunct in the treatment and rehabilitation of patients infected with the COVID-19 virus? Lechaschi Vrach. 2021;(4):43–49. (In Russ.) doi: 10.51793/OS.2021.99.23.008.Кузьмина Л. П., Пилат Т. Л., Безрукавникова Л. М., Коляскина М. М. Оценка лабораторных показателей эндогенной интоксикации при различных патологиях профессиональной и инфекционной этиологии // Терапия. 2021. –№ 9.–С. 174–182. doi: 10.18565/therapy.2021.9.174–182.Kuzmina L. P., Pilat T. L., Bezrukavnikova L. M., Kolyaskina M. M. Estimation of endogenic intoxication laboratory indexes in case of diff erent pathologies of professional and infectious etiology. Th erapy. 2021;(9):174– 182. (in Russ.) doi: 10.18565/therapy.2021.9.174–182.Жданов К. В. с соавт. Методические рекомендации по профилактике, диагностике и лечению дизентерии и других острых кишечных диарейных инфекций в Вооруженных силах Российской Федерации. Острые кишечные диарейные инфекции. Указания по диагностике, лечению и профилактике в Вооруженных силах Российской Федерации, М. 2019, 136 с.Zhdanov K. V., et al. Guidelines for the prevention, diagnosis and treatment of dysentery and other acute intestinal diarrheal infections in the Armed Forces of the Russian Federation. Acute intestinal diarrheal infections. Guidelines for diagnosis, treatment and prevention in the Armed Forces of the Russian Federation, Moscow. 2019, 136 p. (in Russ.)Пилат Т. Л., Кузьмина Л. П., Коляскина М. М., Безрукавникова Л. М. Роль желудочно- кишечного тракта в процессах интоксикации и детоксикации организма. Экспериментальная и клиническая гастроэнтерология. 2020;183(11):118–125. doi: 10.31146/1682–8658-ecg-183–11–118–125.Pilat T. L., Kuzmina L. P., Kolyaskina M. M., Bez ruka vnikova L. M. Th e role of the gastrointestinal tract in the processes of intoxication and detoxification of the body. Experimental and Clinical Gastroenterology. 2020;183(11):118–125. (In Russ.) doi: 10.31146/1682–8658-ecg-183–11–118–125.Лазебник Л. Б., Белоусова Н. Л., Бордин Д. С. Резистентность Helicobacter pylori к кларитромицину в Москве и прополис как средство, повышающее эффективность эрадикации. Экспериментальная и клиническая гастроэнтерология, 2012. – № 8. – С. 10–14.Lazebnik L. B., Belousova N. L., Bordin D. S. [Resistance of Helicobacter pylori to clarithromycin in Moscow and propolis as a means of increasing the eff ectiveness of eradication]. Experimental and clinical gastroenterology. 2012;(8):10–14. (in Russ.)Стома И. О. Микробиом в медицине: руководство для врачей. М. ГЭОТАР – Медиа. 2020. – 320 с.Stoma I. O. [Microbiome in medicine: a guide for physicians]. Moscow. GEOTAR–Media. 2020. 320 p. (in Russ.)Neri- Numa IA, Pastore GM. Novel insights into prebiotic properties on human health: A review. Food Res Int. 2020 May;131:108973. doi: 10.1016/j.foodres.2019.108973.Neri- Numa IA, Pastore GM. Novel insights into prebiotic properties on human health: A review. Food Res Int. 2020 May;131:108973. doi: 10.1016/j.foodres.2019.108973.Методические рекомендации «Нутрициологическая профилактика и реабилитация при заболеваниях желудочно- кишечного тракта / Пилат Т. Л., Кузьмина Л. П., Гуревич К. Г. и др. – М. – 2019. – 36 с.Pilat T. L., Kuzmina L. P., Gurevich K. G., et al. Nutritional prevention and rehabilitation in diseases of the gastrointestinal tract. Moscow. 2019. 36 p. (in Russ.)Пилат Т. Л., Кузьмина Л. П., Лашина Е. Л., и др. Овсяная каша с травами и семенами льна способствует уменьшению абдоминального болевого синдрома при заболеваниях желудочно- кишечного тракта. Доказательная гастроэнтерология. 2020; 9(2):20–28. doi: 10.17116/dokgastro2020902120.Pilat T. L., Kuzmina L. P., Lashina E. L., et al. Oatmeal with herbs and fl ax seeds reduces abdominal pain in patients with gastrointestinal diseases. Russian Journal of EvidenceBased Gastroenterology. 2020;9(2):20–28. (In Russ.) doi: 10.17116/dokgastro2020902120.Щикота А. М., Погонченкова И. В., Турова Е. А., Стародубова А. В., Носова Н. В. Диарея, ассоциированная с COVID-19. Вопросы питания. 2021. Т 90, № 6. С. 18–30. doi: 10.33029/0042–8833–2021–90–6–18–30.Shchikota A. M., Pogonchenkova I. V., Turova E. A., Starodubova A. V., Nosova N. V. COVID-19-associated diarrhea. Voprosy pitaniia = Problems of Nutrition. 2021; 90 (6): 18–30. (in Russ.) doi: 10.33029/0042–8833–2021–90–6–18–30.D'Amico F, Baumgart DC, Danese S, Peyrin- Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol. 2020 Jul;18(8):1663–1672. doi: 10.1016/j.cgh.2020.04.001.D'Amico F, Baumgart DC, Danese S, Peyrin- Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol. 2020 Jul;18(8):1663–1672. doi: 10.1016/j.cgh.2020.04.001.Zhang X, Tang C, Tian D, Hou X, Yang Y. Management of Digestive Disorders and Procedures Associated With COVID-19. Am J Gastroenterol. 2020 Aug;115(8):1153– 1155. doi: 10.14309/ajg.0000000000000728.Zhang X, Tang C, Tian D, Hou X, Yang Y. Management of Digestive Disorders and Procedures Associated With COVID-19. Am J Gastroenterol. 2020 Aug;115(8):1153– 1155. doi: 10.14309/ajg.0000000000000728.Осадчук М. А., Свистунов А. А. Антибиотикоассоциированная диарея в клинической практике. Вопросы современной педиатрии. 2014;13(1):102–108. doi: 10.15690/vsp.v13i1.918.Osadchuk M. A., Svistunov A. A. Antibiotic- associated diarrhea in clinical practice. Current Pediatrics. 2014;- 13(1):102–108. (In Russ.) doi: 10.15690/vsp.v13i1.918.Managing Adult Malnutrition. A Community Healthcare Professional Guide to the Nutritional Management of Patients during and aft er COVID-19 Illness. (Available at: https://www.malnutritionpathway.co.uk/covid19-community-hcp, Accessed: 05.05.2022).Managing Adult Malnutrition. A Community Healthcare Professional Guide to the Nutritional Management of Patients during and aft er COVID-19 Illness. (Available at: https://www.malnutritionpathway.co.uk/covid19-community-hcp, Accessed: 05.05.2022).Марченкова Л. А., Макарова Е. В., Юрова О. В. Роль микронутриентов в комплексной реабилитации пациентов с новой коронавирусной инфекцией COVID-19. Вопросы питания. 2021;90(2):40–49. doi: 10.33029/0042–8833–2021–90–2–40–49.Marchenkova L. A., Makarova E. V., Yurova O. V. Th e role of micronutrients in the comprehensive rehabilitation of patients with the novel coronavirus infection COVID-19. Voprosy pitaniia = Problems of Nutrition. 2021;90(2):40–9. (in Russ.) doi: 10.33029/0042–8833–2021–90–2–40–49.Barrea L, Grant WB, Frias- Toral E, Vetrani C, Verde L, de Alteriis G, Docimo A, Savastano S, Colao A, Mus cogiuri G. Dietary Recommendations for Post- COVID-19 Syndrome. Nutrients. 2022 Mar 20;14(6):1305. doi: 10.3390/nu14061305.Barrea L, Grant WB, Frias- Toral E, Vetrani C, Verde L, de Alteriis G, Docimo A, Savastano S, Colao A, Mus cogiuri G. Dietary Recommendations for Post- COVID-19 Syndrome. Nutrients. 2022 Mar 20;14(6):1305. doi: 10.3390/nu14061305.Vetrani C, Costabile G, Di Marino L, Rivellese AA. Nutrition and oxidative stress: a systematic review of human studies. Int J Food Sci Nutr. 2013 May;64(3):312–26. doi: 10.3109/09637486.2012.738651.Vetrani C, Costabile G, Di Marino L, Rivellese AA. Nutrition and oxidative stress: a systematic review of human studies. Int J Food Sci Nutr. 2013 May;64(3):312–26. doi: 10.3109/09637486.2012.738651.Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fl uctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006 Apr 12; 295(14):1681–7. doi: 10.1001/jama.295.14.1681.Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fl uctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006 Apr 12; 295(14):1681–7. doi: 10.1001/jama.295.14.1681.El Khoury CN, Julien SG. Inverse Association Between the Mediterranean Diet and COVID-19 Risk in Lebanon: A Case- Control Study. Front Nutr. 2021 Jul 30;8:707359. doi: 10.3389/fnut.2021.707359.El Khoury CN, Julien SG. Inverse Association Between the Mediterranean Diet and COVID-19 Risk in Lebanon: A Case- Control Study. Front Nutr. 2021 Jul 30;8:707359. doi: 10.3389/fnut.2021.707359.Majumder D, Debnath M, Sharma KN, Shekhawat SS, Prasad GBKS, Maiti D, Ramakrishna S. Olive Oil Consumption can Prevent Non-communicable Diseases and COVID-19: A Review. Curr Pharm Biotechnol. 2022;23(2):261–275. doi: 10.2174/1389201022666210412143553.Majumder D, Debnath M, Sharma KN, Shekhawat SS, Prasad GBKS, Maiti D, Ramakrishna S. Olive Oil Consumption can Prevent Non-communicable Diseases and COVID-19: A Review. Curr Pharm Biotechnol. 2022;23(2):261–275. doi: 10.2174/1389201022666210412143553.Seal KH, Bertenthal D, Carey E, Grunfeld C, Bikle DD, Lu CM. Association of Vitamin D Status and COVID-19- Related Hospitalization and Mortality. J Gen Intern Med. 2022 Mar;37(4):853–861. doi: 10.1007/s11606–021–07170–0.Seal KH, Bertenthal D, Carey E, Grunfeld C, Bikle DD, Lu CM. Association of Vitamin D Status and COVID-19- Related Hospitalization and Mortality. J Gen Intern Med. 2022 Mar;37(4):853–861. doi: 10.1007/s11606–021–07170–0.Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D Supplementation Could Reduce Risk of Infl uenza and COVID-19 Infections and Deaths. Nutrients. 2020 Apr 2; 12(4): 988. doi: 10.3390/nu12040988.Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D Supplementation Could Reduce Risk of Infl uenza and COVID-19 Infections and Deaths. Nutrients. 2020 Apr 2; 12(4): 988. doi: 10.3390/nu12040988.Mercola J, Grant WB, Wagner CL. Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity. Nutrients. 2020 Oct 31;12(11):3361. doi: 10.3390/nu12113361.Mercola J, Grant WB, Wagner CL. Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity. Nutrients. 2020 Oct 31;12(11):3361. doi: 10.3390/nu12113361.Gupta S, Mitra A. Challenge of post- COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2. Heart Fail Rev. 2022 Jan;27(1):239–249. doi: 10.1007/s10741–021–10076-y.Gupta S, Mitra A. Challenge of post- COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2. Heart Fail Rev. 2022 Jan;27(1):239–249. doi: 10.1007/s10741–021–10076-y.Cooney J, Appiahene P, Findlay R, Al- Hillawi L, Rafique K, Laband W, Shandro B, Poullis A. COVID-19 infection causing residual gastrointestinal symptoms – a single UK centre case series. Clin Med (Lond). 2022 Mar;22(2):181– 183. doi: 10.7861/clinmed.2021–0522.Cooney J, Appiahene P, Findlay R, Al- Hillawi L, Ra fi que K, Laband W, Shandro B, Poullis A. COVID-19 infection causing residual gastrointestinal symptoms – a single UK centre case series. Clin Med (Lond). 2022 Mar;22(2):181– 183. doi: 10.7861/clinmed.2021–0522.Khazaal S, Harb J, Rima M, Annweiler C, Wu Y, Cao Z, Abi Khattar Z, Legros C, Kovacic H, Fajloun Z, Sa batier JM. Th e Pathophysiology of Long COVID throughout the Renin- Angiotensin System. Molecules. 2022 May 2;- 27(9):2903. doi:10.3390/molecules27092903.Khazaal S, Harb J, Rima M, Annweiler C, Wu Y, Cao Z, Abi Khattar Z, Legros C, Kovacic H, Fajloun Z, Sa batier JM. Th e Pathophysiology of Long COVID throughout the Renin- Angiotensin System. Molecules. 2022 May 2;- 27(9):2903. doi: 10.3390/molecules27092903.Quiles JL, Rivas- García L, Varela- López A, Llopis J, Battino M, Sánchez- González C. Do nutrients and other bioactive molecules from foods have anything to say in the treatment against COVID-19? Environ Res. 2020 Dec;191:110053. doi: 10.1016/j.envres.2020.110053.Quiles JL, Rivas- García L, Varela- López A, Llopis J, Battino M, Sánchez- González C. Do nutrients and other bioactive molecules from foods have anything to say in the treatment against COVID-19? Environ Res. 2020 Dec;191:110053. doi: 10.1016/j.envres.2020.110053.Avery A. Can Diet Influence the COVID-19 Mortality Rate? Komp Nutr Diet. 2021;1:16–18. doi:10.1159/000512841.Avery A. Can Diet Influence the COVID-19 Mortality Rate? Komp Nutr Diet. 2021;1:16–18. doi: 10.1159/000512841.Sahu S, Patil CR, Kumar S, Apparsundaram S, Goyal RK. Role of ACE2-Ang (1–7)-Mas axis in post- COVID-19 complications and its dietary modulation. Mol Cell Biochem. 2022 Jan;477(1):225–240. doi: 10.1007/s11010–021–04275–2.Sahu S, Patil CR, Kumar S, Apparsundaram S, Goyal RK. Role of ACE2-Ang (1–7)-Mas axis in post- COVID-19 complications and its dietary modulation. Mol Cell Biochem. 2022 Jan;477(1):225–240. doi: 10.1007/s11010–021–04275–2.Ramdani LH, Bachari K. Potential therapeutic effects of Resveratrol against SARS-CoV-2. Acta Virol. 2020;64(3):276–280. doi: 10.4149/av_2020_309.Ramdani LH, Bachari K. Potential therapeutic effects of Resveratrol against SARS-CoV-2. Acta Virol. 2020;64(3):276–280. doi: 10.4149/av_2020_309.van Brummelen R, van Brummelen AC. Th e potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 –A formulator's perspective. Biomed Pharmacother. 2022 Apr;148:112767. doi: 10.1016/j.biopha.2022.112767.van Brummelen R, van Brummelen AC. Th e potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 –A formulator's perspective. Biomed Pharmacother. 2022 Apr;148:112767. doi: 10.1016/j.biopha.2022.112767.Maurya VK, Kumar S, Prasad AK, Bhatt MLB, Sa xe na SK. Structure- based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor. Virusdisease. 2020 Jun;31(2):179–193. doi: 10.1007/s13337–020–00598–8.Maurya VK, Kumar S, Prasad AK, Bhatt MLB, Sa xe na SK. Structure- based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor. Virusdisease. 2020 Jun;31(2):179–193. doi: 10.1007/s13337–020–00598–8.Bardelčíková A, Miroššay A, Šoltýs J, Mojžiš J. Th e ra peutic and prophylactic eff ect of fl avonoids in post- COVID-19 therapy. Phytother Res. 2022 May;36(5):2042–2060. doi: 10.1002/ptr.7436.Bardelčíková A, Miroššay A, Šoltýs J, Mojžiš J. Th e ra peutic and prophylactic eff ect of fl avonoids in post- COVID-19 therapy. Phytother Res. 2022 May;36(5):2042–2060. doi: 10.1002/ptr.7436.Oscanoa TJ, Amado J, Vidal X, Laird E, Ghashut RA, Romero- Ortuno R. Th e relationship between the severity and mortality of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration – a metaanalysis. Adv Respir Med. 2021;89(2):145–157. doi: 10.5603/ARM.a2021.0037.Oscanoa TJ, Amado J, Vidal X, Laird E, Ghashut RA, Romero- Ortuno R. Th e relationship between the severity and mortality of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration – a metaanalysis. Adv Respir Med. 2021;89(2):145–157. doi: 10.5603/ARM.a2021.0037.D'Ecclesiis O, Gavioli C, Martinoli C, et al. Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis. PLoS One. 2022 Jul 6;17(7): e0268396. doi: 10.1371/journal.pone.0268396.D'Ecclesiis O, Gavioli C, Martinoli C, et al. Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis. PLoS One. 2022 Jul 6;17(7): e0268396. doi: 10.1371/journal.pone.0268396.A Alruwaili M, Jarrar Y. Eff ects of vitamin C and D on the mRNA expression of angiotensin converting enzyme 2 receptor, cathepsin L, and transmembrane serine protease in the mouse lungs. Libyan J Med. 2022 Dec;17(1):2054111. doi: 10.1080/19932820.2022.2054111.A Alruwaili M, Jarrar Y. Eff ects of vitamin C and D on the mRNA expression of angiotensin converting enzyme 2 receptor, cathepsin L, and transmembrane serine protease in the mouse lungs. Libyan J Med. 2022 Dec;17(1):2054111. doi: 10.1080/19932820.2022.2054111.Barrea L, Verde L, Grant WB, Frias- Toral E, et al. Vitamin D: A Role Also in Long COVID-19? Nutrients. 2022 Apr 13; 14(8):1625. doi: 10.3390/nu14081625.Barrea L, Verde L, Grant WB, Frias- Toral E, et al. Vitamin D: A Role Also in Long COVID-19? Nutrients. 2022 Apr 13; 14(8):1625. doi: 10.3390/nu14081625.Stephensen CB, Lietz G. Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2. Br J Nutr. 2021 Dec 14;126(11):1663–1672. doi: 10.1017/S0007114521000246.Stephensen CB, Lietz G. Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2. Br J Nutr. 2021 Dec 14;126(11):1663–1672. doi: 10.1017/S0007114521000246.Pisoschi AM, Pop A, Iordache F, Stanca L, Geicu OI, Bilteanu L, Serban AI. Antioxidant, anti-infl ammatory and immunomodulatory roles of vitamins in COVID-19 therapy. Eur J Med Chem. 2022 Mar 15;232:114175. doi: 10.1016/j.ejmech.2022.114175.Pisoschi AM, Pop A, Iordache F, Stanca L, Geicu OI, Bilteanu L, Serban AI. Antioxidant, anti-infl ammatory and immunomodulatory roles of vitamins in COVID-19 therapy. Eur J Med Chem. 2022 Mar 15;232:114175. doi: 10.1016/j.ejmech.2022.114175.He R, Wang Y, Yang Y, et al. Rapeseed protein- derived ACE inhibitory peptides LY, RALP and GHS show antioxidant and anti-infl ammatory eff ects on spontaneously hypertensive rats. J Funct Foods. 2019;(55):211–219. doi: 10.1016/j.jff.2019.02.031.He R, Wang Y, Yang Y, et al. Rapeseed protein- derived ACE inhibitory peptides LY, RALP and GHS show antioxidant and anti-infl ammatory eff ects on spontaneously hypertensive rats. J Funct Foods. 2019;(55):211–219. doi: 10.1016/j.jff.2019.02.031.Maeda Y, Motooka D, Kawasaki T, et al. Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity. BMC Infect Dis. 2022 Jun 24;22(1):572. doi: 10.1186/s12879–022–07358–7.Maeda Y, Motooka D, Kawasaki T, et al. Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity. BMC Infect Dis. 2022 Jun 24;22(1):572. doi: 10.1186/s12879–022–07358–7.Edwinson A, Yang L, Chen J, Grover M. Colonic expression of Ace2, the SARS-CoV-2 entry receptor, is suppressed by commensal human microbiota. Gut Microbes. 2021 JanDec;13(1):1984105. doi: 10.1080/19490976.2021.1984105.Edwinson A, Yang L, Chen J, Grover M. Colonic expression of Ace2, the SARS-CoV-2 entry receptor, is suppressed by commensal human microbiota. Gut Microbes. 2021 JanDec;13(1):1984105. doi: 10.1080/19490976.2021.1984105.Viana SD, Nunes S, Reis F. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities –Role of gut microbiota dysbiosis. Ageing Res Rev. 2020 Sep;62:101123. doi: 10.1016/j.arr.2020.101123.Viana SD, Nunes S, Reis F. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities –Role of gut microbiota dysbiosis. Ageing Res Rev. 2020 Sep;62:101123. doi: 10.1016/j.arr.2020.101123.Coles MJ, Masood M, Crowley MM, Hudgi A, Okereke C, Klein J. It Ain't Over 'Til It's Over: SARS CoV-2 and Post-infectious Gastrointestinal Dysmotility. Dig Dis Sci. 2022 Dec;67(12):5407–5415. doi: 10.1007/s10620–022–07480–1.Coles MJ, Masood M, Crowley MM, Hudgi A, Okereke C, Klein J. It Ain't Over 'Til It's Over: SARS CoV-2 and Post-infectious Gastrointestinal Dysmotility. Dig Dis Sci. 2022 Dec;67(12):5407–5415. doi: 10.1007/s10620–022–07480–1.Costantini L, Molinari R, Farinon B, Merendino N. Impact of Omega-3 Fatty Acids on the Gut Microbiota. Int J Mol Sci. 2017 Dec 7;18(12):2645. doi: 10.3390/ijms18122645.Costantini L, Molinari R, Farinon B, Merendino N. Impact of Omega-3 Fatty Acids on the Gut Microbiota. Int J Mol Sci. 2017 Dec 7;18(12):2645. doi: 10.3390/ijms18122645.Yang Q, Liang Q, Balakrishnan B, Belobrajdic DP, Feng QJ, Zhang W. Role of Dietary Nutrients in the Modulation of Gut Microbiota: A Narrative Review. Nutrients. 2020 Jan 31;12(2):381. doi:10.3390/nu12020381.Yang Q, Liang Q, Balakrishnan B, Belobrajdic DP, Feng QJ, Zhang W. Role of Dietary Nutrients in the Modulation of Gut Microbiota: A Narrative Review. Nutrients. 2020 Jan 31;12(2):381. doi: 10.3390/nu12020381.Gutiérrez-Castrellón P, Gandara-Martí T, Abreu Y Abreu AT, Nieto-Rufino CD, López-Orduña E, Jiménez-Escobar I, Jiménez-Gutiérrez C, LópezVelazquez G, Espadaler-Mazo J. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14(1):2018899. doi:10.1080/19490976.2021.2018899.Gutiérrez-Castrellón P, Gandara-Martí T, Abreu Y Abreu AT, Nieto-Rufino CD, López-Orduña E, Jiménez-Escobar I, Jiménez-Gutiérrez C, LópezVelazquez G, Espadaler-Mazo J. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14(1):2018899. doi: 10.1080/19490976.2021.2018899.De Biase S, Cook L, Skelton DA, Witham M, Ten Hove R. Th e COVID-19 rehabilitation pandemic. Age Ageing. 2020 Aug 24;49(5):696–700. doi: 10.1093/ageing/afaa118.De Biase S, Cook L, Skelton DA, Witham M, Ten Hove R. Th e COVID-19 rehabilitation pandemic. Age Ageing. 2020 Aug 24;49(5):696–700. doi: 10.1093/ageing/afaa118.Lopez M, Bell K, Annaswamy T, Juengst S, Ifejika N. COVID-19 Guide for the Rehabilitation Clinician: A Review of Nonpulmonary Manifestations and Complications. Am J Phys Med Rehabil. 2020 Aug;99(8):669–673. doi: 10.1097/PHM.0000000000001479.Lopez M, Bell K, Annaswamy T, Juengst S, Ifejika N. COVID-19 Guide for the Rehabilitation Clinician: A Review of Nonpulmonary Manifestations and Complications. Am J Phys Med Rehabil. 2020 Aug;99(8):669–673. doi: 10.1097/PHM.0000000000001479.Малявин А. Г., Адашева Т. В., Бабак С. Л., Губернаторова Е. Е., Уварова О. В. Медицинская реабилитация больных, перенесших COVID-19 инфекцию. Методические рекомендации (утверждены на заседании Президиума РНМОТ 15 июня 2020 г., протокол № 2) Москва 2020. – 65 с.Malyavin A. G., Adasheva T. V., Babak S. L., Gu ber na to rova E. E., Uvarova O. V. [Medical rehabilitation of patients with COVID-19 infection. Methodological recommendations]. [approved at the meeting of the Presidium of the Russian New York Times on June 15, 2020, protocol No. 2]. Moscow 2020. 65 p. (in Russ.)Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020 Jun;83(6):521–523. doi: 10.1097/JCMA.0000000000000319.Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020 Jun;83(6):521–523. doi: 10.1097/JCMA.0000000000000319.Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023–1026. doi: 10.1111/jth.14810.Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023–1026. doi: 10.1111/jth.14810.Hunt B., Retter A., McClintocket C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. March 25, 2020. (Available at: https://thrombosisuk.org/downloads/T&H%20and%20COVID.pdf, Accessed: 05.05.2022).Hunt B., Retter A., McClintocket C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. March 25, 2020. (Available at: https://thrombosisuk.org/downloads/T&H%20and%20COVID.pdf, Accessed: 05.05.2022).Gris JC, Perez- Martin A, Quéré I, Sotto A. COVID-19 associated coagulopathy: Th e crowning glory of thromboinfl ammation concept. Anaesth Crit Care Pain Med. 2020 Jun;39(3):381–382. doi: 10.1016/j.accpm.2020.04.013.Gris JC, Perez- Martin A, Quéré I, Sotto A. COVID-19 associated coagulopathy: Th e crowning glory of thromboinfl ammation concept. Anaesth Crit Care Pain Med. 2020 Jun;39(3):381–382. doi: 10.1016/j.accpm.2020.04.013.Wade DT. What is rehabilitation? An empirical investigation leading to an evidence- based description. Clin Rehabil. 2020 May;34(5):571–583. doi: 10.1177/0269215520905112.Wade DT. What is rehabilitation? An empirical investigation leading to an evidence- based description. Clin Rehabil. 2020 May;34(5):571–583. doi: 10.1177/0269215520905112.Infusino F, Marazzato M, Mancone M, et al. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. Nutrients. 2020 Jun 8;12(6):1718. doi: 10.3390/nu12061718.Infusino F, Marazzato M, Mancone M, et al. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. Nutrients. 2020 Jun 8;12(6):1718. doi: 10.3390/nu12061718.Крюков, А. Е. Особенности кишечного микробиоценоза у лиц молодого возраста с внебольничной пневмонией: автореф. дис. … канд. мед. наук: 14.00.05 / Крюков Александр Евгеньевич. – СПб., 2006. – 27 с.Kryukov A. E. [Features of intestinal microbiocenosis in young people with community- acquired pneumonia]. [Cand. Med. Sciences: 14.00.05]. SPb., 2006. 27 p. (in Russ.)Белова Г. В. Рекомендации по эндоскопии и клинической практике в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2020;177(5): 4–7. doi: 10.31146/1682–8658-ecg-177–5–4–7.Belova G. V. Recommendations for endoscopy and clinical practice in gastroenterology. Experimental and Clinical Gastroenterology. 2020;174(5):4–7. (In Russ.) 10.31146/1682–8658-ecg-177–5–4–7.Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И., и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter Pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология. 2017;(2):3–21.Lazebnik L. B., Tkachenko E. I., Abdulganiyeva D. I., et al. VI National guidelines for the diagnosis and treatment of ACID-related and Helicobacter pylori- associated diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017;(2):3–21. (In Russ.)Мартынов А. И., Шептулин А. А., Маев И. В., Ка зюлин А. Н., Каратеев А. Е., Мелехов А. В., Пальгова Л. К., Райхельсон К. Л. Новые возможности цитопротекции в лечении и профилактике заболеваний желудка и кишечника (резолюция Экспертного совета и обзор литературы). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):7–14. doi: 10.22416/1382–4376–2020–30–2–7–14.Martynov A. I., Sheptulin A. A., Mayev I. V., Ka zyulin A. N., Karateev A. Y., Melekhov A. V., Pal’go va L.K., Raikhel’son K. L. New Prospects of Cytoprotection in the Treatment and Prevention of Gastric and Intestinal Diseases (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):7–14. (In Russ.) doi: 10.22416/1382–4376–2020–30–2–7–14.Belova G.V., Lazebnik L. B. ENDOSCOPIC ATLAS. Experimental and Clinical Gastroenterology. preprint 2022;208(12) (In Russ.)Belova G.V., Lazebnik L. B. ENDOSCOPIC ATLAS. Experimental and Clinical Gastroenterology. preprint 2022;208(12) (In Russ.)Wang J., Zhang L., Hou X. Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2021 Dec;15(12):1385–1399. doi: 10.1080/17474124.2021.2005579.Wang J., Zhang L., Hou X. Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2021 Dec;15(12):1385–1399. doi: 10.1080/17474124.2021.2005579.Menees S.B., Maneerattannaporn M., Kim H. M., Chey W. D. Th e effi cacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan;107(1):28–35; quiz 36. doi: 10.1038/ajg.2011.355.Menees S.B., Maneerattannaporn M., Kim H. M., Chey W. D. Th e effi cacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan;107(1):28–35; quiz 36. doi: 10.1038/ajg.2011.355.Schoenfeld P., Pimentel M., Chang L., Lembo A., Chey W. D., Yu J., et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, doubleblind, placebo- controlled trials. Aliment Pharmacol Ther. 2014;39:1161–8.Schoenfeld P., Pimentel M., Chang L., Lembo A., Chey W. D., Yu J., et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, doubleblind, placebo- controlled trials. Aliment Pharmacol Th er. 2014;39:1161–8.Gao J., Gillilland M. G.-3rd, Owyang C. Rifaximin, gut microbes and mucosal infl ammation: unraveling a complex relationship. Gut Microbes. 2014;5(4):571–575. doi: 10.4161/gmic.32130.Gao J., Gillilland M. G.-3rd, Owyang C. Rifaximin, gut microbes and mucosal infl ammation: unraveling a complex relationship. Gut Microbes. 2014;5(4):571–575. doi: 10.4161/gmic.32130.Stamps B. W., Kuroiwa J., Isidean S. D., et al. Exploring Changes in the Host Gut Microbiota During a Controlled Human Infection Model for Campylobacter jejuni. Front Cell Infect Microbiol. 2021 Aug 31;11:702047. doi: 10.3389/fcimb.2021.702047.Stamps B. W., Kuroiwa J., Isidean S. D., et al. Exploring Changes in the Host Gut Microbiota During a Controlled Human Infection Model for Campylobacter jejuni. Front Cell Infect Microbiol. 2021 Aug 31;11:702047. doi: 10.3389/fcimb.2021.702047.

The authors declare that there are no conflicts of interest present.